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SUMMARY 
 
Fatty acids (FAs) are fundamental constituents of cell structure, but they can also influence 
cellular functions and molecular mechanisms with different effects according to their chain 
length and degree of saturation. Different pathological conditions have been linked to FAs 
profile, including dyslipidemia and hypertriglyceridemia. However, data concerning the effects 
of FAs on lipid metabolism and cardiovascular disease are still scarce and controversial. 
Therefore, the aim of the first part of the present PhD thesis (Section 1) has been to investigate 
the presence of possible significant correlations between plasma FAs profile and lipid 
parameters (including levels of the major apolipoproteins) in a population of Coronary Artery 
Disease (CAD) patients and controls. The analysis, performed on plasma of 1,370 subjects, 
revealed that Myristic acid (C14:0) positively predicted both Triglycerides (TG) and 
Apolipoprotein C-III (ApoC-III) plasma levels, confirming the preliminary data obtained in my 
master’s degree thesis on 57 CAD patients. ApoC-III being an important regulator of plasma 
TG levels, the influence of C14:0 on the expression of this protein has been investigated in a 
HepG2 cell model. Mass spectrometry results, together with Real Time PCR findings, suggest a 
slight but significant increase in ApoC-III protein and mRNA levels in C14:0 treated cells. 
Therefore, the in vitro investigations supported the positive connection observed in-vivo 
between C14:0, TG and ApoC-III plasma levels, suggesting a possible important role of this 
saturated FA in the onset of cardiovascular disease.  
The effects of FAs on liver metabolism have been studied during the last few years for the 
influence they have on lipid metabolism, the onset of nonalcoholic fatty liver disease (NAFLD) 
and cardiovascular disease. However, proteomics investigations in this direction are still scarce 
and the influence of C14:0 on liver metabolism still needs to be elucidated. Therefore, in the 
second part of the present PhD thesis (Section 2) the effects of different concentrations of 
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C14:0 on HepG2 cells proteome and secretome have been investigated by means of high–
resolution mass spectrometry. The results obtained highlighted the influence of this FA on 
proteins involved in lipid droplets formation, cytoskeleton organization, endoplasmic reticulum 
stress, exosome release and cell-cell stress communication. To highlight the proteome changes 
specifically related to C14:0, a comparative study of the proteomic modulations induced by 
C14:0, palmitic (C16:0) and oleic acid (C18:1) has been performed. Interestingly, the 
overlapping of modulated proteins induced by the three FAs treatments was limited to just one 
protein, highlighting their different mechanisms of action. 40 proteins were found to be 
deregulated specifically by C14:0. These results suggested a unique influence of this saturated 
FA on specific proteins involved in different biological processes, mainly protein homeostasis 
counteracting ER stress (e.g. ENTPD5, VAPB and SGTA) and lipid metabolism (e.g. ApoE).  
In conclusion, the present PhD thesis highlights for the first time a possible in-vivo fundamental 
role of C14:0 on lipid metabolism, particularly on ApoC-III and TG plasma levels and 
represents the first investigation shedding light on the in-vitro C14:0 effects on a human 
hepatocyte-derived cell line.  
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CHAPTER 1 
CORONARY ARTERY DISEASE AND FATTY ACIDS 
 
1. CORONARY ARTERY DISEASE  
Cardiovascular diseases (CVD) consist of group of health diseases involving heart, blood or 
vascular diseases of the brain (Mendis S., 2011). To date CVD account for nearly one-third of 
worldwide deaths and are still the main cause of mortality (http://www.who.int) (Fig.1A). In 
2015 the World Health Organization (WHO) estimated that 17.7 million deaths were caused by 
CVD, which corresponds to 31% of global deaths (http://www.who.int). 
 
Fig.1 CVDs incidence and distribution in the world population. Percentage of world deaths caused by 
CDVs (A) and their distribution among men (B) and women global populations (C) NCDs: non-
communicable diseases (Mendis S., 2011).  
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From the survey it emerged that the majority of those deaths (7.4 million) were caused by 
Coronary Artery Disease (CAD) (Fig.1B-C), including stable and unstable angina, myocardial 
infarction and coronary death, characterised by the progressive or even sudden occlusion of 
coronary arteries. Low and middle-income countries account for 80% of these deaths, with 
Eastern Europe and Central Asian countries having the highest number. Despite the decrease in 
CAD mortality by more than one half in wealthy countries over the last 25 years,  the general 
tendency in low and middle-income countries is still flat or even rising due to a shift in lifestyle 
towards that seen in rich countries (Finegold et al., 2013). These data highlight that it is 
actually possible to prevent this pathology, but further research will be necessary in order to 
counteract the onset of CAD, which still also remains a major risk in wealthy countries. 
 
1.1 THE ATHEROSCLEROTIC PROCESS 
Like stroke and peripheral vascular disease, CAD belongs to the group of CVD caused by the 
development of atherosclerosis inside blood vessels (Mendis S., 2011; Wong, 2014). While in 
the past it was seen just as a cholesterol storage disease, recent evolutions in our understanding 
of atherosclerosis allow us to describe atherosclerosis as a complex and progressive 
inflammatory process due to the accumulation of cells, connective-tissue elements, lipids and 
debris inside the intima, the innermost layer of vessel wall (Hansson, 2005; Libby et al., 2005).  
The first and trigger event of this process is the infiltration of circulating Low Density 
Lipoproteins (LDL), as well as of other Apolipoprotein B (ApoB) containing lipoproteins, 
inside the vessel walls, in areas of arterial branching or curvature, where disturbed flow permits 
an increased permeability (Lusis, 2000). LDL undergo a series of modifications including 
lipolysis, proteolysis, aggregation and oxidation. LDL oxidation is caused by the action of 
enzymes, such as myeloperoxidase and lipoxygenases, or by reactive oxygen species (ROS) 
that give rise to the pro-inflammatory oxLDL. These molecules inhibit the production of nitric 
oxide (NO), a molecule with antiatherogenic effects, and cause the release of phospholipids 
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that in turn activate the overlaying endothelial cells (ECs) (Hansson et al., 2011). The 
activation induces ECs to produce pro-inflammatory molecules, growth factors and adhesion 
molecules (e.g. E-selectin and vascular cell adhesion molecule 1 (VCAM1)) that, in synergy 
with chemokines (e.g. CCL2), promote the sticking leucocytes, in particular monocytes and 
lymphocytes, to the inner surface of the artery wall, in correspondence with the endothelial 
lesion (Fig.2A) (Hansson et al., 2011). High density lipoproteins (HDL) play a protective role 
both by the removal of cholesterol form peripheral tissues and also by inhibiting lipoprotein 
oxidation through the action of paraoxonase on their surfaces (Lusis, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 Stages of atherosclerotic plaque development inside artery wall. Lesion formation implicates the 
sticking of monocytes to vessel endothelial cells (ECs) and their transformation in macrophages and 
foam cells (A). Smooth Muscle Cells (SMCs together with extracellular matrix molecules, lipids, 
microvessels and necrotic cells form the atherosclerotic plaque (B). Rupture of the fibrous cap expose 
tissue factor to the blood flow causing thrombus formation (C) (Nabel et al., 2012). 
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Inside the inflamed intima, the Macrophage Colony-Stimulating factor (M-CFS) induces the 
differentiation of those monocytes in macrophages that, through the up-regulation of 
Scavengers Receptors and Tool like Receptors, internalise bacteria and toxins, apoptotic cell 
fragments and also oxLDL particles (Hansson, 2005). When lipids accumulate inside 
monocytes, they evolve into the so-called “foam cells” which have been defined as the 
hallmark of both early and late atherosclerotic lesions (Glass et al., 2001). Such “fatty 
streaks” are not clinically significant but they are the base for the formation of more 
dangerous “fibrous lesions” (Lusis, 2000) (Fig.2B). As a consequence of inflammatory 
situation, the underlying Smooth Muscle Cells (SMCs) migrate from the media layer to the 
intima or subendothelial space and, internalising oxLDL, they contribute to foam cells 
formation. In addition, SMCs synthesise the extracellular matrix proteins, like collagen and 
elastin, which contribute to the formation of a fibrous cap on the atherosclerotic lesion 
(Glass et al., 2001).  
Clinical symptoms of the atherosclerotic plaque involve the progressive limitation of blood 
flow by stenoses or acute events that completely block blood flow, temporarily or 
permanently (Nabel et al., 2012). The rupture of the plaque and subsequent thrombosis 
(Fig.2C) provoke the latest situation. Unstable plaques seem to be those with thin fibrous 
caps, increased number of inflammatory cells and large necrotic cores (Lusis, 2000; Glass et 
al., 2001). Macrophages and SMCs in the plaque can undergo apoptotic or necrotic process, 
which also seems to be stimulated by the presence of oxLDL. Lipids released by these cells 
give rise to the formation of classical features of the advanced lesions and contribute to the 
thrombogenic potential of the atherosclerotic plaque (Glass et al., 2001). In addition, when 
the clearance of these dead cells through the efferocytosis process is inefficient or weak, the 
accumulation of cell debris and extracellular lipids form the necrotic core of the plaque 
(Libby et al., 2011). In addition to necrotic core formation, other events can contribute to 
plaque instability: for example, T cells produce INF- which inhibits the release of matrix 
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proteins by SMCs, while macrophages secrete proteases, in particular metalloproteinases 
(MMPs) and cysteine proteases (Lusis, 2000; Hansson, 2005), which contribute to 
extracellular matrix degradation, giving rise to unstable plaques prone to rupture. Moreover, 
neovascularisation phenomena contribute to plaque instability both with a physical 
destabilisation and also by allowing the entrance of additional inflammatory cells inside the 
lesion (Lusis, 2000). Furthermore, in response to inflammatory cytokines, pericytes, cells 
surrounding ECs, induce the production of a matrix scaffold that later becomes the base for 
the calcification process taking place inside the lesion. Taken together, all these events 
impair plaque stability and cause its rupture, exposing lipids and tissue factor. ECs and 
apoptotic macrophages can induce the accumulation of extracellular tissue factor which, 
when exposed to coagulation proteins and platelets present in the blood flow, can trigger 
thrombus formation (Libby et al., 2005).   
 
 
1.2 CAD OUTOMES 
In the case of CAD pathology, the atherosclerotic process affects coronary arteries, vessels 
accountable for oxygen supply to the myocardium. Due to the reduced oxygen supply, this 
complex disease gives rise to a wide range of clinically relevant manifestations, ranging from 
asymptomatic angina pectoris to acute events such as Acute Coronary Syndrome (ACS), heart 
failure and sudden cardiac death (Boudoulas et al., 2016). 
CAD manifestations are frequently caused by the stenosis of coronary lumen, due to the 
increasing plaque formations. Most patients may live in this pathological condition for many 
years, even decades, without any symptoms. This happens because of the presence of an 
important vessels-balancing mechanism involving artery remodelling, aimed at counteracting 
plaque development. Therefore, despite the presence of the atherosclerotic plaque, the arteries 
preserve their original luminal area. The drawback of this compensation lies in the fact that the 
degree of stenosis is not directly correlated with the size and the dangerousness of the 
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atherosclerotic plaque, postponing its detection (Boudoulas et al., 2016). In some patients, 
however, the artery stenosis can cause stable angina pectoris, a pathological condition caused 
by myocardial ischemia. This manifestation follows the severe narrowing of one or more 
coronary arteries but also happens in the case of non-obstructive coronary arteries, or even 
angiographically normal coronary arteries. Stable angina pectoris is described as a recurring 
pressure or choking sensation in the chest or adjacent areas, often in association with physical 
or emotional stress. Affected patients have to reduce their activities and, as a consequence, their 
quality of life is definitely impaired (Rousan et al., 2017).  
While in the past years CAD manifestations were thought to be dependent only on arterial 
narrowing and stenosis, today our understanding of the pathology has improved, and we now 
recognise that dangerous atherosclerotic lesions can also evolve inside artery walls without 
inducing arterial stenosis. Indeed, occurring in the late stages when plaque growth overtakes 
artery expansion mechanism, stenosis has been described as the “tip of the iceberg” of 
atherosclerosis, and atherosclerotic lesions are normally widespread when steatosis emerges 
(Libby et al., 2005; Libby, 2013). Studies on patients undergoing medical intervention 
following CAD manifestations demonstrated that only half of those cases were generated by 
stenosis (Libby, 2013). Many CAD symptoms arise from the subsequent appearance of ACS, 
due to plaque damaging rather than to stenosis. Tomography study on ACS patients showed 
that 44% of those events were caused by plaque rupture (Fig.3, top images), 31% by plaque 
erosion (Fig.3, lower images) and only 8% by the presence of calcified nodules (Santos-
Gallego et al., 2014). Most studies aimed at disclosing the pathogenesis of coronary artery 
thrombus formation focused on the mechanism of plaque rupture, the main cause of ACS. 
Results highlighted that unstable plaques are characterised by large lipid pools, high 
concentrations of macrophages, minor amounts of collagen, thin caps (50 to 65 m thick) and 
spotty calcification (Libby, 2013; Boudoulas et al., 2016). Interestingly, while an unstable 
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plaque may become stabilised, a stable plaque may transform into an unstable plaque at any 
time. Rupture of the fibrous cap causes the exposure of coagulation factors to blood circulation.  
 
 
 
Fig.3 Clinical events caused by Coronary Artery Disease evolution in coronary arteries. The 
atherosclerotic plaque is represented in a typical location, the proximal left anterior descending artery 
(on the left). On the right the three lesion types are shown. When a plaque rupture occurs, thrombus 
formation arises, occluding artery lumen (top images). Alternatively, thrombus can be generated by 
erosion of the proteoglycan rich plaque (bottom images). In both cases, myocardial infarction can arise 
or the healing of the lesion can promote the evolution to a more fibrous cap causing stable ischemic 
syndromes (Libby, 2013). 
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This event has been described as a “solid state stimulus” for both coagulation and 
atherosclerosis, two pathways reinforcing each other (Libby et al., 2005). Subsequent thrombus 
formation may lead to the generation of lethal myocardial infarction (MI). For this reason, early 
diagnosis of those plaques is essential. Alternatively, if the thrombus formation does not 
occlude the artery, unstable angina events may occur (Boudoulas et al., 2016). Plaque erosion 
events can also cause thrombus formation and, even though less studied, these lesions have a 
lower content of inflammatory cells and more proteoglycan accumulation (Libby, 2013). 
Sometimes plaque rupture and erosion occur without any symptoms and the healing of these 
lesions gives rise to a progression in plaque volume, contributing therefore to the increase in 
artery steatosis (Fig.3, middle figures) (Libby, 2013; Santos-Gallego et al., 2014).  
 
 
 
 
2. LIPID METABOLISM: THE IMPORTANCE OF LIPOPROTEINS  
The already mentioned LDL and HDL belong to the family of lipoproteins, highly 
heterogeneous macromolecules, accountable for the transport and emulsification of 
hydrophobic lipids in blood and organs. Because of this important function, since the discovery 
of lipoproteins(in 1929 for HDL and 1950 for LDL), efforts have been made in order to clearly 
elucidate their regulation and their relationship with CVD and also with CAD (Olson, 1998). 
Lipoproteins have an outer single phospholipid layer that protects the inner hydrophobic core 
composed of lipids that would have a lower solubility inside blood flow (Fig.4). 
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Fig.4 Components of the inner core and outer shall of all lipoproteins  
 
The various lipoproteins mainly differ in their density and they have been classified based on 
their separation during ultracentrifugation steps (Fig.5). However, lipoproteins do not differ just 
in their density but also in their lipid composition, protein composition and dimensions. 
Chylomicrons, representing the largest and lowest density type of lipoprotein, rapidly flow on 
the top of plasma vial after ultracentrifugation. They are mainly responsible for the transport of 
triglycerides (TG) from the intestine to the liver. Also, Very Low Density (VLDL) lipoproteins 
transport TG and before the transformation into LDL, they turn into Intermediate Density 
Lipoproteins (IDL), surviving in the blood flow for a very short period. The smaller class of 
lipoproteins is represented by HDL, which are enriched mainly in protein component. In fact, 
while the dimensions of these macromolecules decrease, their density increases together with 
their protein content. The abovementioned lipoprotein classes are however only the main 
category of lipoproteins, which are composed of extremely heterogeneous molecules. Since the 
existence of lipoprotein subfractions has emerged, their connection with CVD has been 
investigated and still remains the object of many cardiovascular studies (Krauss, 2010).  
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Fig.5 Different density and diameter of lipoprotein particles (A) (from The British Journal of 
Cardiology). As a consequence, they stratify in a peculiar order after plasma ultracentrifugation (B) 
(Dashti et al., 2011)(PLFF, plasma lipoprotein free fraction). 
 
2.1  LIPID COMPONENTS OF LIPOPROTEINS 
Lipoproteins have an outer single phospholipid layer in which cholesterol molecules as well as 
proteins are embedded. This shell protects the inner hydrophobic core composed mainly of TG 
and cholesterol esters. These compounds are essential for the correct maintenance of body 
function. Cholesterol represents an essential component of cell membranes, managing their 
fluidity, and it is necessary for the synthesis of steroid hormones. While some cholesterol 
derives from dietary intake, the majority comes from endogenous synthesis in the liver and 
needs to be redistributed to the other organs. TG may also derive from diets or from liver 
synthesis. TG, being esters of a molecule of glycerol and three of fatty acids (FAs), represent a 
way of FAs storage and transport, involved not only in phospholipid formation but also an 
important source of energy for the body. The main lipoproteins involved in TG transport are 
chylomicrons and VLDL: chylomicrons are involved in so-called “exogenous transport” 
(Fig.6), the transport of lipids coming from dietary intake from the intestine to the liver. TG 
composed of long chain FAs are decomposed by gastric and pancreatic lipase to form FAs and 
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2-monoacylglycerols (2-MG). Micellar solubilisation of FAs and 2-MG is essential for their 
uptake by enterocytes. Inside these cells they are transported toward the endoplasmic reticulum 
(ER), probably by the action of FAs-binding proteins. TG are then recreated and, together with 
diet cholesterol, phospholipids and Apolipoprotein B-48 (ApoB-48), are incorporated in 
chylomicrons (Kindel et al., 2010). Short chain FAs TG instead are hydrolysed and FAs are 
transported to the liver bounded to the albumin. While they are flowing into the bloodstream, 
chylomicrons undergo TG hydrolysis by lipoprotein lipases (LPL) bound to the wall of vessels. 
In this manner, FAs are delivered directly to peripheral tissue. As a result, new types of 
molecules are formed called chylomicrons remnants, enriched in cholesteryl esters, ApoB-48 
and Apolipoprotein E (ApoE) and apolipoproteins C, originating from circulating HDL. 
Apolipoprotein A-I (ApoA-I), secreted by the intestine together with chylomicrons, is lost in 
the bloodstream and destined to the HDL surface. The acquired ApoE is essential for the 
absorption of chylomicron remnants by the liver, as through their binding to LDL receptor on 
the liver surface they start the chylomicrons endocytosis internalisation process. Part of the 
cholesterol adsorbed by the liver is then used for bile formation and is redistributed to the 
intestine for digestive processes. In the so-called “endogenous transport” (Fig.6) lipids are 
redistributed from the liver to other organs, following secretion of lipoproteins. TG and 
cholesterol esters are packed into VLDL particles, together with the liver-synthesised 
ApoB100, and releases into the blood circulation (Tiwari et al., 2012). These macromolecules 
contain only a small amount of ApoC, but they rapidly attract many ApoE and ApoC-II on their 
surfaces. The latest apolipoprotein is essential for VLDL metabolism, as it stimulates LPL 
activity inside capillaries. LPL hydrolyses TG inside the VLDL faction, allowing the 
distribution of FAs to peripheral muscles cells, where they are taken up and used for energy 
production, or to adipose cells where FAs are mainly stored. 
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Fig.6 Schematic representation of exogenous and endogenous lipoprotein metabolism (Marais et al., 
2015). 
 
Remaining VLDL have fewer TG, phospholipids and proteins. These molecules can be 
absorbed by the liver or alternatively can remain in the blood circulation where they are called 
VLDL remnants, or IDL, floating in the blood circulation for a short period. IDL can also be 
internalised by the liver, because of the recognition of ApoE and ApoB100 by liver receptors, 
or, if exposed to LPL hydrolysis, can transform into LDL molecules. The smaller and denser 
LDL molecules are mainly composed of cholesterol and they have ApoB100 as unique 
apolipoprotein. As described in the first part of the chapter, if LDL remain in blood circulation 
they become extremely dangerous for cardiovascular health due to their atherogenic potential. 
LDL can be internalised again by the liver through an endocytosis process by LDL-receptor or 
they are absorbed by adipocytes or extra-hepatic cells, where they are used for cell membrane 
as well as for steroid hormone synthesis. Cholesterol intake is also associated with a reduction 
in endogenous cholesterol biosynthesis, in particular through the inhibition on the hydroxyl-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, inhibition of LDL receptor and the 
activation of acyl-coenzyme A cholesterol acyltransferase, which synthesise cholesterol esters 
for lipid storage (Goldstein et al., 2009). The final step in cholesterol metabolism is the so-
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called “reverse cholesterol transport” (RCT), in which cholesterol is removed from peripheral 
tissues and returns to the liver. This process is mediated by the action of the HDL, the smallest 
and densest type of lipoprotein. These small lipoproteins may be secreted by the liver or small 
intestine (~70-80% of total HDL) or alternatively they may form through the action of ApoA-I. 
ApoA-I, representing the skeleton of HDL and 70% of its structure, has a pivotal role in the 
HDL assembly process. This apolipoprotein through its -helix structures has a high affinity to 
lipids and it can attract phospholipids and cholesterol, present in the blood flow or coming from 
cells. ATP- Binding cassette A1 are lipid transporters on cell surfaces, which only in presence 
of ApoA-I can mediate the efflux of cholesterol from cell. This is the rate-limiting step in HDL 
biosynthesis and generates the assembly of nascent HDL, heterogeneous in size, disc-shaped 
and containing 2-4 ApoA-I proteins. Under the stimulus of ApoA-I, Lecithin-cholesterol 
Acyltransferase (LCAT) converts free cholesterol molecules inside nascent HDL into 
cholesterol esters, increasing its hydrophobicity and allowing its redistribution inside the core 
of the lipoprotein. Together with the acquisition of other apolipoproteins, such as ApoA-II, A-
IV, B, C-I and C-II, this process generates the mature form of the HDL. The liver is also 
involved in the production of Cholesteryl Ester Transfer protein (CETP), an enzyme involved 
in the exchange of lipids among HDL and LDL or VLDL. During this process that involves the 
formation of a ternary complex (HDL-CETP-LDL or HDL-CETP-VLDL), cholesterol esters of 
HDL are transported to TG-rich lipoproteins (TRLs), and TG from VLDL or LDL are targeted 
to mature HDL. This process is essential for the release of ApoA-I and the uptake of HDL from 
the liver, as TG-rich HDL are natural substrates for hepatic lipase, promoting HDL clearance 
from blood circulation. The cholesterol absorbed is used for bile acids synthesis and HDL can 
undergo a new cycle upon liver secretion (Zhou et al., 2015). Mainly because of this unique 
role in cholesterol clearance, HDL have been linked for decades to cardioprotective effects.  
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2.2  PROTEIN COMPONENTS: FOCUS ON APOA-I, B, C-III AND E 
The protein components of lipoprotein are called apolipoproteins. Apolipoproteins can be 
described as the proteins associated with lipoproteins, synthesised by the liver or the intestine, 
that increase the solubility of the lipophilic components of lipoproteins. A hallmark of 
apolipoproteins (except for ApoD and Apo[a]) is the presence of highly conserved amphipathic 
-helixes, that facilitate the binding of lipids. Key features of these helices are one face inserted 
among phospholipid tails interacting with the hydrophobic core and the other interacting with 
phospholipid heads, in contact with the aqueous phase (Li et al., 1988; Elliott et al., 2010). 
More than one type of amphipathic helices have been described and variations in the number of 
these helices can define the high or low lipid affinity (Segrest et al., 1992). Unlike other 
apolipoproteins, ApoB has a relatively high content of -sheet chain content, allowing a 
stronger and irreversible binding to the lipid components. In fact, ApoB is the only 
apolipoprotein that is not transferred among the lipoproteins particles (Li et al., 1988). Many 
apolipoproteins also contain additional domains such as signal peptides or receptor-binding 
domain: this is because apolipoproteins are not only structural components of the lipoproteins 
external shell, but they also have many essential roles in lipoprotein metabolism. Some 
apolipoproteins, such as ApoA-I, are needed for the assembly of the lipoproteins in which they 
are embedded. Another possible task performed by apolipoproteins is the regulation of 
enzymatic molecules. Many apolipoproteins can act as cofactor for enzymes and this is the case 
of the already mentioned ApoC-II that positively influences the activity of LPL or ApoA-I 
activating LCAT induced cholesterol esterification. Some other apolipoproteins are instead 
essential for the lipoprotein recognition by cellular receptors, such as ApoB-100 and ApoE 
recognized by LDL receptors.  
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Apolipoproteins are divided into seven classes and some of them have corresponding subclasses: 
 A (apo A-I, apo A-II, apo A-IV, and apo A-V) 
 (a) 
 B (apo B48 and apo B100) 
 C (apo C-I, apo C-II, apo C-III, and apo C-IV) 
 D 
 E 
 H 
 
The above information describes the general common features of apolipoproteins, but it is 
important to note that these are specialised molecules acting on different lipoproteins 
metabolism and guiding in some cases contrasting actions. Therefore, in the following part the 
features of the major and more studied apolipoproteins will be discussed, underlining their 
possible connections with CVD and CAD. 
    
Apolipoprotein A-I. ApoA-I is a protein of 243 amino acids, with an estimated weight of 28 
KDa, generated by APOA1 gene that is located inside the APOA1/C3/A4/A5 gene cluster on 
choromosome11. As described above, ApoA-I is not only a structural component of HDL but is 
also essential for their assembly process. In particular, ApoA-I represents 70% of HDL 
lipoproteins and is the most abundant human apolipoprotein in human blood (Dominiczak et 
al., 2011). The liver and the intestine synthesise it and when lipid-free ApoA-I acquires 
phospholipids and cholesterol they transform into pre-HDL, which contain 2 or 3 molecules 
of ApoA-I per particle. These molecules represent only a minor component of all HDL 
circulating in plasma and they suddenly transform into mature HDL (Rye et al., 2004). ApoA-I 
positively influence cholesterol efflux from peripheral cells and macrophages, through the 
stimulation of the ATP-binding cassette transporter A1 (ABCA1), contributing to the 
cardioprotective action of HDL. However, this important physiological function can be 
impaired by oxidative damage of HDL by myeloperoxidase (MPO) which, generating the 
oxidation of specific tyrosine and methionine residues in ApoA-I, induces the loss of ABCA1 
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stimulation, as observed in ACS patients (Shao, 2012; Rosenson et al., 2016). Moreover, 
ApoA-I also promotes the activity of LCAT and the binding of HDL to scavenger receptor 
class B type I (SR-BI), which are responsible for HDL liver recognition and internalisation. 
The binding of lipid-free ApoA-I to SR-BI was also observed but it seems to take place through 
a weaker interaction.  In particular, it has been demonstrated that this binding happens through 
multiple interactions between -helices of ApoA-I and HDL binding is strictly connected with 
ApoA-I conformation (de Beer et al., 2001). Mainly because of this important function in RCT, 
ApoA-I strongly contributes to HDL cardioprotective effects, even though a recent analysis 
demonstrated that it does not represent a better indicator of CAD events when compared with 
HDL levels (van Capelleveen et al., 2017). The favourable cardiovascular effect of ApoA-I 
plasma levels induced researchers to focus their attention not only on the management of 
cholesterol biosynthesis with statins therapy but also on the stimulation of the RCT, as an 
alternative strategy to combat atherosclerosis. The increase of HDL levels would also promote 
their antioxidant and anti-inflammatory actions. In animal models HDL and ApoA-I 
administration significantly reduced atherosclerosis  (Valenta et al., 2006; Puranik et al., 2008; 
Patel et al., 2010), therefore -helices ApoA-I mimetic peptides have been studied in order to 
simulate Apo A-I physiological functions and to promote cholesterol transport (Leman et al., 
2014). Recent investigations demonstrated discrepancies among in vitro and in vivo effects of 
ApoA-I mimetic peptides administration, highlighting the necessity of further experimental 
studies to better predict and implement their in vivo cardioprotective effects (Ditiatkovski et al., 
2017).  
 
Apolipoprotein B. ApoB represents the framework necessary for the correct assembly of TRLs 
in the liver and in the intestine. While the liver secretes VLDL enriched in Apo B-100, 
chylomicrons secreted by the intestine have ApoB-48embedded on their surfaces. ApoB-48 
corresponds to 48% of the ApoB-100 N-terminal part, and it is produced by a premature stop 
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codon inducing the termination of protein synthesis. ApoB is unique in its ability to associate 
with TG coming from cell stores; this process gives rise to new VLDL lipoproteins that 
normally contain just a single molecule of ApoB. ApoB as well as a substantial pool of neutral 
lipids and the microsomal TG transfer protein (MTP) are key ingredients for the assembly of 
such TG-rich lipoproteins. This process is strictly controlled by the degradation of ApoB co-
translationally or even after complete protein production, through the ER associated 
degradation (ERAD) by ubiquitin proteasome system and autophagy. However, it is still 
unclear if these processes are independent or collaborate for ApoB degradation (Fisher et al., 
2014). Once in blood flow ApoB remains on VLDL, IDL and finally LDL as, because of its 
irreversible binding with lipids, it cannot be exchanged with other lipoproteins. Interestingly, 
ApoB is the only apolipoprotein of the LDL fraction and is therefore essential for their 
recognition by LDL-receptors on cell surfaces. Mutations in the ApoB gene may reduce the 
binding affinity for LDL receptors triggering the development of an important autosomal 
dominant genetic disorder, the familial defective apolipoprotein B-100 (FDB), associated with 
hyperlipidemia and elevated risk for atherosclerosis (Andersen et al., 2016). These processes, 
secretion ApoB process and absorption are extremely important because of their strict 
connection with cardiovascular risk; increased hepatic secretion of ApoB, together with a 
decreased removal from blood circulation, lead to increased ApoB plasma concentration, 
correlated with the onset of the atherosclerotic process and CAD (St-Pierre et al., 2006). As 
mentioned in the first part of the chapter, circulating LDL can undergo oxidative modifications, 
also involving modification of ApoB fragment. Modified ApoB fragments are no longer 
recognised by LDL-receptors but interact with macrophages Scavenger Receptors, leading to 
the formation of the so-called foam cells, and fatty streak development (Witztum et al., 1991). 
This process has also been connected with immune system activation, leading to a rapid 
aggravation of plaque inflammation (Nilsson et al., 2012). 
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It has been discovered that atherosclerotic process seems to be more strictly connected with the 
number of circulating proteins rather than with cholesterol concentration. Accordingly, it has 
been suggested that ApoB could be a better predictor of cardiovascular risk than the content of 
cholesterol in LDL fraction. In the Copenhagen City Heart Study, ApoB was found to be a 
better predictor of cardiovascular events in both genders than LDL cholesterol (Benn et al., 
2007). Later it was proposed that the ratio between fasting ApoB/A-I may be a better indicator 
of acute myocardial infarction risk -as assessed in the INTERHEART study- even when 
computationally inferred from serum total, HDL cholesterol and TG plasma levels (McQueen 
et al., 2008; Raitakari et al., 2013).  
Other recent investigations also focused on the mechanisms to inhibit the synthesis of ApoB, 
using the strategy of antisense oligonucleotides which, having a complementary sequence to 
the ApoB, may promote its degradation, therefore inhibiting LDL production. Mipomersen is 
an FDA-approved antisense oligonucleotide-based drug for homozygous familial 
hypercholesterolemia that reduces ApoB and LDL levels in up to 76% of patients, but the risk 
of adverse effects including hepatotoxicity requires strategies for risk evaluation and 
management (Ellis et al., 2016).  
 
Apolipoprotein C-III. ApoC-III is a small apolipoprotein of just 79 amino acids, synthesised 
mainly by the liver and to a lesser extent by the intestine. ApoC-III gene is located on the long 
arm of chromosome 11, in cluster with ApoA-I and ApoA-V genes and is regulated by many 
factors. Insulin in particular can down-regulate the expression of ApoC-III, through binding to 
the IRE promoter (Insulin Responsive Element) and, as a consequence, ApoC-III expression 
was found to be increased in patients affected by metabolic syndrome (MetS) and type 2 
diabetes, pathologies associated with insulin resistance conditions (Olivieri et al., 2003; 
Kawakami et al., 2009). Down regulation of this protein also occurs through the action of 
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Peroxisome Proliferator Receptors (PPAR), in particular PPAR, following fibrates 
administration (Staels et al., 1995). On the contrary, activator of ApoC-III gene transcription is 
instead the transcription factor NF-B (Ooi et al., 2008). After transcription ApoC-III exists in 
three isoforms: the non-glycosylated isoform (ApoC-III0) and the isoforms with one or two 
molecules of sialic acid (ApoC-III1 and 2 respectively); the distribution of these glycoforms 
was found to be sensitive to the presence of pathological states, such as sepsis or liver diseases 
(Zhang et al., 2012). The presence of fucosylated forms of ApoC-III has also been established 
by mass spectrometry analysis (Nicolardi et al., 2013) 
ApoC-III is associated with Apo-B containing lipoproteins and HDL and undergoes continuous 
exchanges among them. In particular, it is secreted by the liver on VLDL particles and after 
VLDL hydrolysis it is targeted to HDL surfaces, in order to be secreted again on TG-rich 
lipoparticles (Ooi et al., 2008). A higher number of ApoC-III molecules are normally on HDL 
fraction but it has been established that in hypertriglyceridemia conditions ApoC-III is found 
mainly on TG–rich lipoproteins (Huff et al., 1981).  
Many studies have demonstrated the strict connection between ApoC-III and CVD (Sacks et 
al., 2000; Olivieri et al., 2003; Onat et al., 2003). In particular, ApoC-III is an important 
regulator of lipoproteins metabolism and, besides CVD progression, variations in ApoC-III 
levels are strongly associated with the severity of hypertriglyceridemia. ApoC-III is able to 
inhibit LPL activity, impairing TRLs, the formation of lipoprotein remnants and therefore their 
clearance from blood circulation (Wang et al., 1985) (Fig.7). In addition ApoC-III is 
responsible for the inhibition of the hepatic lipase, so reducing the possibilities of TRLs uptake 
by the liver (Kinnunen et al., 1976; Ooi et al., 2008). Moreover, the impaired uptake of 
lipoproteins by the liver is caused by ApoC-III inhibition of ApoB and ApoE binding to liver 
surface Low Density Lipoprotein Receptor (LDLR) and Low density Lipoproteins receptor- 
related protein 1 (LRP-1) (Fig.7) (Gordts et al., 2016). It has been demonstrated that ApoC-III 
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has the ability to stimulate the secretion of VLDL from the liver cells, increasing the amount of 
plasma TRLs (Ooi et al., 2008). It is important to note that not only are LDL levels risk factors 
for CVD but also TRLs remnants can penetrate in the intima layer of vessels and contribute to 
atherosclerotic process development (Nordestgaard et al., 2014).  
 
 
Fig.7 ApoC-III plasma effects, contributing to the associated hypertriglyceridemia (Gordts et al., 2016). 
This evidence linking ApoC-III with TG plasma levels agrees with genome-wide association 
studies, where the role of ApoC-III gene polymorphisms was investigated. In particular, the TG 
and HDL Working Group of the Exome Sequencing Project reported that loss-of-function 
mutations on ApoC-III gene caused a reduction in ApoC-III levels together with decreased 
plasma TG levels (lower than 39% in carrier compared to non-carrier) and decreased CAD risk 
(Crosby et al., 2014). On the contrary, genetic variants increasing ApoC-III levels have been 
associated with higher plasma TG contents and increased CVD risk (Olivieri et al., 2002). 
Besides its role in VLDL secretion and clearance, connected with TG plasma content, ApoC-III 
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seems to be connected with the atherosclerotic process by many other direct mechanisms, such 
as the activation of NF-B, expression of VCAM-1 and Intracellular adhesion molecule-1 
(ICAM-1) and recruitment of monocytes to the artery wall (Kawakami et al., 2006; Kawakami 
et al., 2007). Finally, ApoC-III was positively linked to the coagulation process, also involved 
in the progression of atherosclerotic process (Olivieri et al., 2013). Recently the Bruneck study 
confirmed the association of ApoC-III with CVD and also with MI and stroke (Pechlaner et al., 
2017). Taken together, all this evidence highlights the strong and direct link existing between 
ApoC-III plasma levels and CVD and suggests ApoC-III as a possible therapeutic target for 
lowering VLDL levels and preventing CVD.  For many years the therapies used to decrease 
CVD risk were aimed at reducing only LDL cholesterol levels, considered the most dangerous 
risk factor. Even though this approach remains effective, many patients continue to be at high 
residual cardiovascular risk, therefore targeting ApoC-III to reduce cardiovascular risk has 
become the new challenge. Many molecules have been employed, including fibrates, n-3 FAs 
and statins. Antisense inhibition of ApoC-III synthesis by means of the Volanesorsen is 
currently in phase III study (Khetarpal et al., 2016). Recent evaluations of its therapeutic effects 
reported that approach reduced ApoC-III levels by more than 75% and there was a concurrent 
50% decrease in plasma TG content (Pechlaner et al., 2017). These results highlighted the 
importance in ApoC-III targeting in CVD risk patients and opens the road to the use of new 
therapeutic approaches.  
Apolipoprotein E. ApoE is a protein of 299 amino acids and a potent modulator of plasma 
lipoprotein and cholesterol concentration. Liver cells account for 75% of total ApoE 
production, while the remaining portion is synthesised by many other organs such as the brain, 
spleen and kidneys but also macrophages and adipocytes where it is involved in lipid 
homeostasis (Dose et al., 2016). ApoE is present in a wide range of lipoproteins: chylomicrons, 
VLDL, IDL and in particular 60% are on HDL surfaces. It is therefore involved both in the 
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exogenous and endogenous lipoprotein pathways. It has an important structural role for 
lipoproteins and facilitates their solubility in blood circulation. However, its fundamental 
function is in lipid metabolism which derives from its ability to bind lipoprotein receptors such 
as LDLR and LRP (Dominiczak et al., 2011). Furthermore, lipid-bound ApoE is able to 
promote cholesterol efflux from peripheral cells through the stimulation of SR-B1, promoting 
RCT (Chroni et al., 2005). This function is particularly important in macrophages, where ApoE 
prevents foam cells formation. It also stimulates LPL, hepatic lipase and LCAT activity. 
Therefore, ApoE is absolutely involved in lipoprotein metabolism and explains about 20-40% 
of TG plasma levels variability (Dominiczak et al., 2011). Many other atheroprotective ApoE 
mechanisms have been described for their ability to inhibit platelet aggregation, the inhibition 
of SMC proliferation and the down regulation of VCAM-1 (Greenow et al., 2005). ApoE 
knockout mice have been widely used as a model for in vivo studies on CVD because they 
develope atherosclerosis (Meir et al., 2004). However, these studies also highlight many other 
functions of ApoE, not only related to lipid metabolism. Knockout mice developed 
neurological disorders, type II diabetes, defects in immunity response, age-related features and 
elevated marker of oxidative stress (Hayek et al., 1994; Roselaar et al., 1998; Robertson et al., 
2000). Further in vivo studies revealed the antioxidant properties of ApoE, which is also 
isoform dependent (Miyata et al., 1996). ApoE has in fact three main isoforms E2, E3 and E4 
which, despite differing by only one amino acid at positions 112 or 158, behave quite 
differently.  It was reported that the distribution of these three variants is in the range from 0 to 
20% for E2, 60-90% for E3 (the most common isoform) and 10-20% for E4 (Singh et al., 
2006). The E4 isoform is associated with a decrease in its anti-oxidant activity and in general 
with a decreased response to stressors. E2 isoform differs for its lower affinity for the LDLR, 
having only 1% of the binding capacity shown by the other two isoforms. Due to this feature, 
ApoE2 has been connected with increased levels of plasma cholesterol and TG, causing type III 
hyperlipoproteinemia onset (Weisgraber et al., 1982). In particular, it has been observed that 
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while ApoE2 is connected with decreased levels of ApoB and cholesterol but increased levels 
of ApoE and TG, on the contrary ApoE4 is linked with increased ApoB and cholesterol and 
decreased ApoE levels: this is because the latter isoform is present mainly on TRLs 
accelerating their uptake and the consequent down-regulation of LDLR expression, increasing 
plasma LDL levels (Greenow et al., 2005). Compared to E3 the isoform E4 showed to be 
associated to the 42% increase in cardiovascular risk (Song et al., 2004). 
The evidence mentioned above highlight the ApoE actions that can affect either indirectly, 
acting on receptors, and directly, acting on enzymes and cells involved in the atherosclerotic 
process. Isoforms of this protein need however to be considered as they also have important 
consequences on CVD and neurodegenerative diseases.  
 
 
3. CAD RISK FACTORS 
Due to the high incidence of CVD and in particular of CAD, the study of cardiovascular risk 
factors has been carried out for a long time. The first study analysing elements involved in this 
pathology started in 1948 and was called the Framingham Heart Study (Dawber et al., 1951). 
Since then many interconnected cardiovascular risk factors, contributing to the progression of 
the atherosclerotic process, have been identified. CVD has been described as the most complex 
human disease, due to the interplay of a high number of risk factors involving genes, lifestyle 
and environment (Messner et al., 2014). The WHO listed cardiovascular risk factors as follows 
(Mendis S., 2011): 
Behavioural risk factors: 
1. Smoking: cigarette smoking represents one of the most important and preventable 
cardiovascular risk factors. The WHO estimated that tobacco smoking is responsible for 10% 
of all deaths caused by CVD (WHO, 2012). It seems that it is not the presence of a single 
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compound that provokes adverse health effects, but rather the complex mix of compounds 
used. The interaction between the effects of these compounds and genetic predisposition 
determines the onset of the pathology. Many mechanisms contributing to smoking’s adverse 
effects have been discovered and they are mainly related to the early steps of the atherosclerotic 
process. Smoking is responsible for vascular dysfunction, reduced NO production, increased 
expression of adhesion molecules and adherence of platelets (Messner et al., 2014). Moreover, 
it has been associated with the prothrombotic and the inflammatory process, as reflected by the 
increased levels of C-reactive protein and fibrinogen in smokers (McEvoy et al., 2015).  
 
2. Physical inactivity: a sedentary lifestyle is closely associated with the onset of cardiovascular 
events and its connection with obesity development. Guidelines for proper cardiovascular 
prevention suggest mild but regular physical activity. Studies on mice revealed that physical 
inactivity contributes to ROS production in the endothelium and the media of blood vessels. 
This event triggers endothelial dysfunction and atherosclerosis (Laufs et al., 2005).  
 
3. Harmful use of alcohol: alcohol consumption has been described as a “double-edged sword” 
because of its different effects depending on dose consumption (Massaro et al., 2012). Many 
studies have revealed that low levels of alcohol intake are inversely associated with total 
mortality but at high doses its healthy effects are overcome by the widely recognised adverse 
consequences, particularly increased pressure levels (Di Castelnuovo et al., 2006; Foerster et 
al., 2009).  
 
Metabolic risk factors: 
4. Hypertension: treatments aimed at reducing high blood pressure are among the most 
effective and used for the prevention of cardiovascular outcomes. An interplay between 
hypertension and diabetes has recently been observed, as hypertension is approximately twice 
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as frequent in patients with diabetes compared with patients without the disease (Sowers et al., 
2001).  
 
5. Diabetes: diabetes mellitus is a chronic state of hyperglycemia. It has been reported that 
CVD is the leading cause of death among people suffering from diabetes (>50%). There are 
two forms of diabetes: type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). 
The risk of cardiovascular events is particularly high in T1DM patients, particularly in patients 
under 40, who present a risk >10 fold higher than that of the general population. T2DM 
patients instead have threefold to fourfold increased risk of cardiovascular mortality. The 
general pathophysiology of the atherosclerotic process is the same as in the normal population, 
but insulin resistance and hyperglycemia contribute with unique characteristics to the process 
by impairing endothelial function, triggering low-grade inflammation, thrombosis fibrinolysis 
and modification of lipoprotein particles (Laakso et al., 2014). 
 
6. Dyslipidemia: the term dyslipidemia refers to the abnormal amount of lipids (cholesterol, TG 
or phospholipids) inside blood flow. This risk factor is therefore representative of many 
different pathological conditions that differ in their etiology and in their contribution to CVD 
onset. A detailed report of dyslipidemia conditions will be discussed in the following chapter.  
 
7. Being overweight and obesity: obesity is an important factor of CVD. Atherosclerosis and 
obesity are shown to share common pathological features. While for many years scientists 
believed that both these conditions were caused just by lipid accumulation, today it is evident 
they are both inflammatory processes, involving the activation of immune cells, cytokine 
production and cell death. Adipokines released by adipocytes induce many events, such as 
endothelial dysfunction, inflammation and insulin resistance, that can stimulate atherosclerosis 
development (Rocha et al., 2009).  
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Other risk factors: 
8. Poverty and low educational status: it has been described that poverty, as well as social 
stress or living alone, can promote CVD onset. Mental stress is strictly connected with 
oxidative and hemodynamic stress, as in this condition ROS production is increased and 
atherosclerotic process aggravated (Inoue, 2014).  
 
9. Advancing age:  the atherosclerotic process may start its evolution in the early phase of life 
but with the passing of time it can develop and progress. Many age-related processes have been 
connected with atherosclerosis evolution, such as ROS production and DNA damage (Niccoli 
et al., 2012).  
 
10. Gender: despite women sharing the same cardiovascular risk factors with men, it is well 
known that they have a decreased cardiovascular risk compared to men and they are protected 
from cardiovascular events until older age (Vaccarino et al., 2011). Many studies have 
investigated sex differences in CVD risk, also focusing on genetic differences (Winham et al., 
2015). Different elements able to diversify men and women have been identified, such as 
hormone influence, artery size – being smaller in women, it allows a prompt diagnosis - and a 
different propensity to risk-associated behaviours, such as smoking or excessive alcohol 
consumption (Spence et al., 2015).  
 
11. Inherited (genetic) disposition: the association between increased personal cardiovascular 
risk and a family history of CVD represents strong evidence underlining the important role of 
genetic factors in the onset of CVD. Due to the advance in sequencing technology, over the last 
decade many Genome Wide Association Studies (GWAS) have been performed in order to 
elucidate genetic variants associated with specific CVD and also with their risk factors (Smith 
et al., 2015). Many loci involved in the development of these diseases have been identified: for 
35 
 
example, loss of function mutations in APOC3 gene have been connected with a decrease in 
plasma TG levels and cardiovascular risk (Crosby et al., 2014).  
 
12. Psychological factors:  Growing evidence suggests that these factors, including stress and 
depression, are closely involved in the onset of cardiovascular events, especially for women. 
Depression is more prevalent in women than in men and affects 40% of young women with MI. 
Not only depression, but also anxiety, maternal stress and exposure to early life adversities are 
associated with cardiovascular outcomes. Finally, circumscribed events, such as sudden anger 
and stressful events can trigger MI or sudden cardiac death in predisposed subjects (Vaccarino 
et al., 2011).  
 
3.1 DYSLIPIDEMIA 
Described for the first time by Fredrickson in 1965, dyslipidemia is a term referring to lipid 
disorders involving different lipid types (Fredrickson et al., 1965). Knowledge of the 
concentration of cholesterol and TG levels permits the identification of three different types of 
hyperlipidemia: high cholesterol levels, high TG levels and high cholesterol and TG levels in 
the same condition. However, as plasma lipids levels are strictly connected with the amount of 
circulating lipoproteins, many dyslipidemias are connected to lipoproteins disorder, so called 
hyperlipoproteinemias, and so a classification based on lipoprotein levels, rather than lipids 
alone, offers more information. Despite hyperlipoproteinemias having been studied in depth 
over the last 50 years, as they are extremely and directly connected with cardiovascular 
outcomes, their classification still remains inspired by that of Fredrickson (Beaumont et al., 
1970):  
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 Type I: also known as Hyperchylomicronaemia, it is connected with an increased 
content of TG coming from diet and therefore with an increase in  chylomicrons plasma 
content.  
 Type II: this type of hyperlipoproteinemia is connected to an increase in LDL 
cholesterol plasma content (type IIa) and is also called hypercholesterolemia. This 
condition is associated with a 10 to 13-fold increase in the risk of CVD and derives 
mainly from genetic disorders. Common causes are mutations on LDL receptor, APOB 
or proprotein convertase subtilisin/kexin type 9 genes, despite many  individuals with 
familial hypercholesterolemia phenotype having polygenic instead of monogenic 
mutations causing hypercholesterolemia (Santos et al., 2014). When the increase in 
LDL cholesterol levels is also associated with an increase in VLDL plasma levels, and 
therefore in TG content, this condition is called type IIb hyperlipoproteinemia. 
 Type III: this condition is accompanied by an increase in VLDL remnants, the IDL. 
These lipoproteins derive from VLDL and are denser and richer in cholesterol content.   
 Type IV: this hyperlipoproteinemia can be described as an increase in VLDL content 
when plasma LDL are in the normal range and chylomicrons are nearly absent.. 
Because of the increased VLDL, there is an increase in TG plasma levels. This 
condition, called hypertriglyceridemia, is strictly connected with CVD onset. For many 
years major efforts to prevent CVD have been made to reduce LDL cholesterol levels, 
e.g. with statin therapy. However, it has been established that  an increase in TG plasma 
levels, in particular greater than 10 mmol/L can possibly lead to cardiovascular events 
(Nordestgaard et al., 2014). In fact,  as previously mentioned, TG in plasma can trigger 
the atherosclerotic process similarly to LDL (Schwartz et al., 2012).  
 Type V: hypertriglyceridemia can derive also from this last type of 
hyperlipoproteinemia, caused by an increase in VLDL concurrent with an increase in 
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chylomicrons. Increased TG derive therefore both from the exogenous and endogenous 
lipoprotein pathways.  
Tab. I Fredrickson classification of dyslipidemias (Beaumont et al., 1970) 
 
Due to their different etiology, dyslipidemias can be divided into primary dyslipidemias, 
derived from a genetic defect, or secondary dyslipidemias, caused by lifestyle and unhealthy 
habits. Among secondary dyslipidemias there are also cases of genetic predisposition followed 
by incorrect dietary habits. Aside from the familiar predisposition, food intake and the 
consumption of specific FAs plays a major role in dyslipidemia onset and CVD outcomes.  
 
3.2 FATTY ACIDS INTAKE  
The relationship between FAs and cardiovascular health has been widely investigated for many 
decades and a special emphasis has been given to the impact of dietary FAs on plasma levels of 
lipids and lipoproteins (Hegsted et al., 1993; Michas et al., 2014). Omega3 polyunsaturated 
fatty acids (n-3 PUFAs) have attracted growing attention over the last decade as they have 
gained a prominent position, presumed to be one of the healthiest nutrients. Anti-atherogenic, 
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anti-arrhythmic and anti-inflammatory effects of n-3 PUFAs, as well as their inverse 
association with death resulting from cardiovascular diseases, have been established (De 
Caterina, 2011). n-3 PUFAs, through the activation of PPAR (Schoonjans et al., 1996), are 
effective in the reduction of TG plasma levels (Ito, 2015). In 2002 the American Heart 
Association  recommended n-3 PUFA for patients with ischemic heart disease and subjects 
with hypertriglyceridemia, although some recent studies on patients with multiple 
cardiovascular risk factors and meta-analysis have questioned their real clinical usefulness for 
major cardiovascular outcomes (Rizos et al., 2012; Roncaglioni et al., 2013).  
In addition to n-3 PUFAs, other FAs are involved in the regulation of lipid profile and 
cardiovascular risk. Generally, it has been proposed that mono- and poly-unsaturated fatty acids 
(MUFA and PUFA respectively) lower total and LDL-cholesterol, when replacing saturated 
fatty acids (SFA) and carbohydrates, with the latest ones having a stronger effects (Mensink et 
al., 2003; Mensink, 2016). MUFA in particular has been shown to increase the secretion of 
ApoC-III and ApoE containing VLDL and to decrease at the same time the secretion of other 
more slowly metabolised TRLs, a major precursor of LDL, while reducing their flux to LDL 
(Zheng et al., 2008). On the other hand SFA and trans unsaturated FA (TFA) - in particular 
those derived from industrial partially hydrogenated oils- increase ApoB, total and LDL-
cholesterol and TG (Mensink, 2016; Mozaffarian, 2016). Accordingly, it has been suggested 
that replacing SFA and TFA with unhydrogenated, monounsaturated and polyunsaturated fats 
may be more effective in preventing CVD, even more than reducing overall fat intake (Hu et 
al., 1997; Mensink et al., 2003). In particular, reduction in SFA consumption to under 10% of 
total energy intake remains a regular WHO recommendation for cardiovascular prevention 
(Mensink, 2016; Zong et al., 2016). 
Concerning the influence on cardioprotective HDL cholesterol levels, studies replacing 
carbohydrates intake with different FAs type, showed that HDL levels were raised by MUFA, 
PUFA and in particular SFA. Apo A-I levels are also increased after carbohydrates substitution 
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with SFA (Mensink et al., 2003; Mensink, 2016). In contrast, TFA have been reported to exert 
an HDL-and plasmatic Apo A-I lowering effect (Matthan et al., 2004).  
Although the role of FA intake on CVD has been widely investigated, some limitations to these 
studies exist: 
i. The effects of dietary fat quality on health, intermediate phenotype, and subsequent 
disease incidence are difficult to investigate in intervention studies, partly because of 
short study durations. Moreover, such trials usually replaced FAs with carbohydrates 
(Mensik et al., 2003), thus intrinsically altering the related metabolic pathways (high-
carbohydrate diets are known to induce dyslipidemia (Lichtenstein et al., 1998). 
ii. On the other hand, in epidemiological and observational studies the assessment of 
dietary FAs intake from different food sources with the use of food frequency 
questionnaires is potentially biased by substantial measurement errors (Warensjo et al., 
2008; Niknam et al., 2014). 
iii.  Furthermore, most of these studies considered the dietary intake of general FA classes, 
i.e. SFA, MUFA, and PUFA, while the distinct effects of the singles FAs, which may be 
biochemically highly heterogeneous even within the same category, were not taken into 
account and remained elusive and very difficult to disentangle. 
 
 
4. IN VIVO STUDIES ON MYRISTIC ACID ROLE IN CAD       
SFAs intake represents a well-known risk factor for CAD and their replacement with 
unsaturated FAs has been associated with a decreased cardiovascular risk. However, SFA are a 
heterogeneous FA species that differ in their structure, function and source, and recent studies 
have demonstrated that single SFAs also have different effects on plasma lipids as well as on 
subclinical inflammation (Zong et al., 2016; Santaren et al., 2017). Potential protective effects 
have been observed for odd chain SFA and very-long chain SFA (VLSFA), while shorter chain 
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SFA have been positively associated with proinflammatory markers and to incident type 2 
diabetes (Forouhi et al., 2014; Santaren et al., 2017). Myristic acid is a 14-carbon saturated 
(C14:0) FA and is a major component of diary fats as well as of coconut oil, nutmeg, butter and 
palm oil. First studies on the role of individual FAs described C14:0 as the most potent 
saturated FA. They reported the high cholesterolemic effects of C14:0, even in comparison 
with palmitic acid (C16:0) and oleic acid (C18:1) (Katan et al., 1994; Zock et al., 1994; Kris-
Etherton et al., 1997). In particular, it was shown to raise both total and LDL cholesterol when 
substituted for C16:0 and C18:1. The same effects on total and LDL cholesterol were observed 
years later in large meta-analysis when carbohydrates constituting 1% of dietary energy intake 
were replaced with C14:0 (Mensink et al., 2003; Mensink, 2016). The intake of C14:0 has been 
also associated with elevated risk of CAD development (Johnson et al., 1998; Zong et al., 
2016). Accordingly, it has been reported that risk for CVD, myocardial infarction and stroke 
can be decreased by reducing the intake of C14:0, palmitate and simple carbohydrates and 
improved by a greater intake of linoleic acid and marine n-3 FAs (Ebbesson et al., 2015). A 
moderate intake of C14:0 together with alpha-linolenic acid has however been associated with 
a positive increase in LCAT activity that promotes cholesterol efflux from peripheral tissues 
(Vaysse-Boue et al., 2007). MetS is represented by the concurrent presence of different medical 
conditions (such as high blood pressure, high TG plasma levels, obesity and high blood sugars) 
and is considered a risk factor for CVD onset (Galassi et al., 2006). Higher proportions of 
C14:0 plasma levels were found in people with MetS compared to healthy controls, and high 
proportions of C14:0 as well as of C16:0 were associated with adverse profiles of several 
metabolic risk factors (Mayneris-Perxachs et al., 2014). However, a recent investigation 
showed the association of C14:0 with decreased risk of T2DM (Ericson et al., 2015). Moreover, 
in recent population–based studies C14:0 has been associated with the increase of inflammatory 
markers, including fibrinogen and C-reactive protein (Santos et al., 2014; Santaren et al., 2017). 
However, only few studies focused their attention specifically on C14:0 effects on lipids and 
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lipoproteins levels. One of these studies demonstrated that meals enriched with C14:0 resulted 
in a higher increase in postprandial HDL TG plasma levels than meals enriched with stearic 
acid (C18:0); furthermore in the same study higher levels of HDL cholesterol 24 hours after the 
C14:0-enriched meal were reported (Tholstrup et al., 2003). This result is in contrast with a 
recent study on a Mediterranean population, in which C14:0 was found to be strongly 
associated with decreased plasma HDL-C levels (Noto et al., 2016). It was demonstrated that 
this inverse correlation could be explained with the C14:0 ability to increase HDL trapping to 
cell surface heparan sulphate proteoglycans in the liver and the consequent highest 
internalisation of HDL-derived cholesteryl esters. These recent findings revealed that, despite 
decades of investigation into the role of FAs in cardiovascular health, some of their 
cardiovascular effects - and in particular some effects of the less-studied C14:0 - remain to be 
disclosed. 
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CHAPTER 2 
IN VIVO INVESTIGATION OF POSSIBLE NEW ASSOCIATIONS 
BETWEEN CARDIOVASCULAR RISK FACTORS:                                 
THE EMERGING ROLE OF MYRISTIC ACID  
 
 
1. INTRODUCTION 
The purpose of the present research project has been to discover new possible associations of 
FAs with lipids and apolipoprotein levels, to disclose potential underlying mechanisms related 
to the development of CAD.  
This in vivo investigation of possible new associations between cardiovascular risk factors 
represented a broadening of my master’s degree thesis, where these correlations were 
investigated in a limited number of subjects previously enrolled in the Verona Heart Study 
(VHS). VHS is an ongoing project which started in 1996 with the aim of creating a biobank of 
plasma samples to research and shed light on cardiovascular risk factors.  In particular, 57 CAD 
patients had been enrolled in that exploratory research and for each of these patients lipid (TG, 
HDL, LDL and total cholesterol) and apolipoprotein (ApoA-I, A-V,B,C-III and E) levels as 
well as LPL activity and iron-metabolism related parameters (iron, ferritin, transferrin and 
hepcidin) were measured and statistically analysed to evaluate their possible correlations. The 
most interesting correlations emerging from that exploratory research were related to classical 
cardiovascular risk factors. A SFA, C14:0, showed interesting positive correlations with 
parameters connected with the onset of CVD (TG, ApoB and ApoC-III) and negative 
correlations with cardioprotective elements (HDL, ApoA-I and ApoA-V). Because of these 
interesting and unexpected correlations, related to classical risk factors - rather than new risk 
factors such as iron parameters - the present research was aimed at deepening the influence of 
C14:0 on lipid and apolipoproteins metabolism. 
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The analysis has been expanded to a larger cohort of subjects (n=1,370), to further investigate 
the relationships between plasma FAs and parameters related to lipid metabolism, and to 
validate and strengthen the previous C14:0 correlations observed in the restricted group of VHS 
subjects.  
This phase of the project was possible thanks to a collaboration with the Laboratory of Genetic 
and Non-Genetic Risk Factors for Atherothrombotic Disorders, Department of Medicine, 
present at the LURM (University Laboratory of Medical Research) research centre of The 
University of Verona.   
In this phase of the study a higher number of subjects enrolled in the VHS was selected and 
major FAs levels were analysed in the plasma sample of each patient by means of plasma FAs 
extraction and subsequent gas-chromatographic analysis. Correlations between all FAs and 
lipid and apolipoprotein (ApoA-I, B, C-III and E) were evaluated and regression analyses were 
used to deepen the relationships among significantly correlated lipids and FAs and to 
disentangle the most relevant relationships of dependency.   
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2. EXPERIMENTAL DESIGN AND PROCEDURES 
The gas-chromatographic analyses of fatty acids and the statistical tests were performed thanks to the 
kind collaboration of Prof. Oliviero Olivieri’s and Prof. Nicola Martinelli’s laboratory (Laboratory of 
Genetic and Non-Genetic Risk Factors for Atherothrombotic Disorders), Department of Medicine, 
University of Verona. 
 
 
2.1 Study subjects 
Plasma samples were obtained from 1,370 subjects previously enrolled in the VHS, in 
collaboration with the University Hospital of Verona (AOUI). Details on the enrolment criteria 
have been described in previous VHS publications (Girelli et al., 1998; Olivieri et al., 2003). 
Patients that were candidates for coronary artery bypass grafting, with angiographically 
documented severe multivessel coronary atherosclerosis at the time of sampling, were gathered 
in the CAD group. In the control group (CAD-free group) subjects with angiographically 
documented normal coronary arteries were enrolled. These patients had been examined for 
reasons other than possible CAD and were required to have neither history nor evidence of 
atherosclerosis in vascular beds. For this project 1,370 samples from the VHS biobank were 
chosen: 1,004 samples were selected from the CAD group of patients, while 366 belonged to 
the group of CAD-free subjects. Both CAD patients and controls came from the same 
geographical area (Northern Italy), with a similar socio-economic background. Oral or written 
informed consent was obtained at the time of sampling for every subject after a full explanation 
of the study. A complete clinical history, including cardiovascular risk factors such as smoking 
and hypertension, was gathered for all participating subjects.  
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Overnight fasting plasma samples were collected in Vacutainer tubes containing 
ethylenediaminetetraacetic acid (EDTA) as anticoagulant. Plasma samples were centrifuged at 
3500 rpm at 4°C for 15 minutes, to remove cellular components, and stored at -80°C until use, 
as indicated in the following experimental design (Fig.1).  
Fig.1 Experimental design.  
 
 
 
 
1004 CAD 
enrolled in theVHS
366 CAD-free 
enrolled in the VHS
methanol
acetyl chloride
hexane
FAs
Total, LDL, HDL cholesterol, TG
ApoA-I,ApoB,ApoC-III, ApoE
Fatty Acids plasma levels
Correlation and 
regression analyses
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2.2 Clinical chemistry analyses of plasma lipid parameters  
Plasma lipid parameters, including TG, HDL, LDL and total cholesterol, as well as ApoA-I, 
ApoB, ApoC-III and ApoE parameters were determined as previously described (Girelli et al., 
1998) by the Analysis Laboratory of the University Hospital of Verona. Plasmatic ApoC-III 
was measured by a fully automated turbidimetric immunoassay. The reagents (catalog number: 
KAI-006) were obtained from Kamiya (Seattle, WA, USA), and the procedure described by the 
manufacturer was implemented on a COBAS auto analyzer e501 (Roche). Precision was 
assessed on three pools of control sera with low, medium and high ApoC-III values. 1.8%, 
2.02% and 1.98% intra assay coefficient of variation (CV) and 4.4%, 3.4% and 2.29% inter 
assay CV were maintained. Plasmatic ApoA-I, ApoB and ApoE were measured by a 
nephelometric immunoassays on a nephelometer BNII Siemens (Dade Behring, Murbyrg, 
Germany). Intraassay CV -calculated on 10 control replicates- were 2.1%, 1.6% and 1.98%, 
while interassay CV –determined measuring duplicates over 10 days- were 3.2%, 2.36% and 
3.98% for ApoA-I, ApoB and ApoE, respectively. 
 
2.3 Gas-chromatography analysis of plasma fatty acid levels 
Levels of plasmatic FAs were measured as previously described (Martinelli et al., 2008). In 
particular, FAs were extracted from 100 l of plasma sample by means of a direct 
transesterification reaction by adding 2 ml of reaction mix containing 1.9 ml of methanol and 
100 l of acetyl chloride (Lepage et al., 1984). 2,6-di-ter-p-cresol/L (BHT)(Sigma-Aldrich) 
was added to each vial as an antioxidant agent. The transesterification reactions were carried 
out for one hour at 100°C. To each cooled sample 1 ml of water and 1 ml of hexane were added 
and, after two minutes of centrifugation at 2500 rpm, the upper hydrophobic phase containing 
esterified FAs was collected, dried in a SpeedVac system, resuspended in 0.5 ml of hexane and 
transferred into a glass vial for further analysis. Gas-chromatography was performed by using a 
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Hewlett-Packard 5980 chromatograph, equipped with an HP-INNOWax Polyethylene Glycol 
column. Detailed instrumental conditions are reported below: 
Column: HP-INNOWax Polyethylene Glycol 30.0 m x 250 µm x 0,25 µm phase column, 
Agilent 
Gas carrier: Helium 
Solvent: Hexane 
Oven starting temperature: 150 °C 
Temperature increase: 1 °C/min 
Oven final temperature: 230 °C for 90 min 
Pressure of carrier: 31.39 psi 
Column flux: 29.4 ml/min 
Detector: FID-Flame Ionisation Detector  
Hydrogen flux for FID: 30 ml/min 
Air flux for FID: 400 ml/min 
FID temperature: 300 °C  
Injection volume: 5 l 
Injection type: on-line 
Injector: split 
Split ratio: 1:10 
He Split Flow: 24.3 ml/min 
 
Peak identification was done using commercially available reference FAs (Sigma, St Louis, 
MO). Three vials containing 100 l of the standard mix solution were processed in parallel to 
every analysed series of plasma samples. The comparison of the retention time of the peaks in 
the standard mix run with retention times in the samples permitted the reliable identification of 
each FA. To quantify FAs, a known amount of C19:0 –FA with an odd number of carbon 
atoms, not present in biological samples- was used as internal standard in all samples. The 
peaks areas were measured and subsequently quantified using HP-3365 Chem Station 
software (Hewlett Packard). The estimations of FAs concentrations were performed 
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normalizing the intensity of each peak with the intensity of the internal standard with a known 
concentration. Moreover, the concentrations of each single FA were estimated by comparing 
the peak intensity in the sample with the intensity of the corresponding peak in the standard 
mix of FAs with known concentrations. In particular, this estimation was performed as follows, 
by means of a specific factor related to the FA in the standard mix: 
 
 
Where: 
Csample: concentration of the FA in the plasma sample (g/ml of plasma) 
Cst: concentration of the FA in the standard mix (g/ml of plasma) 
hst:  height of the FA peak in the standard mix 
hC19st: height of the C19:0 (internal standard) peak in the standard mix of FAs 
hsample: height of the FA peak in the plasma sample 
hC19sample: height of the C19:0 (internal standard) peak in the plasma sample 
 
 
The levels of each FA were expressed as g/100 g total FAs methyl esters (% by wt). Each 
sample was analyzed in duplicate and all CV were <5%. 
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2.4 Statistical analysis 
The SPSS software version 22.0 statistical package (IBM Corporation, Armonk, USA) was 
used to perform statistical analyses. Continuous variables were expressed as mean ± standard 
deviation (SD). Variables showing a skewed distribution (e.g. TG, ApoC-III and ApoE) were 
logarithmically transformed and therefore expressed as geometric mean with 95% confidence 
interval (95% CI). The correlations between plasma lipid parameters and FA profile, as well as 
among FAs levels, were analysed by Pearson’s test. The correlations were evaluated in total 
subjects, as well as in population stratified on the basis of CAD pathology (CAD and CAD 
free), sex (male and female) and age (< 62 and > 62 years old).  
The SIMCA 13.0 (Umetrics) software was used to perform the Principal Component Analysis 
(PCA). PCA was applied in order to obtain an overview of the results and get some insights on 
the data structure, clustering and correlations. All variables were autoscaled before performing 
PCA. The autoscaling procedure transforms the variables so that they all have a null average 
value and a unit variance: this last feature is fundamental since it allows all the variables to 
bring the same amount of information to the overall dataset. With the aim to perform a more 
comprehensive analysis, at first a regression model with backward stepwise selection of 
variables (including all the FAs showing significant correlations at univariate analysis) was 
performed and then a regression model with forward stepwise selection of variables, estimating 
R
2
 modification, with the aim to identify the best predictive variables. Linear regression models 
were also adjusted for potential confounding factors like sex, age, diabetes, diagnosis, lipid 
lowering therapy and body mass index (BMI). Addressing our interest in C14:0, the study 
population was stratified according to C14:0 quintiles. The distribution of variables across 
C14:0 quintiles were assessed by ANOVA with polynomial contrasts for linear trend or by 2-
test for linear trend. A p-value < 0.05 was considered significant. 
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3. RESULTS 
 
3.1 Clinical characteristics of the studied population 
For all patients involved in the present study, data concerning sex and age were collected at the 
time of blood sampling. All data, in particular age and BMI, refer to the specific moment of 
blood sampling. Mainly middle-aged subjects were enrolled in the study (Tab. I). 
 
 
 
 
 
 
 
 
Tab. I Mean clinical characteristics of the VHS patients included in the present study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Total 
Population 
(n=1,370) 
Age (years) 60.6 ± 11 
Male sex (%) 75.8% 
Diabetes 15.2% 
BMI (kg/m
2
) 25.9 ± 4.6 
CAD diagnosis 73.3% 
Lipid Lowering Therapy 22.6% 
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3.2  Lipid profile and apolipoprotein levels of the studied population 
Characterisation of the lipid profile included TG, HDL, LDL and total cholesterol plasma 
levels. Mean values of these parameters in the whole population are reported in Tab. II.  
Together with lipid parameters, levels of Apo-I, ApoB, ApoC-III and ApoE were also 
measured.  
 
 
 
 
 
 
 
 
 
 
 
Tab. II Mean values related to lipid and apolipoprotein parameters in the whole studied population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Population 
(n=1,370) 
Total cholesterol (mmol/L) 5.49 ± 1.15 
HDL cholesterol (mmol/L) 1.25 ± 0.35 
LDL cholesterol (mmol/L) 3.64 ± 0.98 
Triglycerides (mmol/L) 1.61 (1.57-1.64) 
ApoA-I (g/L) 1.31 ± 0.27 
ApoB (g/L) 1.12 ± 0.30 
ApoC-III (mg/dL) 10.8 (10.6 – 11.0) 
ApoE (g/L) 0.041 (0.040- 0.042) 
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3.3 Fatty acids levels in plasma of the studied population 
In Fig.2 two examples of gas-chromatograms are reported, one obtained from the standard mix 
of FAs and one from a real plasma sample analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 FA gas-chromatographic profiles obtained from the analysis of the FAs standard mix  
(upper image) and from the analysis of a real plasma sample of a studied patient (lower image).  
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Results obtained from the analysis of the 1,370 plasma samples are reported in Tab. III. They 
are expressed as the proportion of the specific FA of the total amount of identified FAs. Mean 
values with standard deviation or confidence interval for skewed values are reported for single 
FAs and for FA classes.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. III Mean values of identified FAs, single and as FA classes, with corresponding standard 
deviations or confidence intervals for skewed values.      
  
 Total Population 
(n=1,370) 
SFA 35.2 ± 2.3 
C12:0 0.118 (0.114-0.122) 
C14:0 1.03 (1.01-1.06) 
C16:0 24.0 ± 1.8 
C18:0 8.07 (8.02- 8.13) 
C20:0 0.34 ± 0.07 
C22:0 0.74 ± 0.17 
C24:0 0.73 ± 0.21 
UFA 64.8 ± 2.2 
MUFA 27.0 ± 4.0 
C16:1n-7 2.02 (1.98-2.06) 
C18:1n-9 24.5 ± 3.8 
C20:1n-9 0.214 (0.211-0.217) 
C22:1n-9 0.13 ± 0.11 
PUFA 37.7 ± 4.4 
n-3 3.76 (3.71-3.82) 
C18:3n-3 0.386 (0.38-0.39) 
C18:4n-3 0.26 (0.25-0.27) 
C20:5n-3 0.68 (0.66-0.7) 
C22:6 2.41 ± 0.77 
n-6 33.8 ± 4.3 
C18:2n-6 23.9 ± 3.9 
C20:2n-6 0.229 (0.226-0.232) 
C20:4n-6 9.68 ± 2.14 
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3.4  Correlation analyses 
The correlations between single FA levels are reported in Tab. IV; those found to be 
statistically significant are highlighted in bold type. FAs and FA classes relationships with lipid 
and apolipoprotein parameters were also investigated. Many statistically significant correlations 
were also found between lipid/apolipoprotein values and single FA levels in the total 
population as reported in bold in Tab. V. Moreover, possible correlation between lipid/ 
apolipoprotein parameters were investigated taking into account the stratification of the 
population. In particular, results of the correlation analyses for CAD and CAD- free 
populations are reported in Tab.VI and VII respectively. The same type of investigations were 
performed also on the population partitioned according to sex (Tab.VIII and IX) and age, with  
results on youngest subjects (age<62) reported in Tab.X and results of the analysis on the older 
population (age>62) reported in Tab.XI.      
 
 
 
 
55 
 
 
  
Tab. IV Correlations between single FAs plasma levels in the whole population. Significant correlations are in bold type. 
* = p-value < 0.05 
** = p-value < 0.01 
*** = p-value < 0.001 
 C12:0 C 14:0 C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C18:4 C20:0 C20:1 C20:2 C20:4 C20:5 C22:0 C22:1 C22:6 
C12:0 
  
               
C14:0 r= 0.741***                 
C16:0 r= 0.285*** r= 0.393***                
C16:1 r= 0.274*** r= 0.485*** r= 0.424***               
C18:0 r= 0.161*** r= 0.096*** r= -0.111*** r= -0.134***              
C18:1 r= -0.068* r= 0.038 r= 0.091** r= 0.252*** r= -0.426***             
C18:2 r= -0.111
*** r= -0.227*** r= -0.556*** r= -0.492*** r= 0.135*** r= -0.619***            
C18:3 r= 0.172
*** r= 0.290*** r= -0.035 r= -0.053* r= 0.027 r= -0.178*** r= 0.203***           
C18:4 r= 0.044 r= 0.091
** r= 0.004 r= -0.035 r= 0.090** r= -0.219*** r= 0.092** r= 0.132***          
C20:0 r= -0.022 r= -0.203*** r= -0.185*** r= -0.250*** r= 0.210*** r= -0.239*** r= 0.146*** r= -0.156*** r= -0.047         
C20:1 r= 0.009 r= 0.089** r= 0.036 r= 0.153*** r= -0.165*** r= 0.514*** r= -0.335*** r= -0.015 r= -0.102*** r= -0.046        
C20:2 r= 0.059
* r= 0.147*** r= -0.302*** r= 0.001 r= 0.223*** r= -0.293*** r= 0.479*** r= 0.215*** r= 0.064** r= -0.043 r= 0.059*       
C20:4 r= -0.240
*** r= -0.382*** r= -0.141*** r= -0.179*** r= 0.156*** r= -0.412*** r= -0.094** r= -0.299*** r= 0.031 r= 0.217*** r= -0.296*** r= -0.196***      
C20:5 r= 0.044 r= 0.111
*** r= 0.044 r= 0.033 r= 0.048 r= -0.176*** r= -0.182*** r= 0.290*** r= 0.118*** r= 0.013 r= 0.019 r= -0.159*** r= 0.120***     
C22:0 r= -0.059* r= -0.184*** r= -0.308*** r= -0.309*** r= 0.143*** r= -0.434*** r= 0.400*** r= -0.080** r= 0.021 r= 0.631*** r= -0.172*** r= 0.063* r= 0.216*** r= 0.106***    
C22:1 r= -0.056* r= -0.051 r= 0.030 r= -0.121*** r= 0.016 r= -0.176*** r= 0.084** r= -0.003 r= 0.285*** r= 0.093** r= -0.015 r= -0.019 r= 0.047 r= 0.014 r= 0.141***   
C22:6 r= -0.203
*** r= -0.260*** r= -0.025 r= -0.168*** r= -0.056* r= -0.133*** r= -0.175*** r= 0.056* r= 0.062* r= 0.076** r= -0.068* r= -0.236*** r= 0.261*** r= 0.531*** r= -0.008 r= 0.111***  
C24:0 r= -0.038 r= -0.164*** r= -0.131*** r= -0.277*** r= 0.196*** r= -0.516*** r= 0.272*** r= -0.037*** r= 0.051 r= 0.462*** r= -0.245*** r= -0.005 r= 0.346*** r= 0.164*** r= 0.729*** r= 0.192*** r= 0.119*** 
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Tab. V Correlations between plasma lipid/ apolipoprotein parameters and fatty acids profile in total 
population. Significant correlations are in bold type. 
*  = p-value < 0.05 
** = p-value < 0.01 
*** = p-value < 0.001 
 
 
 
 
 
 
 
 Tot chol HDL LDL TG ApoA-I ApoB ApoC-III ApoE 
SFA r= 0.008 r= -0.050 r= -0.064* r= 0.245*** r= 0.029 r= 0.055 r= 0.192*** r= 0.106*** 
C12:0 r= 0.039 r= -0.070* r= -0.016 r= 0.229*** r= 0.002 r= 0.043 r= 0.145*** r= 0.065* 
C14:0 r= 0.136*** r= -0.091** r= 0.048 r= 0.441*** r= 0.049 r= 0.157*** r= 0.327*** r= 0.178*** 
C16:0 r= -0.040 r= -0.227*** r= -0.075* r= 0.367*** r= -0.150*** r= 0.074* r= 0.244*** r= 0.134*** 
C18:0 r= -0.013 r=0.273*** r= -0.063* r= -0.205*** r= 0.274*** r= -0.094** r= -0.090** r= -0.028 
C20:0 r= -0.008 r= 0.204*** r= 0.040 r= -0.394*** r= 0.081** r= -0.083** r= -0.313*** r= -0.200*** 
C22:0 r= 0.128*** r=0.249*** r= 0.192*** r= -0.437*** r= 0.138*** r= 0.028 r= -0.307*** r= -0.173*** 
C24:0 r= 0.119*** r= 0.246*** r= 0.137*** r= -0.366*** r= 0.150*** r= 0.026 r= -0.230*** r= -0.183*** 
UFA r= -0.004 r= 0.051 r= 0.066* r= -0.242*** r= -0.026 r= -0.050 r= -0.189*** r= -0.104*** 
MUFA r= -0.158*** r= -0.309*** r= -0.153*** r= 0.380*** r= -0.255*** r= -0.067* r= 0.170*** r= 0.110*** 
C16:1n-7 r= 0.093** r= -0.063* r= 0.056 r= 0.318*** r= 0.012 r= 0.135*** r=  0.249*** r= 0.175*** 
C18:1n-9 r= -0.188*** r= -0.317*** r= -0.173*** r= 0.339*** r= -0.279*** r= -0101*** r= 0.127*** r= 0.078** 
C20:1n-9 r= -0.129*** r= -0.198*** r= -0.161*** r= 0.242*** r= -0.108*** r= -0.067* r= 0.138*** r= 0.112*** 
C22:1n-9 r= -0.007 r= 0.090** r= -0.009 r= -0.127*** r= 0.084** r= -0.058* r= -0.091** r= 0.007 
PUFA r= 0.142
*** r= 0.309*** r= 0.170*** r= -0.471*** r= 0.219*** r= 0.035 r= -0.253*** r= -0.154*** 
n-3 r= 0.104
*** r= 0.039 r= 0.069* r= 0.001 r= 0.054 r= 0.163*** r= 0.074* r= 0.046 
C18:3n-3 r= 0.167
*** r= -0.051 r= 0.093** r= 0.299*** r= 0.022 r= 0.194*** r= 0.271*** r= 0.112*** 
C18:4n-3 r= -0.014 r= 0.122
*** r= -0.027 r= -0.130*** r= 0.107*** r= -0.027 r= -0.064* r= 0.003 
C20:5n-3 r= 0.239
*** r= 0.148*** r= 0.165*** r= 0.038 r= 0.175*** r= 0.245*** r= 0.181*** r= 0.070* 
C22:6n-3 r= -0.006 r= -0.023 r= -0.001 r= -0.065
* r= -0.035 r= 0.068* r= -0.027 r= 0.001 
n-6 r= 0.122
*** r= 0.309*** r= 0.157*** r= -0.482*** r= 0.212*** r= -0.003 r= -0.277*** r= -0.170*** 
C18:2n-6 r= 0.107
*** r= 0.252*** r= 0.141*** r= -0.380*** r= 0.172*** r= -0.021 r= -0.241*** r= -0.140*** 
C20:2n-6 r= 0.027 r= 0.111
*** r= -0.008 r= -0.046 r= 0.188*** r= -0.038 r= 0.011 r= 0.006 
C20:4n-6 r= 0.048 r= 0.157
*** r= 0.057 r= -0.273*** r= 0.107*** r= 0.033 r= -0.120*** r= -0.086** 
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Tab. VI Correlations between plasma lipid/apolipoprotein parameters and fatty acids profile in CAD 
population. Significant correlations are in bold type. 
 
*  = p-value < 0.05 
** = p-value < 0.01 
*** = p-value < 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 Tot chol HDL LDL TG ApoA-I ApoB ApoC-III ApoE 
C12:0 r= 0.066* r= -0.111** r= 0.021 r= 0.264*** r= -0.002 r= 0.088** r= 0.176*** r= 0.081* 
C14:0 r= 0.161*** r= -0.117*** r= 0.077* r= 0.467*** r= 0.071* r= 0.186*** r= 0.360*** r= 0.204*** 
C16:0 r= -0.019 r= -0.232*** r= -0.056 r= 0.366*** r= -0.144*** r= 0.094** r= 0.279*** r= 0.161*** 
C18:0 r= 0.019 r= 0.222*** r= 0.001 r= -0.151*** r= 0.249*** r= -0.035 r= -0.059 r= 0.009 
C20:0 r= -0.042 r= 0.191*** r= 0.014 r= -0.415*** r= 0.048 r= -0.093** r= -0.327*** r= -0.223*** 
C22:0 r= 0.114*** r= 0.225*** r= 0.189*** r= -0.431*** r= 0.100** r= 0.025 r= -0.332*** r= -0.195*** 
C24:0 r= 0.134*** r= 0.217*** r= 0.165*** r= -0.336*** r= 0.106*** r= 0.057 r= -0.248*** r= -0.198*** 
C16:1n-7 r= 0.089** r= -0.071* r= 0.057 r= 0.317*** r= 0.026 r= 0.141*** r= 0.282*** r= 0.184*** 
C18:1n-9 r= -0.228*** r= -0.300*** r= -0.234*** r= 0.284*** r= -0.273*** r= -0.168*** r= 0.104** r= 0.049 
C20:1n-9 r= -0.138** r= -0.187*** r= -0.202*** r= 0.234*** r= -0.090** r= -0.088** r= 0.154*** r= 0.124*** 
C22:1n-9 r= 0.074* r= 0.006 r= 0.100** r= -0.044 r= 0.040 r= 0.071* r= -0.007 r= 0.051 
C18:3n-3 r= 0.179*** r= -0.087** r= 0.101** r= 0.335*** r= 0.022 r= 0.210*** r= 0.300*** r= 0.128*** 
C18:4n-3 r= 0.089** r= 0.087** r= 0.065 r= 0.036 r= 0.116** r= 0.113** r= 0.076* r= 0.062 
C20:5n-3 r= 0.224*** r= 0.130*** r= 0.125*** r= 0.068* r= 0.169*** r= 0.250*** r= 0.192*** r= 0.067* 
C22:6n-3 r= -0.006 r= 0.007 r= -0.034 r= -0.060 r= -0.022 r= 0.075* r= 0.001 r= -0.019 
C18:2n-6 r= 0.118*** r= 0.224*** r= 0.178*** r= -0.350*** r= 0.149*** r= 0.002 r= -0.267*** r= -0.133*** 
C20:2n-6 r= 0.026 r= 0.115*** r= -0.005 r= -0.036 r= 0.200*** r= -0.050 r= 0.017 r= 0.014 
C20:4n-6 r= 0.051 r= 0.215*** r= 0.044 r= -0.279*** r= 0.135*** r= 0.034 r= -0.119*** r= -0.097** 
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 Tot chol HDL LDL TG ApoA-I ApoB ApoC-III ApoE 
C12:0 r= -0.055 r= -0.076 r= -0.108 r= 0.206*** r= -0.039 r= -0.067 r= 0.094 r= 0.041 
C14:0 r= 0.050 r= -0.087 r= -0.029 r= 0.425*** r= -0.007 r= 0.070 r= 0.253*** r= 0.102 
C16:0 r= -0.122* r= -0.226*** r= -0.156** r= 0.369*** r= -0.170** r= -0.015 r= 0.142** r= 0.040 
C18:0 r= -0.115* r= 0.276*** r= -0.210*** r= -0.253*** r= 0.255*** r= -0.182** r= -0.107* r= -0.089 
C20:0 r= 0.088 r= 210*** r= 0.116* r= -0.334** r= 0.101 r= -0.016 r= -0.264*** r= -0.132* 
C22:0 r= 0.183*** r= 0.274*** r= 0.232*** r= -0.426*** r= 0.196*** r= 0.093 r= -0.218*** r= -0.083 
C24:0 r= 0.081 r= 0.228*** r= 0.092 r= -0.381*** r= 0.172** r= 0.031 r= -0.136* r= -0.101 
C16:1n-7 r= 0.102 r= 0.035 r= 0.029 r= 0.283*** r= 0.041 r= 0.069 r= 0.145** r= 0.129* 
C18:1n-9 r= -0.079 r= -0.235*** r= -0.069 r= 0.395*** r= -0.211** r= -0.018 r= 0.120* r= 0.110* 
C20:1n-9 r= -0.109* r= -0.169** r= -0.085 r= 0.210*** r= -0.111* r= -0.052 r= 0.070 r= 0.058 
C22:1n-9 r= -0.068 r= -0.021 r= -0.046 r= -0.055 r= 0.013 r= -0.063 r= -0.070 r= 0.046 
C18:3n-3 r= 0.126* r= -0.023 r= 0.076 r= 0.238*** r= -0.002 r= 0.173** r= 0.214*** r= 0.071 
C18:4n-3 r= -0.086 r= 0.122* r= -0.097 r= -0.165** r= 0.083 r= -0.089 r= -0.094 r= 0.004 
C20:5n-3 r= 0.290*** r= 0.211*** r= 0.270*** r= -0.043 r= 0.202*** r= 0.248*** r= 0.156** r= 0.083 
C22:6n-3 r= -0.009 r= -0.021 r= 0.069 r= -0.156** r= -0.035 r= 0.006 r= -0.137* r= 0.047 
C18:2n-6 r= 0.087 r= 0.188** r= 0.110* r= -0.372*** r= 0.147** r= 0.012 r= -0.116* r= -0.120* 
C20:2n-6 r= 0.030 r= 0.090 r= 0.001 r= -0.055 r= 0.176** r= 0.008 r= -0.004 r= -0.016 
C20:4n-6 r= 0.040 r= 0.082 r= 0.076 r= -0.289*** r= 0.056 r= 0.033 r= -0.126* r= -0.055 
 
Tab. VII  Correlations between plasma lipid/apolipoprotein parameters and fatty acids profile in CAD-free 
population. Significant correlations are in bold type. 
 
*  = p-value < 0.05 
** = p-value < 0.01 
*** = p-value < 0.001 
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 Tot chol HDL LDL TG ApoA-I ApoB ApoC-III ApoE 
C12:0 r= 0.038 r= -0.075* r= -0.011 r= 0.204*** r= 0.015 r= 0.047 r= 0.138*** r= 0.068* 
C14:0 r= 0.143*** r= -0.097** r= 0.059 r= 0.424*** r= 0.079* r= 0.166*** r= 0.326*** r= 0.199*** 
C16:0 r= -0.011 r= -0.179*** r= -0.058 r= 0.342*** r= -0.106** r= 0.082* r= 0.270*** r= 0.160*** 
C18:0 r= -0.007 r= 0.248*** r= -0.026 r= -0.192** r= 0.259*** r= -0.082* r= -0.095** r= -0.023 
C20:0 r= -0.048 r= 0.119*** r= 0.033 r= -0.402*** r= -0.015 r= -0.081* r= -0.346*** r= -0.224*** 
C22:0 r= 0.117*** r= 0.186*** r= 0.220*** r= -0.428*** r= 0.066* r= 0.042 r= -0.333*** r= -0.208*** 
C24:0 r= 0.129*** r= 0.221*** r= 0.170*** r= -0.348*** r= 0.124*** r= 0.040 r= -0.228*** r= -0.206*** 
C16:1n-7 r= 0.092** r= -0.179*** r= 0.058 r= 0.313*** r= 0.018 r= 0.139*** r= 0.259*** r= 0.196*** 
C18:1n-9 r= -0.178*** r= -0.289*** r= -0.184*** r= 0.325*** r= -0.270*** r= -0.105** r= 0.120*** r= 0.086** 
C20:1n-9 r= -0.110*** r= -0.166*** r= -0.151*** r= 0.226*** r= -0.079* r= -0.056 r= 0.150*** r= 0.142*** 
C22:1n-9 r= 0.023 r= 0.016 r= 0.027 r= -0.067* r= 0.055 r= 0.002 r= -0.036 r= 0.025 
C18:3n-3 r= 0.168*** r= -0.077* r= 0.086* r= 0.325*** r= 0.033 r= 0.196*** r= 0.285*** r= 0.133*** 
C18:4n-3 r= 0.045 r= 0.113*** r= 0.013 r= -0.027 r= 0.130*** r= 0.059 r= 0.018 r= 0.049 
C20:5n-3 r= 0.247*** r= 0.114*** r= 0.173*** r= 0.071* r= 0.151*** r= 0.264*** r= 0.193*** r= 0.091** 
C22:6n-3 r= -0.014 r= -0.050 r= -0.011 r= -0.038 r= -0.065 r= 0.068* r= -0.021 r= 0.018 
C18:2n-6 r= 0.090** r= 0.231*** r= 0.128*** r= -0.371*** r= 0.178*** r= -0.034 r= -0.248*** r= -0.165*** 
C20:2n-6 r= 0.013 r= 0.123*** r= 0.004 r= -0.083** r= 0.220*** r= -0.053 r= -0.016 r= 0.005 
C20:4n-6 r= 0.041 r= 0.140*** r= 0.068* r= -0.266*** r= 0.061 r= 0.041 r= -0.128*** r= -0.104** 
 
Tab. VIII Correlations between plasma lipid/apolipoprotein parameters and fatty acids profile in male 
population. Significant correlations are in bold type. 
 
*  = p-value < 0.05 
** = p-value < 0.01 
*** = p-value < 0.001 
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 Tot chol HDL LDL TG ApoA-I ApoB ApoC-III ApoE 
C12:0 r= 0.035 r= -0.106 r= -0.031 r= 0.337*** r= -0.054 r= 0.036 r= 0.167** r= 0.054 
C14:0 r= 0.106 r= -0.153** r= 0.019 r= 0.526*** r= -0.062 r= 0.134* r= 0.329*** r= 0.115* 
C16:0 r= -0.102 r= -0.296*** r= -0.129* r= 0.423** r= -0.209** r= 0.038 r= 0.191** r= 0.094 
C18:0 r= -0.072 r= 0.275*** r= -0.212*** r= -0.226*** r= 0.268*** r= -0.123* r= -0.103 r= -0.082 
C20:0 r= 0.075 r= 0.332*** r= 0.070 r= -0.350*** r= 0.222*** r= -0.069 r= -0.258*** r= -0.181** 
C22:0 r= 0.140* r= 0.353*** r= 0.122* r= -0.447*** r= 0.254*** r= 0.007 r= -0.258*** r= -0.112* 
C24:0 r= 0.096 r= 0.394*** r= 0.027 r= -0.444*** r= 0.256*** r= -0.024 r= -0.235*** r= -0.118* 
C16:1n-7 r= 0.082 r= -0.164** r= 0.054 r= 0.362*** r= -0.057 r= 0.135* r= 0.209*** r= 0.108 
C18:1n-9 r= -0.200*** r= -0.357*** r= -0.150* r= 0.369*** r= -0.270*** r= -0.103 r= 0.162** r= 0.074 
C20:1n-9 r= -0.167** r= -0.216*** r= -0.204** r= 0.270*** r= -0.118* r= -0.121* r= 0.121* r= 0.060 
C22:1n-9 r= 0.076 r= 0.147** r= 0.097 r= -0.122* r= 0.108 r= 0.032 r= -0.063 r= 0.063 
C18:3n-3 r= 0.151** r= -0.069 r= 0.120* r= 0.245*** r= -0.058 r= 0.203*** r= 0.222*** r= 0.045 
C18:4n-3 r= 0.059 r= 0.147** r= 0.031 r= -0.041 r= 0.079 r= 0.044 r= 0.031 r= 0.008 
C20:5n-3 r= 0.210*** r= 0.242*** r= 0.141* r= -0.063 r= 0.230*** r= 0.193** r= 0.138* r= 0.007 
C22:6n-3 r= 0.025 r= 0.077 r= 0.030 r= -0.167** r= 0.063 r= 0.062 r= -0.044 r= -0.042 
C18:2n-6 r= 0.143** r= 0.282*** r= 0.183** r= -0.393*** r= 0.135* r= 0.023 r= -0.231*** r= -0.093 
C20:2n-6 r= 0.053 r= 0.029 r= -0.037 r= 0.083 r= 0.081 r= 0.015 r= 0.077 r= -0.002 
C20:4n-6 r= 0.064 r= 0.197** r= 0.030 r= -0.290*** r= 0.207*** r= 0.017 r= -0.104 r= -0.049 
 
Tab. IX Correlations between plasma lipid/apolipoprotein parameters and fatty acids profile in females 
population. Significant correlations are in bold type. 
 
*  = p-value < 0.05 
** = p-value < 0.01 
*** = p-value < 0.001 
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 Tot chol HDL LDL TG ApoA-I ApoB ApoC-III ApoE 
C12:0 r=  0.012 r=  -0.054 r=  -0.064 r=  0.217*** r=  0.020 r=  -0.005 r=  0.176*** r=  0.095* 
C14:0 r=  0.137*** r=  -0.074 r=  0.016 r=  0.462*** r=  0.073 r=  0.119** r=  0.372*** r=  0.242*** 
C16:0 r=  0.010 r= -0.220*** r= -0.013 r=  0.454*** r= -0.099* r= 0.143*** r= 0.328*** r= 0.221*** 
C18:0 r= -0.083* r= 0.256*** r= -0.103* r= -0.204*** r= 0.242*** r= -0.143** r= -0.083* r= -0.014 
C20:0 r= -0.059 r= 0.196*** r= 0.020 r= -0.449*** r= 0.042 r= -0.125** r= -0.366*** r= -0.246*** 
C22:0 r= 0.058 r= 0.247*** r= 0.160*** r= -0.527*** r= 0.101* r= -0.036 r= -0.372*** r= -0.230*** 
C24:0 r= 0.044 r= 0.263*** r= 0.149*** r= -0.495*** r= 0.138** r= -0.030 r= -0.315*** r= -0.220*** 
C16:1n-7 r= 0.193*** r= -0.075 r= 0.107** r= 0.427*** r= 0.033 r= 0.226*** r= 0.354*** r= 0.248*** 
C18:1n-9 r= -0.091* r= -0.295*** r= -0.130** r= 0.382*** r= -0.275*** r= -0.044 r= 0.154*** r= 0.076 
C20:1n-9 r= -0.100** r= -0.190*** r= -0.151*** r= 0.245*** r= -0.101* r= -0.048 r= 0.149*** r= 0.090* 
C22:1n-9 r= -0.045 r= 0.041 r= -0.013 r= -0.132** r= 0.086* r= -0.065 r= -0.101* r= -0.028 
C18:3n-3 r= 0.109** r= -0.108** r= 0.057 r= 0.297*** r= -0.045 r= 0.144*** r= 0.247*** r= 0.131** 
C18:4n-3 r= 0.029 r= 0.087* r= 0.010 r= -0.040 r= 0.114** r= 0.052 r= 0.015 r= 0.086* 
C20:5n-3 r= 0.171*** r= 0.092* r= 0.136** r= 0.042 r= 0.181*** r= 0.220*** r= 0.178*** r= 0.070 
C22:6n-3 r= -0.078* r= -0.047 r= -0.037 r= -0.104** r= -0.039 r= 0.032 r= -0.095* r= -0.057 
C18:2n-6 r= 0.041 r= 0.235*** r= 0.094* r= -0.438*** r= 0.137** r= -0.072 r= -0.276*** r= -0.188*** 
C20:2n-6 r= 0.028 r= 0.075 r= -0.029 r= -0.015 r= 0.174*** r= -0.030 r= 0.052 r= -0.002 
C20:4n-6 r= 0.011 r= 0.143*** r= 0.071 r= -0.314*** r= 0.079 r= 0.007 r= -0.201*** r= -0.091* 
 
Tab.X  Correlations between plasma lipid /apolipoprotein parameters and fatty acids profile in the 
youngest population (age<62). Significant correlations are in bold type. 
 
*  = p-value < 0.05 
** = p-value < 0.01 
*** = p-value < 0.001 
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 Tot chol HDL LDL TG ApoA-I ApoB ApoC-III ApoE 
C12:0 r= 0.049 r= -0.043 r= 0.029 r= 0.198*** r= 0.027 r= 0.070 r= 0.095* r= 0.039 
C14:0 r= 0.123** r= -0.082* r= 0.078 r= 0.394*** r= 0.054 r= 0.183*** r= 0.265*** r= 0.116** 
C16:0 r= -0.095* r= -0.221*** r= -0.137** r= 0.260*** r= -0.185*** r= -0.007 r= 0.146*** r= 0.055 
C18:0 r= 0.058 r= 0.324*** r= -0.019 r= -0.238*** r= 0.334*** r= -0.044 r= -0.106** r= -0.049 
C20:0 r= 0.048 r= 0.224*** r= 0.067 r= -0.345*** r= 0.134** r= -0.037 r= -0.250*** r= -0.152** 
C22:0 r= 0.197*** r= 0.276*** r= 0.225*** r= -0.366*** r= 0.197*** r= 0.089* r= -0.237*** r= -0.116** 
C24:0 r= 0.174*** r= 0.263*** r= 0.122** r= -0.283*** r= 0.188*** r= 0.061 r= -0.162*** r= -0.154*** 
C16:1n-7 r= 0.002 r= -0.070 r= 0.005 r= 0.222*** r= -0.025 r= 0.049 r= 0.131** r= 0.103* 
C18:1n-9 r= -0.263*** r= -0.350*** r= -0.213*** r= 0.327*** r= -0.296*** r= -0.144*** r= 0.108** r= 0.082* 
C20:1n-9 r= -0.153*** r= -0.216*** r= -0.171*** r= 0.253*** r= -0.114** r= -0.087* r= 0.125** r= 0.135** 
C22:1n-9 r= 0.115** r= 0.049 r= 0.111** r= -0.024 r= 0.048 r= 0.085* r= 0.017 r= 0.093* 
C18:3n-3 r= 0.212*** r= 0.015 r= 0.127** r= 0.283*** r= 0.108** r= 0.232*** r= 0.292*** r= 0.092* 
C18:4n-3 r= 0.071 r= 0.158*** r= 0.023 r= -0.022 r= 0.127** r= 0.058 r= 0.032 r= 0.000 
C20:5n-3 r= 0.286*** r= 0.190*** r= 0.183*** r= 0.031 r= 0.171*** r= 0.261*** r= 0.185*** r= 0.064 
C22:6n-3 r= 0.049 r= -0.017 r= 0.029 r= -0.019 r= -0.045 r= 0.097* r= 0.044 r= 0.044 
C18:2n-6 r= 0.174*** r= 0.272*** r= 0.191*** r= -0.324*** r= 0.206** r= 0.038 r= -0.199*** r= -0.094* 
C20:2n-6 r= 0.037 r= 0.129*** r= 0.019 r= -0.062 r= 0.191*** r= -0.032 r= -0.027 r= 0.016 
C20:4n-6 r= 0.081* r= 0.173*** r= 0.048 r= -0.244*** r= 0.134** r= 0.056 r= -0.047 r= -0.083* 
 
Tab. XI  Correlations between plasma lipid/apolipoprotein parameters and fatty acids profile in the oldest 
population (age>62). Significant correlations are in bold type. 
 
*  = p-value < 0.05 
** = p-value < 0.01 
*** = p-value < 0.001 
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3.5 Principal Component Analysis (PCA) results 
In order to obtain a general description of the relationships existing in the present dataset, 
PCA analysis was performed. This analysis is based on the dimensionality reduction by 
using new variables, the principal components, accounting for the maximum dataset 
variance. The results obtained indicate that the first two PCs explain 17.9% and 11.7% of 
the total variance contained in the original dataset, respectively. 
In particular, PCA allows the graphical representation of samples showing similar 
behaviours, as well as the visualization of the variables responsible for the aforementioned 
similarities and differences. The loading plot obtained by the PCA analysis of the whole 
population  is reported in Fig.3.  
 
 
 
Fig.3 PCA results showing the loading plot obtained from the analysis of lipid/apolipoprotein 
parameters and FAs values in the whole population (n=1,370).  
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3.6 Regression analyses 
To highlight the most important associations between lipid/apolipoprotein parameters and 
single FA, regression analyses were performed. Values of FAs that showed significant 
correlation with the lipid/apolipoprotein parameter in the previous analysis on the whole 
population (Tab. V) were involved in the regression study. Results of regression analysis for 
each parameter in the whole population are reported in Tab.XII. In the right part of the table the 
results after correction for sex, age, BMI, diabetes, CAD diagnosis, and lipid-lowering therapy 
are reported. In the studied population C14:0 was the main statistical predictor, among the 
various FAs, of both plasmatic TG and ApoC-III (Tab. XII), explaining about 20% and 10% of 
their variability, respectively. The significance of these relationships did not change even after 
adjustment for sex, age, BMI, presence of CAD pathology and use of lipid lowering therapy.  
Dependent 
variable: 
 
Total 
Cholesterol 
Standardized 
Beta-
coefficient 
p-value * R
2
 R
2
 change 
Adjusted 
Standardized 
Beta-coefficient 
p-
value
#
 
C20:5n-3 0.232 <0.001 0.057 0.057 0.217 <0.001 
C18:2n-6 0.175 <0.001 0.081 0.023 0.164 <0.001 
C16:1n-7 0.184 <0.001 0.115 0.034 0.192 <0.001 
C20:1n-9 -0.092 0.001 0.122 0.007 -0.075 0.011 
C14:0 0.068 0.028 0.127 0.005 0.059 0.091 
C22:0 0.092 0.002 0.132 0.005 0.102 0.002 
C18:3n-3 0.061 0.046 0.134 0.003 0.062 0.063 
HDL-C 
      
C18:1n-9 0.597 <0.001 0.100 0.100 0.533 <0.001 
C16:0 0.160 0.012 0.140 0.040 0.178 0.007 
C18:0 0.337 <0.001 0.160 0.020 0.277 <0.001 
C16:1n-7 0.302 <0.001 0.173 0.013 0.242 <0.001 
C20:0 0.133 <0.001 0.183 0.011 0.106 <0.001 
C20:5n-3 0.289 <0.001 0.194 0.010 0.257 <0.001 
C20:1n-9 -0.077 0.009 0.200 0.006 -0.061 0.041 
C18:2n-6 0.820 <0.001 0.206 0.006 0.730 <0.001 
C20:4n-6 0.377 <0.001 0.221 0.016 0.356 <0.001 
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C18:4n-3 0.109 <0.001 0.231 0.009 0.095 <0.001 
C24:0 0.099 0.003 0.236 0.006 0.097 0.003 
LDL-C       
C22:0 0.135 <0.001 0.037 0.037 0.156 <0.001 
C20:5n-3 0.150 <0.001 0.058 0.021 0.144 <0.001 
C20:1n-9 -0.127 <0.001 0.079 0.021 -0.111 0.002 
C18:0 -0.137 <0.001 0.091 0.012 -0.098 0.004 
C18:1n-9 -0.089 0.022 0.095 0.004 -0.058 0.170 
Triglycerides 
      
C14:0 0.324 <0.001 0.195 0.195 0.338 <0.001 
C22:0 -0.112 <0.001 0.326 0.131 -0.130 <0.001 
C18:0 -0.065 0.005 0.362 0.037 -0.041 0.093 
C18:3n-3 0.268 <0.001 0.391 0.029 0.246 <0.001 
C18:1n-9 0.251 <0.001 0.418 0.027 0.254 <0.001 
C16:0 0.193 <0.001 0.442 0.024 0.173 <0.001 
C20:0 -0.129 <0.001 0.450 0.008 -0.117 <0.001 
C20:4 0.112 <0.001 0.458 0.007 0.108 <0.001 
C20:1n-9 0.079 0.001 0.463 0.005 0.078 0.002 
C12:0 -0.068 0.027 0.464 0.002 -0.090 0.005 
       
ApoA-I 
      
C18:1n-9 -0.141 <0.001 0.078 0.078 0.002 <0.001 
C18:0 0.173 <0.001 0.108 0.030 0.066 <0.001 
C20:5n-3 0.172 <0.001 0.126 0.018 0.017 <0.001 
C20:2n-6 0.115 <0.001 0.144 0.018 0.035 0.001 
C16:0 -0.102 <0.001 0.154 0.009 0.004 0.006 
ApoB 
      
C20:5n-3 0.227 <0.001 0.060 0.060 0.218 <0.001 
C18:3n-3 0.116 <0.001 0.076 0.016 0.116 <0.001 
C16:1n-7 0.138 <0.001 0.094 0.018 0.150 <0.001 
C18:0 -0.155 <0.001 0.102 0.008 -0.113 <0.001 
C18:1n-9 -0.149 <0.001 0.118 0.015 -0.143 <0.001 
C22:6 -0.072 0.033 0.121 0.003 -0.066 0.063 
       
ApoC-III 
      
C14:0 0.288 <0.001 0.107 0.107 0.310 <0.001 
C20:0 -0.150 <0.001 0.173 0.065 -0.140 <0.001 
C18:3n-3 0.204 <0.001 0.200 0.027 0.188 <0.001 
C22:0 -0.096 0.008 0.214 0.014 -0.122 0.002 
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Tab.  XII Fatty acid predictors of plasma lipid and apolipoprotein profile by linear regression analyses. 
At first a regression model with backward stepwise selection of variables and then a regression model 
with forward stepwise selection of variables were performed. 
 
 
3.7 In vivo evaluation of myristic acid correlation with CAD risk factors: focus on 
triglycerides and ApoC-III plasma levels 
 
As indicated in Tab.XII C14:0 is the strongest predictor of single lipid parameters with 
respect to other FAs and was the first predictor of both TG and ApoC-III plasma levels. 
Therefore, the distribution of all lipid and apolipoprotein values were evaluated in relation to 
C14:0 quintiles, also taking into account the two sub-groups, CAD and CAD-free. The 
statistical evaluation was performed by means of ANOVA test. The mean clinical 
characteristics of subjects included are reported in Tab. XIII.  
 
 
 
C20:5n-3 0.097 <0.001 0.230 0.016 0.074 0.011 
C12:0 -0.112 0.003 0.237 0.007 -0.135 0.001 
C16:0 0.109 <0.001 0.244 0.007 0.102 0.001 
C20:1n-9 0.073 0.016 0.250 0.006 0.093 0.004 
C20:4 0.129 <0.001 0.257 0.006 0.107 0.002 
C18:1n-9 0.097 0.008 0.261 0.004 0.080 0.041 
       
ApoE 
      
C20:0 -0.117 <0.001 0.040 0.040 -0.103 0.004 
C14:0 0.144 0.001 0.061 0.020 0.167 0.001 
C24:0 -0.121 0.001 0069 0.008 -0.118 0.002 
C20:1n-9 0.093 0.005 0.073 0.005 0.098 0.006 
C12:0 -0.086 0.039 0.077 0.003 -0.103 0.025 
C18:1n-9 -0.142 0.001 0.080 0.003 -0.133 0.005 
C18:2n-6 -0.134 <0.001 0.088 0.008 -0.131 0.001 
C18:3n-3 0.068 0.025 0.091 0.004 0.070 0.035 
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 CAD 
(n=1,004) 
CAD-free 
(n=366) 
Age (years) 61 ± 10 58 ±12 
Male sex (%) 79.8% 65% 
Diabetes 18.1% 7,1% 
Lipid Lowering Therapy  29.1% 4,8% 
Total cholesterol (mmol/L) 5.50 ± 1.17 5.47 ± 1.17 
HDL Cholesterol (mmol/L) 1.18 ± 0,3 1.42 ± 0.42 
LDL Cholesterol (mmol/L) 3.69 ± 1 3.5 ± 0.92 
Triglycerides (mmol/L) 1.70 (1.65-1.75) 1.37 (1.31-1.43) 
Apolipoprotein A-I (g/L) 1.27 ± 0.24 1.39 ± 0.31 
Apolipoprotein B (g/L) 1.16 ± 0.31 1.05 ± 0.25 
Apolipoprotein C-III (mg/dL) 11.1 (10.8- 11.3) 10.1 (9.7- 10.5) 
Apolipoprotein E 0.042 (0.041- 0.043) 0.039 (0.038- 0.040) 
Tab.  XIII Clinical characteristics of CAD and CAD-free populations. 
 
As reported in Tab. XIV some parameters were found to be significantly correlated with 
C14:0 quintiles values, including among the most significant total cholesterol, HDL 
cholesterol, TG, ApoB, ApoC-III and ApoE. TG and ApoC-III plasma concentrations in the 
whole population were directly related with C14:0 levels divided into quintiles (p<0.001) 
(Fig.3A and Fig.4A respectively) and were both preserved either in CAD (p<0.001) and 
CAD-free subjects (p<0.001) when separately considered (Fig.4B-C and Fig.5B-C). This 
tendency remained statistically significant also after partitioning between men and women 
inside both populations (Fig.4D-G and Fig.5D-G), as further confirmation of the solid and 
independent association of plasmatic C14:0 with plasma TG and ApoC-III concentration. 
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Tab.  XIV. Distribution of plasma lipid and apolipoprotein parameters concentrations in relation to C14:0 quintiles. 
  
 C 14:0 quintiles 
 I 
(<0.73) 
II 
(0.73-0.91) 
III 
(0.91-1.13) 
IV 
(1.13-1.47) 
V 
(>1.47) 
P 
Age (years) 61.4±10.2 61.3±10.9 62.5±11 59.2±11.3 58.7±11.2 <0.001 
Male sex (%) 81.0% 79.9% 69.0% 74.5% 74.8% 0.007 
CAD diagnosis (%) 81.8% 69.0% 70.8% 70.1% 74.8% 0.004 
Total cholesterol (mmol/L) 5.31±1.07 5.32±1.12 5.50±1.22 5.66±1.17 5.69±1.12 <0.001 
HDL cholesterol (mmol/L) 1.21±0.35 1.32±0.39 1.31±0.35 1.22±0.33 1.17±0.30 <0.001 
LDL cholesterol (mmol/L) 3.55±0.91 3.52±0.96 3.71±1.09 3.77±0.98 3.64±0.95 0.033 
Triglycerides (mmol/L) 1.33(1.27-1.40) 1.35(1.29-1.42) 1.48(1.40-1.55) 1.80(1.72-1.89) 2.23(2.11-2.35) <0.001 
Apo A-I (g/L) 1.25± 0.27 1.31±0.29 1.33±0.26 1.32±0.28 1.31±0.23 0.021 
Apo B (g/L) 1.08±0.27 1.08±0.26 1.11±0.31 1.16±0.29 1.19±0.33 <0.001 
Apo C-III (mg/dL) 9.74(9.41-10.07) 9.77(9.40-10.15) 10.25(9.81-10.70) 11.48(11.04-11.94) 12.98(12.35-13.63) <0.001 
Apo E (g/L) 0.040(0.038-0.041) 0.037(0.036-0.039) 0.040(0.038-0.042) 0.042(0.040-0.044) 0.045(0.043-0.048) <0.001 
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D) 
A) 
B) 
C) 
E) F) G) 
P<0.001 
P<0.001 
P<0.001 
P<0.001 
P<0.001 
P<0.001 P<0.001 
P<0.001 P<0.001 
Fig.4 Representation of triglycerides distribution in relation to C14:0 quintiles in the whole population (A), in CAD patients (B) and CAD-free subject (C). Inside these two 
distinct populations the distribution of triglycerides was also evaluated among males (D for CAD and F for CAD free subjects) and females subjects (E for CAD and G for 
CAD free subjects).   
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D) 
A) 
B) 
C) 
E) F) G) 
Fig.5 Representation of ApoC-III distribution in relation to C14:0 quintiles in the whole population (A), in CAD patients (B) and CAD-free subject (C). Inside these two 
distinct populations the distribution of ApoC-III was also evaluated among male (D for CAD and F for CAD free subjects) and female subjects (E for CAD and G for CAD 
free subjects).   
 
P<0.001 
P=0.008 
P<0.001 
P=0.002 
P<0.001 
P<0.001 P<0.001 
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4. DISCUSSION  
Limitations of previous studies aimed at investigating the relationships between 
lipid/apolipoprotein parameters and FAs plasma levels were mentioned in the first chapter and 
include replacement of FA intake with carbohydrates, use of food frequency questionnaires, 
consideration of FA classes rather than single FAs or finally small population cohorts (Mensink 
et al., 2003; Warensjo et al., 2008; Niknam et al., 2014). Therefore, the present project was 
developed to investigate the existence of possible correlations of lipid and apolipoprotein 
parameters with the gas-chromatographically analysed FAs plasma levels in a large population, 
disclosing new possible FA-related mechanisms involved in CVD onset that are not already 
highlighted. Secondly, this project intended to evaluate and possibly confirm the interesting and 
significant correlations observed during my master’s degree thesis between C14:0 plasma 
levels and lipid/apolipoprotein parameters on a smaller group of subjects (57 VHS CAD 
patients). Therefore, the correlations between lipid profile and plasmatic FAs were investigated 
in 1,370 subjects, with and without CAD, involved in the VHS. Correlation analyses identified 
a high number of significant correlations between lipid and FA levels (Tab. V) in whole as well 
as in stratified population.  
PCA analysis, performed to obtain a general graphical representation of the relationships 
existing among the variables, showed and confirmed the associations of total and LDL 
cholesterol with ApoB -known to be the main protein component of the LDL particles- and also 
identified a new important cluster of variables which comprises TG, ApoC-III and C14:0 (Fig. 
3). In particular, C14:0 was the FA closest to a group of connected lipid parameters, suggesting 
therefore a possible relationship with TG plasma levels and their regulation. Regression 
analyses including only significantly correlated FAs were needed to bring to light only the 
strongest and possibly causal associations. The results obtained from regression analysis 
highlighted the most significant FAs predictors of the lipid/apolipoprotein analysed. Many 
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associations were found, such as the one involving C18:1, the major diet monounsaturated fatty 
acid (MUFA). C18:1 was the first predictor both of HDL and also of ApoA-I plasma levels, the 
main apolipoprotein component of HDL, consistent with literature data describing the 
cardioprotective ability of MUFAs to increase HDL cholesterol (Michas et al., 2014). The main 
interesting result was however related to C14:0 associations: this FA was the strongest 
predictor of both a lipid and an apolipoprotein parameter. C14:0 was confirmed to be correlated 
with cardiovascular risk factors, but the results obtained demonstrated that C14:0 is the first FA 
predictor of both TG and ApoC-III plasma levels, explaining about 20% and 10% of their 
plasma variability, independently of any other possible influencing factor (Tab. XII). C14:0 is a 
SFA that is present at low concentrations in human plasma if compared to some other SFAs. In 
the studied population C14:0 represented only 1% of all identified FAs (Tab. III). However, it 
is the third most common saturated FA in the diet and the hypercholesterolemic effects of this 
FA on both total and LDL cholesterol are already well known. In particular, C14:0 was 
reported to raise LDL cholesterol levels even more than C16:0 (Zock et al., 1994; Kris-Etherton 
et al., 1997). Like C16:0 and stearic acid (C18:0), high levels of C14:0 have been associated 
with an increased CAD risk (Zong et al., 2016). Recently its negative association with HDL 
plasma levels in a Mediterranean population has been highlighted, in agreement with the 
negative correlation observed between these two parameters (Tab. V). It has been suggested 
that C14:0 could influence HDL trapping on liver surface (Noto et al., 2016). This recent 
investigation pointed out how C14:0 could still hide unknown atherogenic effects that need to 
be uncovered. In the present study, for the first time an important new connection between 
C14:0 and TG plasma levels has been demonstrated. It is possible to speculate that this 
mechanism could be due to a C14:0 positive influence on the plasma TG-regulator ApoC-III, 
which was also found to be predicted mainly by C14:0 levels in the studied population (Tab. 
XII).  
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As far as we know this is the first time that such strong associations are highlighted by means 
of regression analysis in a population study, and in particular it is the first time that the relation 
between C14:0 and ApoC-III plasma levels have been reported. These data are in agreement 
with some population-based studies reporting correlation analysis involving FA levels. In the 
study of de Oliveira et al. focused on a multiethnic cohort of 2,837 US subjects, a significant 
increase in the levels of plasma TG in relation to the distribution of plasma phospholipid C14:0 
quintiles was reported (de Oliveira Otto et al., 2013). This trend is like that observed in Tab. 
XIV and Fig.4. In the following year another study based on a Mediterranean population of 427 
subjects at high risk of CVD reported that higher levels of C14:0 were present in people with 
metabolic syndrome (Mayneris-Perxachs et al., 2014), which is strictly connected with the risk 
of CVD. Moreover, in this study C14:0 showed a strong correlation with TG plasma levels. 
Research performed on 758 Western Alaskan Native subjects showed a statistically significant 
correlation of TG with C14:0 extracted from red blood cells (RBCs) and this correlation was 
even stronger when C14:0 extracted from plasma lipids was analysed (Ebbesson et al., 2015). 
Furthermore, in a very recent research C14:0 was found to be correlated to TG levels, together 
with C16:0 and C18:0, and with the presence of atherosclerosis (Polonskaya et al., 2017). 
Unfortunately, dietary supplementation studies failed to reveal the potential TG raising effect 
of C14:0. Zock et al. compared the effect of diet rich in C14:0, C16:0 and C18:1 on plasma 
lipids when supplied by means of synthetic fats accounting for 10% of total energy intake. 
They reported only a slight increase in TG levels following C14:0 diet compared with C18:1 
diet, but no differences in TG levels when compared with C16:0 supplementation (Zock et al., 
1994). However, the study of Zock et al. was limited by a very small sample size (59 subjects). 
In a large meta-analysis including 60 controlled trials, as well as in a recent WHO report based 
on 84 different studies the isocalorical replacement of 1% of total energy in the diet coming 
from carbohydrates with C14:0 was negatively associated with TG plasma levels in a slightly 
significant manner (Mensik et al. 2003, Mensik 2016). However, this study also had 
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limitations. This effect might be explained by the replacement nutrient used, as in the same 
report the replacement of SFA with carbohydrates caused an increase in total plasma TG 
concentration. The TG raising effect of the replacement nutrient used in this study -
carbohydrates- could therefore interfere with the detection of the actual C14:0 impact on TG 
plasma levels.  
The fact that C14:0 was simultaneously the first predictor of ApoC-III plasma levels, 
explaining also in this case a high portion of its plasma variability, represents further evidence 
supporting the association observed with TG plasma levels. As already mentioned, ApoC-III is 
a potent plasma regulator of TG levels, and loss-of-function mutations in APOC-III gene have 
had a favorable effect on the overall cardiovascular risk due to their reducing effect on TG 
plasma levels (Crosby et al., 2014). The important role played by ApoC-III in CAD has already 
been reported and recently our group has investigated the different sialylated isoforms of 
ApoC-III in CAD patients (Olivieri et al., 2002; Olivieri et al., 2003; Martinelli et al., 2007; 
Olivieri Oliviero, 2017). A very recent study reported ApoC-III among the three 
apolipoproteins most significantly associated with incident CVD, together with ApoC-II and 
ApoE (Pechlaner et al., 2017), which was predicted by C14:0 levels in this PhD thesis. The 
authors suggested that targeting TRLs would probably be a better solution for cardiovascular 
treatment, compared to the classical approach focused only on LDL cholesterol levels and 
measurement of classical ApoA-I and ApoB. While reducing LDL cholesterol represented an 
effective method for cardiovascular prevention, many patients maintain a significant residual 
risk. This observation is shifting the medical management of the cardiovascular risk trough the 
reduction of TG plasma levels, therefore current therapy for reducing ApoC-III plasma levels 
include statins, fibrates, thiazolidinediones, niacin and  antisense oligonucleotide currently 
under phase III study (Khetarpal et al., 2016). However, it is already known that ApoC-III 
plasma levels are also regulated by FAs and n-3 PUFA. At high pharmaceutical doses n-3 
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PUFA can decrease TG plasma levels through many mechanisms also involving ApoC-III 
reduction (Ooi et al., 2015; Khetarpal et al., 2016). The transcription of ApoC-III gene is also 
negatively mediated by the PPAR, which is activated by n-3 PUFA (Duval et al., 2007; Ooi et 
al., 2015). 
Interestingly, C14:0 has already been reported to modulate the apolipoprotein metabolism. In 
particular, in vitro experiments revealed that C14:0 treatments can increase ApoB secretion, 
while reducing its degradation, in HepG2 cells and in rat hepatoma cells (Arrol et al., 2000; 
Kummrow et al., 2002). Moreover, a slight negative influence on PPAR activity has also been 
reported when C14:0 has been supplied at high concentrations in HepG2 culture media, despite 
other FAs showing an even greater influence on the receptor activity (Popeijus et al., 2014). 
The disclosure that C14:0 could have an influence on ApoC-III levels, as suggested by the data 
presented in the present PhD thesis, would represent important information that could direct a 
proper cardiovascular prevention. 
In conclusion, this is the first time that regression analyses on such a large number of patients 
have demonstrated that C14:0 is the first FA predictor of TG plasma levels. Importantly, this 
result concurs with some correlation population-based studies supporting a positive association 
between C14:0 and TG. It seems reasonable to hypothesise a possible positive C14:0-related 
influence on TG plasma levels. Furthermore, the strong association observed with the potent 
TG plasma regulator ApoC-III represents an extremely important element in support of this 
theory. The important association found in this first part of the study therefore opened the road 
to further studies aimed at disclosing the possible influence of C14:0 on ApoC-III expression. 
An in vitro validation of this relationship could confirm the potential C14:0 effect on TG 
plasma levels, mediated by the hypothesised influence on ApoC-III levels, and will be 
presented in the following chapter.    
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CHAPTER 3 
ANALYSIS OF THE ASSOCIATION BETWEEN MYRISTIC ACID AND APOC-III IN 
A HEPG2 CELL MODEL 
 
 
1. INTRODUCTION 
The intake of specific FAs has been connected with the onset of different chronic diseases, 
including CVD. In recent years the understanding of the biological effects of FAs and of their 
mechanisms of action has been improved and the concept of “fatty acids sensing” has emerged. 
With this expression it is possible to refer to the ability of FAs to influence biological processes 
by acting as signaling molecules interacting with intra and extracellular receptor systems 
(Georgiadi et al., 2012). For example, the PPAR are nuclear hormone receptors that, also acting 
as transcription factors, regulate the expression of genes involved in lipid-related pathways, 
when activated by long-chain PUFA (Adkins et al., 2010). Other cellular receptor systems 
involved in the response to FAs levels include Toll-like Receptor 4 (TLR4), Sterol-Regulatory 
element Binding Protein 1 (SRBP1), Hepatocyte Nuclear factor 4 and other nuclear receptors 
(Georgiadi et al., 2012).  
To date information on the influence of FAs on apolipoprotein expression mainly refer to the 
negative effect of n-3 PUFA on ApoC-III protein levels and therefore on TG (Ito, 2015). n-3 
PUFA are considered one of the main cardioprotective nutrients. In 2002 the American Heart 
Association recommended n-3 PUFA for patients with ischaemic heart disease and subjects 
with hypertriglyceridemia (De Caterina, 2011), although some recent data have questioned 
their real clinical usefulness (Rizos et al., 2012; Roncaglioni et al., 2013).  
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In the present PhD thesis significant relationships between C14:0 and TG plasma levels, as 
well as between C14:0 and ApoC-III, in plasma of CAD and CAD free subjects have been 
identified. The consequent hypothesis is that these associations could hide a possible still 
unknown influence of this FA on the expression of ApoC-III, that could therefore trigger an 
effect on TG plasma levels. The confirmation of the existence of a positive C14:0 effect on 
the levels of ApoC-III would suggest a consequent reasonable influence on TG plasma 
levels, which were found to be mainly predicted by C14:0 in the plasma of analysed 
subjects. To disclose this possible association, the effects of different concentrations of 
C14:0 have been investigated by the in vitro experiments described in the present chapter.  
Since apolipoproteins are mainly secreted at hepatic levels, for the in vitro investigation of 
C14:0 effect on ApoC-III expression the hepatocellular carcinoma cells (HepG2) have been 
used. HepG2 represent a well-established cellular model for the study of lipoprotein 
metabolism (Meex et al., 2011) and they have been used in many studies on lipoprotein 
synthesis and metabolism, as well as in apolipoprotein expression experiments (Naem et al., 
2013; Wu et al., 2013; Parseghian et al., 2014; Noto et al., 2016).   
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2. EXPERIMENTAL DESIGN AND PROCEDURES  
The experimental part, and in particular the mass-spectrometry analysis, was performed thanks to the 
kind collaboration with Prof. Ruth Birner-Gruenberger and her group, who hosted me for three months 
in their Laboratory of “Functional Proteomics and Metabolic Pathways” at the Medical University of 
Graz, Austria. This placement was supported by the CooperInt exchange programme of the University 
of Verona. 
 
 
2.1 Cell culture and myristic acid conditioning 
HepG2 hepatoma cells were propagated in RPMI medium (RPMI 1640, Sigma Aldrich) 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 g/ml 
streptomycin and 4mM L-glutamine. Cells were maintained in a humidified incubator at 37°C 
with 5% CO2. For the experiment HepG2 cells were grown in a 75 cm
2
 flask (three replicas for 
each treatment) until they were 70% confluent and six hours before the experiment the medium 
was replaced by serum-free media. The treatment was performed by using C14:0 (Sigma 
Aldrich) complexed with fatty acids-free Bovine Serum Albumin (BSA, Sigma Aldrich) in a 
6:1 molar ratio. C14:0 was dissolved in 0.1 M NaOH (55°C) and added to a previously 
prepared 10% FA-free BSA solution, stirred for one hour at 37 °C. The filtered solution 
containing C14:0-BSA complex was supplemented into the serum-free media to obtain the 
following concentrations: 50, 125, 250 and 500 M of C14:0. Control cells were supplemented 
with BSA alone. After 24 hours of incubation, cells were harvested using trypsin. A small 
amount of cells was used to measure cell viability and growth, which were assessed using 
CASY technology (Roche). The viability measurement of this instrument is based on electrical 
current exclusion, since the status and the integrity of the cell membrane distinctively affects 
the electrical signal generated. The percentage of cell viability was expressed as the ratio of 
total viable cells to the sum of total of cells.  Remaining cells were washed three times with 
cold PBS and cell pellets were stored at -20°C until further use, as indicated in the experimental 
design (Fig.1). 
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 Fig.1 Experimental workflow 
2.2 Western Blot analyses on ApoC-III  
For Western Blot analyses cells were lysated directly in culture dish by adding RIPA buffer 
(Sigma Aldrich) on the PBS washed adherent cells. After an incubation step of five minutes in 
ice, cells were rapidly scraped and cell lysate was then transferred to a tube on ice. Sample was 
then subjected to ten minutes at 8000g at 4°C to remove cell debris. Protease inhibitors were 
added to the protein lysates. Protein samples from cell lysate (up to 100 g) and 1l of human 
plasma, loaded as positive control, were diluted in Laemmli’s sample buffer (62.5 mM Tris-
HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol Blue), boiled for three minutes and 
separated by SDS/polyacrylamide gel electrophoresis (PAGE) on 12% T acrylamide gels in 
Tris/glycine/SDS buffer. Proteins were then electroblotted onto a polyvinylidene fluoride 
(PVDF) membrane (Bio-Rad) at 80 V for two hours at 4°C. Amido-black staining was used to 
confirm equal protein loading in different lanes. Non-specific sites were blocked by incubating 
the membranes with 5% non-fat dried milk and 0.05% Tween-20 (Sigma-Adrich) in Tris-
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buffered saline at 37°C for 45 min. The membrane was incubated with the anti-ApoC-III 
antibody (ab108205, Abcam) at the dilution 1:1000 in 1% non-fat dried milk, 0.05% Tween-20 
in Tris-buffered saline for three hours at room temperature. The membrane was then incubated 
for 45 minutes at room temperature with the appropriate horseradish peroxidase (HRP)-
conjugated secondary anti-rabbit antibody. The immunocomplexes were visualised by 
chemiluminescence using the Chemidoc MP imaging system (Bio-Rad).   
2.3 Protein digestion for mass spectrometry analysis 
HepG2 cell lysis was performed by sonication, using an ultrasonic probe with an amplitude of 
70% for few seconds. Cell debris was removed by centrifugation at 3000g for 10 minutes at 
4°C. For each sample 10 g of protein were taken for digestion. Tris-HCl-TFE buffer (25% 
trifluoroethanol, 25% H2O, 50% Tris-HCl 100 mM, pH 8.5) was added to dilute each sample at 
least 1:4. Reduction step was performed using 10 mM TCEP (tris(2-carboxyethyl)phosphine) 
pH 8.5. Chloroacetamide 40 mM pH 8.5 was used for alkylation. After 10 minutes at 95°C, by 
shaking it was diluted to 10% TFE with 50 mM ammonium bicarbonate. For protein digestion 
Trypsin was used. In particular, 1 ug of trypsin was added to 50 ug of total protein and the 
digestion was performed overnight at 37 °C. The peptides obtained were then diluted in solvent 
A (0,3% FA, 5% ACN) and stored at -20 °C until further LC-MS/MS analysis was performed. 
  
2.4 LC-MS/MS targeted analysis of ApoC-III 
An aliquot of 500 ng of each sample was injected in a nano-HPLC (Dionex Ultimate 3000) 
equipped with a C18, 5 µm, 100 Å, 5 x 0.3 mm, enrichment column and an Acclaim PepMap 
RSLC nanocolumn (C18, 2 µm, 100 Å, 500 x 0.075 mm) (Thermo Fisher Scientific, Waltham, 
USA). Samples were concentrated on the enrichment column for six min at a flow rate of 5 
µl/min with 0.1 % heptafluorobutyric acid as isocratic solvent. Separation was carried out on 
the nanocolumn at a flow rate of 300 nl/min at 60 °C using the following gradient, where 
81 
 
solvent A is 0.1 % formic acid in water and solvent B is acetonitrile containing 0.1 % formic 
acid: 0-6 min: 4 % B; 6-94 min: 4-25 % B; 94 -99 min: 25-95 % B, 99 – 109 min: 95 % B; 
109.1-124 min: 4 % B; The maXis II
TM
 ETD high-resolution LC-QTOF mass spectrometer 
(Bruker Daltonics , Bremen, Germany) was operated with the captive source in positive mode 
with the following settings: mass range: 200 - 2000 m/z, 2 Hz, capillary 1300V, dry gas flow 3 
L/min with 150 °C, nanoBooster 0.2 bar, precursor acquisition control top17 (CID). For 
preferred fragmentation of ApoC-III peptides, previously measured peptide m/z were added to 
a preference mass list using a width of 0.02 m/z (R.GWVTDGFSSLK.D 2+, 
K.DALSSVQESQVAQQAR.G 2+/3+, K.DYWSTVK.D 2+, 
K.TAKDALSSVQESQVAQQAR.G 3+, R.GWVTDGFSSLKDYWSTVK.D 2+). The MS/MS 
data were analysed for protein identification and quantification using data analysis software 
(Bruker), Sum Peak algorithm, and by MaxQuant 1.5.3.30 (Cox et al., 2014) against the human 
public database SwissProt database with taxonomy homo sapiens (downloaded on 11.06.2015, 
42150 sequences) and common contaminants. Carbamidomethylation on Cys was entered as 
fixed modification, oxidation on methionine as variable modification. Detailed search criteria 
were used as follows: trypsin, max. missed cleavage sites: 2; search mode: MS/MS ion search 
with decoy database search included; precursor mass tolerance +/- 0.006 Da; product mass 
tolerance +/- 40 ppm; acceptance parameters for identification: 1 % PSM FDR; 1 % protein 
FDR. In addition, a label free quantitation including the Match between runs feature of 
MaxQuant was performed (Cox et al., 2014) requiring a minimum of 1 ratio counts of 
quantified razor and unique peptides. Data processing was performed using Perseus software 
version 1.5.0.31. Contaminants and reverse protein sequences created during the database 
search were removed. For data analysis ApoC-III intensities were normalised on the intensities 
of all peptides identified in each samples and statistical analysis was performed by t-test 
comparison. 
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2.5 Real Time PCR analysis of ApoC-III 
mRNA isolation was carried out adding TRI
 ®
 reagent (T9424, Sigma Aldrich) to cell pellets 
according to the producer’s instructions. Total RNA amount was quantified by means of a QBit 
3.0 fluorometer coupled with specific Qubit RNA BR or HS Assay Kit (Thermo Fisher 
Scientific). Before the reverse transcription step, the purity and integrity of the extracted RNA 
was checked loading 2 g of RNA on 1.2% agarose gel. For the reverse transcription reaction, 
a total of 400 ng of mRNA for each sample were used and cDNA was synthesised using 
SuperScript Vilo cDNA Synthesis Kit (11754, Invitrogen). RT-PCR was performed using 
TaqManUniversal Master Mix II (4440040, Applied Biosystems) and TaqMan Gene 
expression assay for ApoC-III (Hs00163644_m1, Applied Biosystems) according to the 
manufacturer’s protocol, in a real time PCR system (ABI Prism 7500, Applied Biosystems, 
Carlsbad, CA, USA). Relative quantification of the expression levels of transcript in each 
sample was normalised on GAPDH mRNA level, using Human GAPDH endogenous control 
(4326317E, Applied Biosystems). For each treatment RT-PCR were run on three biological 
replicates and on each sample in duplicate. Comparisons of ApoC-III expression levels 
between treated and control samples were performed using Student T-test on ddCt values and 
fold changes were calculated using the 2(-ddCt) method for relative gene expression 
quantification (Schmittgen et al., 2008).  
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3. RESULTS  
 
3.1 Effect of myristic acid treatments on HepG2 cells viability and growth  
After 24 hours of treatments with 0, 50, 125, 250 and 500 μM C14:0, cells were taken for 
viability and growth assessment by means of CASY technology. As reported in Fig.2, cell 
viability, assessed based on measurement of cells membrane integrity, remained above 90% 
for each C14:0 treatment used, although slightly decreasing with higher C14:0 concentrations. 
Measure of cell numbers after 24 hours of incubation with different concentrations of C14:0 
revealed a slight decrease in cell number, and therefore in cell growth, following increasing 
concentration of C14:0 (Fig.3).  
 
Fig.2 HepG2 viability, measured using CASY, after 24h treatment with different C14:0 concentrations.  
Fig.3 HepG2 numbers, estimated using CASY, after 24h treatment with different C14:0 concentrations. 
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3.2 Modulation of ApoC-III protein in HepG2 cells treated with myristic acid 
Despite the efforts, Western blot analyses failed to detect the presence of ApoC-III in the whole 
cellular lysate of HepG2 cells treated with different concentrations of C14:0, even when a 
higher amount of total protein was loaded and antibodies dilution increased. As reported in 
Fig.4 it was impossible to detect the presence of ApoC-III in the lysate of 250 M C14:0 
treated HepG2 cells (used as representative of all treatments), while ApoC-III was 
immunodetected in the sample of plasma used as positive control.  
 
Fig.4 Western Blot analysis of ApoC-III. Lane 1 from the left: marker. Lane 2: lysate of HepG2 cells 
treated with 250M C14:0. Lane 3: plasma sample as positive control.  
 
To obtain information on ApoC-III protein, the analysis on HepG2 lysate proteins was 
performed using a maXis II
TM
 ETD high-resolution LC-QTOF mass spectrometer (Bruker 
Daltonics), by performing a targeted analysis adding previously identified m/z values of ApoC-
III in the preferred list for better and more precise identification. By using this technique, it was 
possible to reveal the presence of intracellular ApoC-III, even though present at very low 
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concentration in samples of HepG2 cell lysates (Fig.6). The identification was possible with 
just one peptide in each sample and in the 0 and 50 M C14:0 treated cells the identification of 
ApoC-III was possible in only one of the three biological replicates analysed. However, the 
data obtained highlighted a slight and gradual increase in ApoC-III protein content following 
increasing C14:0 treatment, which was of statistical significance at 125 M C14:0. 
 
3.3 Modulation of ApoC-III mRNA in HepG2 cells treated with myristic acid 
To assess the possible influence of C14:0 on ApoC-III mRNA, the expression levels of ApoC-
III were assessed by means of reverse transcription and Real Time PCR following 24-hour 
treatment of HepG2 cells with 0, 50, 125, 250, 500 M C14:0. Before proceeding with the 
reverse transcription of mRNA, the purity of total RNA extracted from HepG2 cell lysates was 
assessed by running 2 g on a 1.2% agarose gel. The integrity and purity of total RNA was 
confirmed as shown in Fig.5. Results of the expression analysis were normaliszed on the 
expression levels of GAPDH housekeeping gene and were expressed as ApoC-III fold change 
as reported in Fig.6 (dark grey bars). It is possible to observe a gradual and slight rise in ApoC-
III fold change following the increasing concentration of C14:0. At 250 M C14:0 a 
statistically significant increase was observed (p=0.030). Interestingly, the general trend in 
ApoC-III mRNA expression levels agreed with the trend observed for the protein levels 
detected by means of MS/MS analysis.    
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Fig.5 Control of RNA purity and integrity following total RNA extraction. The loading of two 
exemplifying RNA samples extracted from HepG2 cells is reported.  
 
 
 
Fig.6 ApoC-III protein modulation in HepG2 treated cells measured by high-resolution MS (light grey) 
and ApoC-III mRNA modulation in the same samples, measured by RealTime PCR (dark grey). Data 
are represented as mean ± SD. Three independent samples per each C14:0 treatment were used. 
Significant changes were determined by t-test. * p<0,05 relative to the control group, # ApoC-III 
peptide identified in just one of the three biological replicates used.  
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4. DISCUSSION  
 
The role of plasma FAs on cardiovascular risk factors and on cardiovascular risk itself has been 
widely studied in previous decades (Mensink et al., 2003; Michas et al., 2014). The ability of n-
3 PUFAs of acting on ApoC-III and consequently on TG plasma levels, actually decreasing 
cardiovascular risk, is already known (De Caterina, 2011). However recent publications about 
well-known FAs have pointed out how these FAs may still have unknown important effects on 
cardiovascular parameters (Noto et al., 2016). This observation led to the development of the 
present project that, as shown in the first chapter, was initially aimed at revealing possible new 
links between lipid/apolipoprotein parameters and FAs plasma levels and as a consequence 
possible new FA-related cardiovascular risk mechanisms. Due to the important correlations 
involving C14:0 in the plasma of CAD and CAD-free subjects observed in the previous chapter 
of this thesis, in the present part of the project the possible influence of C14:0 on levels of 
ApoC-III was investigated in an in vitro cell model. The aim was to investigate the C14:0 
influence on both ApoC-III protein and mRNA levels. To assess the influence on protein 
concentrations, intracellular ApoC-III protein levels were investigated at first by means of 
Western Blot analysis. However, as reported in Fig.4, this technique failed to detect ApoC-III 
in HpeG2 cell lysate, possibly because of the extremely low protein levels. A different 
approach was then selected, consisting of high-resolution mass spectrometry analysis with the 
m/z values of some previously identified ApoC-III peptides in the preferred list for a better 
identification of the protein. This approach is very similar to targeted mass spectrometry and 
succeeded in the identification of ApoC-III protein as shown in Fig.6. As a confirmation of the 
initial hypothesis, the concentration of this protein was gradually increased following C14:0 
dosage, being particularly significant at 125 M. This observation supports the in vivo finding 
that C14:0 is the first predictor of both ApoC-III and TG plasma levels. However, some 
limitations in this study must be highlighted, including the identification of the protein with just 
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one peptide, when normally in mass spectrometry analysis at least two peptides are necessary 
for a proper protein identification (Kalli et al., 2012). Furthermore, ApoC-III was identified in 
just one of the three biological replicates for both controls and in the C14:0 50 M treated cells. 
However, the finding obtained by mass-spectrometry (MS) could be seen as a verification that, 
for those C14:0 concentrations (0 and 50 M), ApoC-III was present at lower concentrations, 
being therefore hardly detectable. On the other hand, in cells treated with the highest 
concentrations of C14:0 the identification of ApoC-III was possible in all the replicates, 
probably due to a strong C14:0 influence on ApoC-III protein levels. Finally, it should be 
noticed that the analysis was focused on the intracellular ApoC-III, while as described in the 
first chapter this is also a secreted protein. We decided as a first step to analyse the intracellular 
ApoC-III since it has been reported that that culture conditions have an influence on ApoC-III 
secretion by HepG2 cells which, differently to ApoC-III mRNA, is controlled by unknown 
serum factors (Clavey et al., 1999). Some FBS used for cell culture can impair ApoC-III 
secretion, but others cannot, and when changing the cell medium the secretion could not be 
restored. Importantly, this effect was also present if the experimental media - as in the present 
project - was without FBS, to avoid direct effect of serum on the secretion. Moreover, it was 
reported that in absence of FAs HepG2 cells secrete more LDL-like particle than normal 
hepatocytes that instead secrete buoyant VLDL particles (Ellsworth et al., 1986) and this 
feature could have led to questionable results and probably misinterpretations. For all these 
reasons the present part of the project was focused on the intracellular portion of ApoC-III.   
To have more in-depth results concerning C14:0 influence on ApoC-III expression, its effects 
on the mRNA levels were investigated (Fig.6) confirming the hypothesis of a positive influence 
of this FA on Apo C-III expression at mRNA level. Despite its gradual and slight rise, the 
expression level of ApoC-III actually increased with high concentrations of C14:0 and the 
increase in the mRNA fold change was statistically significant at 250 M.   
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To date this is the first time that ApoC-III protein and mRNA expression have been assessed 
following C14:0 supplementation in a cell culture system. Taken together, these in vitro 
findings suggest a probable influence of C14:0 on ApoC-III expression levels and support the 
positive correlations observed in vivo in plasma of CAD and CAD free patients, where C14:0 
resulted the first predictor of both ApoC-III and TG plasma levels. Further in vitro 
investigations would be necessary to clarify the exact mechanisms through which C14:0 can 
influence ApoC-III expression. The expression of this apolipoprotein is modulated by many 
transcription factors and it is negatively regulated by PPAR (Ooi et al., 2008). Interestingly, 
in HepG2 cells C14:0 showed the ability to lower the activity of this transcription factor even 
though the effect was reduced in comparison with some other FA such as C16:0 (Popeijus et 
al., 2014). Moreover, ApoC-III is positively regulated by insulin levels (Ooi et al., 2008), and 
accordingly SFAs are strictly connected with the onset of insulin resistance (Kennedy et al., 
2009; Sears et al., 2015). A possible major role of C14:0 on insulin resistance would need to be 
investigated in further in vitro experiments. An in vivo confirmation of a possible direct 
relationship between C14:0 consumption and TG plasma levels, as already done for n-3 PUFA 
(Tang et al., 2012), would also be needed. As hypertriglyceridemia is an important risk factor 
for CVD onset (Nordestgaard et al., 2014) and ApoC-III an important target to contrast this 
dangerous condition (Zheng, 2014; Khetarpal et al., 2016), the confirmation of a possible in 
vivo direct relationship between C14:0 consumption and TG plasma levels would represent an 
important landmark for proper and more complete cardiovascular prevention and treatment. 
 
5. Concluding remarks 
Both the in vivo and in vitro data obtained demonstrated an important role of the SFA C14:0 in 
the regulation of plasma TG levels. The results obtained suggest that this relationship could be 
mediated by a possible influence of C14:0 on the TG plasma regulator ApoC-III. Further 
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studies in this direction could help the elucidation of the negative role of C14:0 on 
cardiovascular health, probably confirming the opposite effect that C14:0 may have on TG 
plasma levels when compared with the well-known effect of n-3 PUFAs. 
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 CHAPTER 1 
PROTEOMICS AND FATTY ACIDS 
 
1. Proteomics investigations of fatty acids effects  
Over last few years the role of FAs has been studied and today the important influence of FA 
intake on many chronic diseases, including also CVD, has been established. For this reason, the 
importance of detecting and identifying biomarkers that can predict FA influence on specific 
diseases has emerged. Modulations in the protein expressions as well as in their post-
translational modifications in tissues and in biofluids (mainly plasma and urine) may highlight 
the real consequences of the intake of specific FAs, providing important information about their 
mechanisms of action. The disclosure of this information would be essential for proper 
prevention and precise treatment of many chronic diseases. Proteomic approaches today offer 
important opportunities to deepen our understanding of the mechanisms of action of different 
FAs and accordingly the number of proteomic investigations on FAs effect has increased over 
the last few years  (de Roos et al., 2012). First studies in this direction took advantage of the 
use of the two-dimensional gel electrophoresis (2-DE) for the visualisation of differently 
modulated proteins after specific FAs treatments, followed by an identification step using MS 
instruments. They investigated the modulations in tissues or biofluid proteomes of human or 
animal models. For example, the role of long chain n-3 PUFA intake on the levels of serum 
proteins was evaluated in a double blind randomised trial on 81 healthy volunteers (de Roos et 
al., 2008). 2-DE followed by MS technique revealed that some proteins such as ApoA-I, serum 
amyloid P and antithrombin III- like protein were down-regulated in the serum of those 
subjects who had fish oil supplements, demonstrating that fish oil activated anti-inflammatory 
and lipid-related mechanisms. The effects of n-3 PUFA was studied also on tissues by Sidhu at 
al. who studied the proteomics modulation following Docosahexenoic acid (DHA) 
supplementation on mouse brain synaptic plasma membrane (Sidhu et al., 2011). The authors 
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of this research found that 18 proteins, important for synaptic physiology, were significantly 
downregulated, including CREB and caspase-3 related proteins, and they suggest that this 
mechanism could be relevant for a suboptimal brain function. Furthermore, many studies 
investigated the roles of other FAs, and in particular of cis-9 trans-11-conjugated linoleic acid 
(CLA). The results of these analyses are controversial compared to studies highlighting the 
improvement of systemic insulin sensitivity in obesity-induced diabetes and others reporting no 
plasma proteome changes (de Roos et al., 2011; Rungapamestry et al., 2012). The analysis of 
mouse colon tissue proteome was also performed to shed light on the effects of n-3 and n-6 
PUFAs on bacterially induced intestinal inflammation. This study demonstrated the increase of 
proteins with anti-inflammatory activity following n-3 PUFA administrations and the 
modulation of proteins involved in cytoskeletal organisation and cellular stress after n-6 PUFA 
exposure (Cooney et al., 2012). Another study compared changes induced by the intake of 
different FA classes (SFA, MUFA and long-chain n-3PUFA) in the proteome of peripheral 
blood mononuclear cells (PBMC) of metabolic syndrome patients. Results of this study 
highlighted the increase in the expression of proteins related to oxidative stress, degradation of 
ubiquitinated proteins and DNA repair following SFA diet; these changes in the proteomic 
profile were associated with an increase in CVD risk factors (Rangel-Zuniga et al., 2015). 
Many researches were also focused on proteome changes in different cell culture models 
induced by FA treatments. As high levels of FAs play a role in inducing loss of function in 
pancreatic beta-cells, the effects of C18:1 in combination with glucose were studied in INS-1E 
model cells (Maris et al., 2011). Results showed that the treatment with oleate down-regulates 
chaperones impairing insulin signaling and proteasome degradation and provided an important 
insight into the molecular mechanism through which oleate induces beta cells dysfunction. 
More recent studies substituted the use of 2-DE technique with LC-MS/MS methods, as in the 
case of Sargsyan et al., who in 2016 proceeded with the study of FA effects on beta cells 
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(Sargsyan et al., 2016). The results of their study showed that C18:1 plays a pro-survival role 
targeting ER stress proteins and protecting beta cells from the toxic effects of C16:0. This case 
highlighted how proteomics can provide a complete overview of molecular mechanisms 
involved in pathological conditions. FAs have not only an important role in insulin secretion at 
pancreatic level, but also play a fundamental role in insulin sensitivity in many part of the body, 
such as in muscles. Last year a study investigated the effects of C16:0 and C18:1 on mouse 
C2C12 myoblasts (Chen et al., 2016). C18:1 was shown to revert the toxic effects of C16:0 in 
this type of cells, lowering levels of Cox-2, previously found to be strongly up-regulated by 
C16:0. The overall positive effect of C18:1 therefore lies in the ability of relieving cellular 
stress and restoring insulin sensitivity. A very recent study instead investigated the role of 
Eicosapentaenoic acid  (EPA), an n-3 PUFA, on the proteome of HUVEC cells stimulated with 
TNF in order to simulate a model of endothelial activation (Zhang et al., 2017). Many 
enriched pathways were identified, such as glutathione metabolism, oxidation reduction, and 
DNA replication, giving important insights into the protective role of n-3 PUFA in the 
atherosclerotic process.  All this research underlines how FAs have important effects on many 
different mechanisms taking place in different organs and how proteomics may represent a 
crucial technique for their detection.  
During the last few years many proteomic studies have also aimed at investigating the effects 
of FA intake at hepatic level (Tab. I). The liver is involved in the absorption of chylomicrons 
lipids and in the simultaneous secretion of VLDL with their related apolipoproteins, 
representing an important hub in lipid metabolism and metabolic disorders - as described in 
detail in the first section. Furthermore, the understanding of the molecular changes in response 
to FA intake could help the treatment and prevention of Nonalcoholic fatty liver disease 
(NAFLD), the most common form of liver disease in the US (Charlton, 2004). This is a 
pathological condition where fat accumulates in the liver in patients with no history of 
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excessive alcohol consumption. NAFLD is characterised by a wide spectrum of liver diseases, 
ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) which can eventually 
evolve into fibrosis and cirrhosis and liver cancer. The strong interplay between NAFLD and 
MetS has been described and both disorders can predict T2DM and CVD (Yki-Jarvinen, 2014). 
It has been demonstrated that NAFLD can be detected in a high percentage of patients with 
documented CAD (Baharvand-Ahmadi et al., 2016). Dietary FA composition seems to be 
involved in the pathogenesis of hepatic steatosis (Ferramosca et al., 2014), having a central role 
in fat accumulation, and for this reason many studies have focused on the study of FA effects 
on hepatic metabolism (Malhi et al., 2006; Ricchi et al., 2009; Mei et al., 2011; Hetherington et 
al., 2016). Because of their roles in lipid metabolism - and therefore on CVD -, and for their 
influence on NAFLD, the role of FAs on liver metabolism has also been analysed during the 
last few years with proteomic approaches. In some studies, high-fat diet mice were used as 
models of NASH, and their proteome changes were analysed in comparison to control groups. 
Results highlighted the activation of some pathways following high-fat diet, involving 
xenobiotic, lipid metabolism, inflammatory response and cell-cycle control (Kirpich et al., 
2011). Moreover, the specific proteomic analysis of liver mitochondria from rats with NASH 
confirmed the involvement of lipid metabolism  and cell cycle control pathways and 
highlighted some new pathways, for example FAs -oxidation and cell polarity maintenance 
(Li et al., 2014) . The proteomic effects of n-3 PUFA- rich diet was also investigated on mouse 
liver samples, to elucidate their beneficial health effects (Ahmed et al., 2014). Several novel 
proteins were found to be modulated by this treatment, such as regucalcin, an important protein 
involved in lipid metabolism. Other proteins were found to be deregulated, mainly involved in 
the regulation of lipid and carbohydrate metabolism, one carbon-metabolism, citric cycle and 
protein synthesis. The strength of this research lies in the use of a proteomic approach, which 
highlighted both specific proteins involved in the beneficial effects of n-3 PUFA and general 
pathways. The anti-inflammatory properties of n-3 PUFA were confirmed at molecular levels 
96 
 
in another proteomic investigation on ApoE-knockdown mice (Huang et al., 2015). They 
demonstrated that n-3 PUFA are involved in many steps of the hepatic metabolism and they 
also verified the exact anti-inflammatory molecular mechanism in HepG2 cells, reporting that 
n-3 PUFA can actually inhibit nuclear factor- B (NF-B) activation. HepG2 represent an 
important cellular model for the study of liver metabolism; due to the scarce availability of 
human hepatocytes for research purposes, they are generally used (Ramboer et al., 2015). Even 
though some limitations when using this type of cells should be borne in mind, as there are also 
some differences in comparison with hepatocytes from a proteomic point of view (Wisniewski 
et al., 2016), HepG2 showed more proteomic features characteristic of hepatocytes than other 
hepatoma cell lines (Slany et al., 2010). Over the last few years HepG2 cells have been used as 
a model to investigate the proteomic hepatic response to elaidic acid, in combination with 
lipidomic and transcriptomic approaches (Vendel Nielsen et al., 2013). HepG2 were also used 
as cellular model in a subsequent study on the effects of TFA (Krogager et al., 2015). The 
effects of elaidic and trans-vaccenic acids were compared at proteomic levels. A notable 
adverse effect of elaidic acid was demonstrated, as only this FA induced an increase in proteins 
involved in cholesterol synthesis and transport.  
All these findings emphasise the importance and opportunities offered by proteomics in the 
study of metabolism disorders and especially in FA effects. Furthermore, recent studies aimed 
at investigating molecular mechanisms related to lipid metabolism and NAFLD introduced the 
use of HepG2 cells as a model for the investigation of FA response from a proteomic point of 
view. However, to date only the proteomic effects of some specific FAs – but not of C14:0 - 
have been analysed and more investigations in this direction are necessary.  
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Fatty acid 
supplementation/ 
Diet 
Sample analysed Proteomic approach Reference 
High-fat diet Mice liver 
2D-DIGE 
MALDI-TOF/MS-MS 
Kirpich, 2011 
High-fat diet Mice liver mitochondria 
2DE 
MALDI-TOF/MS-MS 
Li, 2014 
Diets high or low 
in n-3 PUFA 
C57BL/6 mice liver 
2D-PAGE 
MALFI TOF MS 
Ahmed, 2014 
PUFA 
ApoE-knockout mice 
liver 
HepG2 cells 
2DE 
Ion trap LC/MS 
Huang, 2015 
Elaidic acid 
HepG2 SILAC 
DIGE 
Vendel Nielsen, 2013 
Elaidic acid and 
trans-vaccenic acid 
HepG2 
SILAC 
TRIPLE-TOF MS 
Krogager, 2015 
 
Tab. I Most recent proteomic research analysing the influence of fatty acids and fats on liver 
metabolism. 
 
2. In-vitro studies on myristic acid 
Myristic acid (C14:0) is a saturated FA, present in many oils and particularly diary fats. The in 
vivo effects of this FA have been studied over the years in population-based studies, as 
described in detail in the first section of the present thesis. However, in vitro investigations 
were performed - mainly on hepatoma cell lines - to elucidate C14:0 molecular mechanisms 
and interactions. Some studies aimed at investigating its possible influence on lipid metabolism 
showed that incubation of McA-RH7777 cells with C14:0 caused the secretion of dense ApoB 
containing lipoproteins (Kummrow et al., 2002). A reduction in ApoB degradation was also 
reported, together with an increase in its secretion (Arrol et al., 2000; Kummrow et al., 2002). 
Subsequent research in this direction recently confirmed the increase in VLDL after C14:0 
treatment in primary hepatocytes (Tiwari et al., 2016). Moreover, it was reported that C14:0 
enhances VLDL transport vesicle budding and the recruitment of their main protein 
small valosin-containing protein-interacting protein (SVIP) to the ER. An increased secretion 
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of ApoB in presence of C14:0 was also observed both in HepG2 and McA-RH7777, together 
with a decrease in ApoB degradation in the latter cells (Arrol et al., 2000; Kummrow et al., 
2002). Furthermore, like other FAs, C14:0 showed an influence on ApoA-I by decreasing Sp1 
binding to APOA-1 promoter and therefore its synthesis (Haas et al., 2004). This 
apolipoprotein is among the main proteins of HDL, as described in the first section. HDL 
metabolism seems to be influenced by C14:0 administration. Recently it has been reported that 
C14:0 increases HDL binding to HepG2 cells by a nonsaturable pathway suggesting a possible 
explanation for the association with decreased HDL levels found in plasma of the 
Mediterranean population (Noto et al., 2016). Moreover, the expression of ApoA-I - as for 
other apolipoproteins, such as ApoC-III - is controlled by Peroxisome Proliferator Activated 
Receptors, principally the PPAR form (Duval et al., 2007; Ooi et al., 2008). Like other SFAs, 
C14:0 showed the ability to decrease the activity of this ligand-activated receptor when 
supplied in a concentration greater than 10 M in HepG2 culture media (Popeijus et al., 2014).  
C14:0 seems to have a role not only in molecular mechanisms underlying lipid metabolism but 
also in the insulin pathway. Human G protein-coupled receptor 40 (hGPR40), also known as 
free fatty acid receptor 1, is an important player in the glucose-dependent insulin secretion in 
pancreatic -cells and a recent study investigated its binding affinity for 18 FAs (Ren et al., 
2016). FAs with carbon chain longer than C14:0 had molecular size too large for entering the 
receptor binding pocket, while among shorter FAs C14:0 showed the highest affinity for the 
receptor, suggesting a potential important involvement in insulin secretion. Moreover, C14:0 
seems to play an important role in the skeletal muscle, the major insulin-target organ involved 
in glucose uptake. In mouse C2C12 myotubes C14:0 was seen to increase by 1.4 fold the 
insulin-dependent glucose uptake, increasing the expression of diacylglycerol kinase (DGK)  
(Wada et al., 2016). This evidence suggested an important aspect of C14:0 that would therefore 
protect and improve glucose homeostasis in T2DM.  
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Besides being one of their target molecule, C14:0 has an important influence on desaturases 
activities (Rioux et al., 2011). In 2004  an increase in Δ6-desaturase activity in a dose 
dependent manner when cultured rat hepatocytes were incubated with C14:0 was reported (Jan 
et al., 2004). This evidence highlighted the important role of this FA in the regulation of PUFA 
bioavailability. Some years later the Rioux research group found that the activity of 
Sphingolipid Δ4 desaturase 1 (DES1) was increased in presence of increasing concentrations of 
C14:0 in COS-7 cells (Beauchamp et al., 2007). As DES-1 is an enzyme involved in the 
catalysis of the last step of the de novo ceramide biosynthesis, through the introduction of a 
trans Δ4-double bond in the carbon chain of the dihydroceramide, this evidence suggested an 
important role of C14:0 in the biosynthesis of ceramide and in sphingolipid metabolism. Some 
years later, they demonstrated that the treatment with C14:0 targeted DES1, initially present in 
the ER, to the mitochondrial membrane, causing an increase in ceramide levels and apoptotic 
consequences (Beauchamp et al., 2009). Later on, the increase in DES1 activity and the 
consequent increase in the number of apoptotic cells were confirmed in culture rat hepatocytes 
(Ezanno et al., 2012). A further study reported that C14:0 is not lipotoxic to primary mouse 
hepatocytes but can potentiate C16:0-mediated apoptosis, ER stress, cytochrome c release and 
caspase-3 activation (Martinez et al., 2015). These findings were confirmed in vivo in mice fed 
with a combination of palmitic and C14:0, exhibiting a wide range of effects, including 
lipodystrophy, hepatosplenomegaly, increased liver ceramide content and cholesterol levels, 
ER stress, liver damage, inflammation and fibrosis. 
The effects of C14:0 on DES1 are due to the N-myristoylation of the enzyme (Rioux et al., 
2011). Through the irreversible covalent linkage to the N-terminal glycine of many eukaryotic 
and viral proteins - called myristoylation - C14:0 can regulate many protein features, including 
protein subcellular localisation, protein-protein interaction and protein-membrane interactions 
(Martin et al., 2011). As C14:0 is hydrophobic by nature, myristoylated proteins are targeted to 
hydrophobic regions, such as lipid rafts, plasma membrane, Golgi, ER, nuclear membrane and 
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mitochondria. Due to the specific localisation of these proteins, C14:0 can regulate different 
cellular functions. While in the beginning this modification was described as a co-translational 
reaction, it was further observed as a post-translational event in apoptotic cells. N-
myristoyltransferase (NMT) is the enzyme that catalyses the irreversible attachment of C14:0 to 
an N-terminal - or internal when the myristoylation occurs post-translationally - glycine of the 
target protein; in some rare cases the attachment can also occur in correspondence with an 
internal lysine by means of an amide bond. NMT inhibition causes loss of N-myristoylation 
and cytotoxicity in cancer cells and a recent proteomic study revealed that this inhibition has 
important consequences in HeLa cells, such as ER stress, cell cycle arrest and apoptosis 
(Thinon et al., 2016). Another previous proteomic study showed, by means of a chemistry-
based approach, more than 100 protein myristoylated in Hela cells during normal growth and 
apoptosis (Thinon et al., 2014). Among those proteins they found nucleolar proteins that 
mediate nuclear process, component of the ubiquitination machinery, proteins involved in cell 
cycle regulation, in microtubule dynamics and in many other cell functions. Studies specifically 
aimed at identifying the N-terminally myristoylated protein in the liver used cultured rat 
hepatocytes as a model and found both signal transduction proteins, such as the  subunit of the 
heterotrimeric G protein, and also cytoskeleton proteins, such as actin and cytokeratin (Rioux et 
al., 2002). Recent research has highlighted the role of myristoylation in carcinogenesis and in 
immune functions, due to its ability to modulate immune cell signaling cascade (Udenwobele et 
al., 2017). However, even though this modification has many cellular consequences, it should 
be noted that only 0.05% of the radiolabeled C14:0 added in cell culture media is used for N-
myristoylation (Martin et al., 2011). 
In conclusion, even though many studies investigated the effects of C14:0 on different cellular 
pathways, data are to date fragmentary and a complete overview of its biochemical effects does 
not exist. As mentioned above, proteomics techniques represent an efficient tool to study the 
effects of FAs at molecular level from a global point of view. Therefore, the use of these 
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techniques would be essential for the study of overall C14:0 effects, particularly on liver cells 
where this FA may mediate pathological conditions such as cardiovascular disease, following 
perturbation of lipid metabolism, and NAFLD. 
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CHAPTER 2 
IN VITRO PROTEOMIC ANALYSIS OF HEPG2 CELLS TREATED 
WITH MYRISTIC ACID 
 
 
1. INTRODUCTION  
 
As mentioned in Chapter 1 a general and complete overview of the proteomic effects of C14:0 
on liver cells does not exist.  
In vivo studies described C14:0 as an independent predictor of the liver pathology NASH 
(Tomita et al., 2011). Moreover, in the first section of the present thesis, evidence supporting its 
involvement in the regulation of ApoC-III and plasma TG levels -and therefore in 
cardiovascular health- have been reported. This suggests that the influence of this FA on lipid 
metabolism to date is still only partially disclosed. For this reason, a more in-depth 
investigation of C14:0 effects, in particular at liver level, is required to elucidate the association 
of this FA with NASH and cardiovascular disease.   
The proteome, as well as the secretome, of C14:0-treated HepG2 cells have been investigated, 
with the aim of disclosing the overall proteomic and biochemical effects linking this unhealthy 
FA with pathological conditions. This type of investigation could contribute to a better 
understanding of the molecular mechanisms behind clinical findings related to the plasmatic 
C14:0 levels and its adverse health effects.  
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2. EXPERIMENTAL DESIGN AND PROCEDURES 
This experimental part, and in particular the MS analysis, was performed thanks to the kind 
collaboration with Prof. Ruth Birner-Gruenberger and her group, Medical University of Graz, Austria.  
 
2.1 Cell culture and treatment with myristic acid 
 
HepG2 cells were cultured in RPMI 1640 media (Sigma-Aldrich), supplemented with 10% 
FBS, 100 U/ml penicillin and 100 g/ml streptomycin, 4 mM L-glutamine and were maintained 
in a humidified incubator at 37°C in an atmosphere of 5% CO2. The FBS was removed from 
the HepG2 culture media six hours before C14:0 treatments. C14:0 was complexed to Bovine 
Serum Albumin (Fatty Acid Free BSA, Sigma-Aldrich) by mixing a solution 10 mM C14:0 
(previously dissolved in NaOH 0.1M at 55°C) with a solution of 10% BSA and stirring one 
hour at 37°C, as previously described (Noto et al., 2016). A limpid solution was obtained and 
was then filtered with 0.22 m filters. The C14:0-BSA solution obtained was added to cell 
culture FBS-free media at the following concentrations: 50, 125, 250 μM and 500 μM.  10% 
BSA was added to controls. C14:0-BSA incubation was performed for 24 hours. To ensure no 
interference of the BSA at proteomic analysis level, for the secretome analysis C14:0 was 
dissolved in dimethyl sulfoxide (DMSO), as previously described (Popeijus et al., 2014). The 
C14:0 dissolved in DMSO was added to cell culture FBS-free media at 50, 125, 250 μM while 
to obtain controls only DMSO was added to the medium. Notably, the same quantity of DMSO 
(0.5%) was used for all treatments, in order to exclude possible DMSO effects. For this analysis 
the incubation was also performed for 24 hours. Three biological replicates for each C14:0 
concentration were used both for the proteome and secretome analyses. Immediately after the 
incubation the cells were washed twice with PBS, and the viability was checked by analysing 
three times an aliquot of cells with CASY Cell Counter and Analyzer. Then the cells were 
subjected to the experimental workflow indicated in Fig.1. The viability measurement of this 
instrument is based on the electrical current exclusion, since the status and the integrity of the 
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cell membrane distinctively affects the electrical signal generated. The percentage of cell 
viability was expressed as the ratio of total viable cells to the sum of total cells.  
 
Fig.1 Experimental Workflow 
 
2.2 Oil Red O staining 
HepG2 cells were grown on a cover slip inside a 6-well plate. Cells were incubated with C14:0-
BSA at the concentrations mentioned above for 24 hours, washed with phosphate-buffered 
saline (PBS) and then fixed with 4% formaldehyde solution for five min at room temperature. 
After fixation, cells were washed gently with 60% isopropanol and stained with the working 
solution of 0.6 % Oil Red O in 60% isopropanol for 15 min. The HepG2 stained cells were 
washed with distilled water several times to remove unincorporated dye. Then, the samples 
were stained with hematoxylin for 4 min for nuclei visualisation. Slides were examined using a 
light microscope with 100X magnification. 
 
2.3 Proteome and Secretome sample Preparation  
C14:0 treated cells were harvested using trypsin and centrifuged at 3000g for 10 min at 4°C to 
discard RPMI media. After two washes with cold PBS, cells were lysed in PBS by sonication, 
using an ultrasonic probe with an amplitude of 70% for few seconds. Cell debris was removed 
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with centrifugation at 3000g for 10 minutes at 4°C. For secretome preparation, the HepG2 cell 
media containing secreted proteins were collected by centrifugation at 5,000g for 10 min to 
pellet floating cells. Proteins in the media were concentrated using Amicon Ultra-4 filers 3K 
(Merk Millipore, Darmstadt, Gemany) to reduce sample volume. Protein concentrations were 
determined using Bradford Protein assay (Bio-Rad). 10 g of protein were taken from each 
sample for protein digestion, as described in Paragraph 2.3, Chapter 3 of Section 1.  Tris-HCl-
TFE buffer (25% trifluoroethanol, 25% H2O, 50% Tris-HCl 100 mM) was added to dilute each 
sample at least 1:4. Reduction step was performed using TCEP, (tris(2-
carboxyethyl)phosphine), 10 mM final concentration. CAA (chloroacetamide) 40 mM was used 
for alkylation. Samples were shaken 10 minutes at 95° and diluted to 10% TFE with 50 mM 
ammonium bicarbonate. Proteins digestion was performed by adding 1g/L of trypsin to 
every 50 g of proteins and an overnight incubation at 37 °C was performed. Obtained peptides 
were then diluted in solvent A (0.3% FA, 5% ACN) and stored at -20 °C until further LC-
MS/MS analysis. 
 
2.4 LC-MS/MS and data analysis 
Label free mass spectrometry analysis and protein identification were performed as described 
in Chapter 2 Section 1. An aliquot of 500 ng of each sample was injected in a nano-HPLC 
(Dionex Ultimate 3000) equipped with a C18, 5 µm, 100 Å, 5 x 0.3 mm, enrichment column 
and an Acclaim PepMap RSLC nanocolumn (C18, 2 µm, 100 Å, 500 x 0.075 mm) (Thermo 
Fisher Scientific, Waltham, USA). Separation was carried out on the nanocolumn at a flow rate 
of 300 nl/min at 60 °C using an acetonitrile and formic acid gradient. The maXis II
TM
 ETD 
high-resolution LC-QTOF mass spectrometer (Bruker Daltonics, Bremen, Germany) was 
operated with the captive source in positive mode. 
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The MS/MS data were analysed for protein identification and quantification using Data 
analysis software (Bruker), Sum Peak algorithm, and by MaxQuant 1.5.3.30 against the human 
public database SwissProt database with taxonomy homo sapiens (downloaded on 11.06.2015, 
42150 sequences) and common contaminants. Carbamidomethylation on Cys was entered as 
fixed modification, oxidation on methionine as variable modification. In addition, a label free 
quantification including the match between runs of MaxQuant was performed (Cox et al., 
2014) requiring a minimum of two ratio counts of quantified razor and unique peptides. Data 
processing was performed using Perseus software version 1.5.0.31. Contaminants and reverse 
protein sequences created during database search were removed. LFQ intensities were log2 
transformed to lower the effect of the outlier values. Filtering for three valid values in at least 
one condition - C14:0 concentration - was used for both proteome and secretome analysis. For 
protein groups missing LFQ values, this value was obtained by means of an imputation step in 
which the values were replaced with random values taken from the Gaussian distribution of 
values, to simulate an LFQ value for those low abundant protein groups. Perseus default 
parameters (width of 0.3 and downshift of 1.8 separately for each column) were maintained 
during this passage. For each protein group log differences were calculated as the difference 
between the averages of log2 LFQ intensities of the treated samples and the average of log2 
LFQ intensities of the controls. R software (RCoreTeam, 2015) was employed for statistical 
analysis. ANOVA with subsequent multiple testing correction with Benjamini-Hochberg  
method was used to identify altered protein groups (Benjamini et al., 1995). Tukey's Honest 
Significant Differences test on protein groups significant after the ANOVA was used for the 
comparison of protein groups among different samples. Only proteins with p-value < 0.05 and 
fold change  1.3 in both directions were considered significantly modulated.  
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2.5 Protein annotation, secretion prediction, protein networks and pathways analysis 
The analysis of identified proteins was performed according to Gene Ontology (GO) using the 
DAVID v6.8 Functional Annotation Bioinformatics Tools (https://david.ncifcrf.gov/) (Huang 
da et al., 2009). Using this tool, the enrichment analysis for GO cellular component, biological 
process and molecular function was performed by comparing the GO terms of identified 
proteins against the rest of the genome. This analysis revealed the over-represented GO terms 
(p < 0.05) in the submitted dataset.  
In order to investigate the secretion mechanisms of the proteins found to be modulated in the 
secretome of C14:0-treated HepG2 cells, the potential secretion pathways were predicted by 
using the SecretomeP v2.0 server (Bendtsen et al., 2004) 
(http://www.cbs.dtu.dk/services/SecretomeP/). This tool predicted classically and non- 
classically secreted proteins. For those proteins predicted to be secreted by non-classical 
secretion pathways, the potential exosomal and microvesicle release was investigated by 
annotation on the ExoCarta database (Mathivanan et al., 2009) (http://exocarta.ludwig.edu.au/). 
To investigate possible interaction networks between the proteins modulated by C14:0, the 
STRING database v10.5 (http://string-db.org) (Snel et al., 2000) was used. The network was 
built using associations with a medium score (≥ 0.4) based exclusively on experimental and 
database knowledge while excluding all other prediction methods implemented in STRING 
(such as text-mining and co-expression). Additional white nodes and network depth were kept 
to the minimum value (5 and 1 respectively), to exclude as many false positive interactions as 
possible.  
In addition, ClueGO v2.3.3 (Bindea et al., 2009), a Cytoscape v3.5.1 plug-in, was used for 
analysing significantly enriched GO biological process and KEGG pathways (p-value < 0.05) 
by using the human genome as background. In ClueGO settings the kappa score level was set 
to 0.4 and the GO Tree Levels ranged from levels 3−8. 
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2.6 Western Blot analysis of selected proteins  
To confirm the protein trend detected by MS/MS and deepen the effect of C14:0 on ER stress, 
western blot analyses were performed. Samples from two different biological replicates were 
diluted 1:1 with Laemmli’s sample buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 
0.01% Bromophenol Blue), kept at 95°C for seven minutes and separated by 
SDS/polyacrylamide gel electrophoresis on 12% T acrylamide gels in Tris/glycine/SDS buffer. 
Proteins were then electroblotted onto polyvinylidene fluoride membranes (Bio-Rad) at 80 V 
for two hours at 4°C. Amido black staining was used to confirm equal protein loading in 
different lanes. Non-specific sites were blocked by incubating the membranes with 5% non-fat 
dried milk and 0.05% Tween-20 (Sigma Adrich) in Tris-buffered saline at 37°C for 45 min. 
Membranes were incubated with the different primary antibodies at the appropriate dilutions 
(as reported in Tab. I) in 1% non-fat dried milk, 0.05% Tween-20 in Tris-buffered saline.  
 
Antibody Gene Name Source Supplier Dilution 
Perilipin 2 PLIN2 mouse 
Santa Cruz Biotechnology 
(sc-377429) 
1:100 
Vesicle associated 
membrane protein 
associated protein B/C 
VAPB mouse 
Santa Cruz Biotechnology 
(sc-293364) 
1:100 
Eukaryotic peptide chain 
release factor GTP-binding 
subunit ERF3A 
GSPT1 mouse 
Santa Cruz Biotechnology 
(sc-515615) 
1:1000 
-Actin ACTB mouse Sigma A2228 1:3000 
Fatty Acids Synthase FASN 
mouse Santa Cruz Biotechnology 
(sc-55580) 
1:1000 
Heterogeneous nuclear 
ribonucleoprotein A2/B1 
HNRNPA2B1 mouse 
Santa Cruz Biotechnology 
(sc-374053) 
1:1000 
Heat shock cognate 71 KDa 
protein 
HSPA8 mouse 
Santa Cruz Biotechnology 
(sc-7298) 
1:1000 
Complement C4 C4A/B mouse 
Santa Cruz Biotechnology 
(sc-271181) 
1:100 
Retinol Binding Protein 4 RBP4 mouse 
Santa Cruz Biotechnology 
(sc-48384) 
1:100 
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Tab. I Primary antibodies used for Western Blot analysis.  
 
 
The incubation lasted for three hours at room temperature, except for Vesicle associated 
membrane protein associated protein B/C (VAPB) for which an overnight incubation was used. 
Blots were then incubated for 45 minutes at room temperature with horseradish peroxidase 
(HRP)-conjugated secondary antibody (Santa Cruz Biotechnology, sc-2005, diluted 1:5000). 
The immunocomplexes were visualised by chemiluminescence using the Chemidoc MP 
Imaging System (Bio-Rad, Hercules, USA).  
  
Cyclic AMP-dependent 
transcription factor ATF-6 
alpha 
ATF-6 mouse 
Santa Cruz Biotechnology 
(sc-166659) 
1:100 
Serine/threonine-protein 
kinase/endoribonuclease 
IRE1 
ERN1 mouse 
Santa Cruz Biotechnology 
(sc-390960) 
1:100 
Eukaryotic translation 
initiation factor 2-alpha 
kinase 3 PERK 
EIF2AK3 mouse 
Santa Cruz Biotechnology 
(sc-377400) 
1:100 
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3. RESULTS 
 
3.1  Effects of myristic acid on HepG2 viability and on lipid droplets accumulation 
The effects of different concentrations of C14:0 (50-125-250-500 M) on HepG2 cell 
viability were determined after 24 hours’ incubation by means of CASY technology, based 
on cell membrane integrity assessment (Section1, Chapter 3, Fig.2). Cell viability remained 
above 90% after 24 hours’ incubation with each C14:0 treatment used. The effect on cell 
viability of different dosages of C14:0 when dissolved in DMSO - used for secretome 
analysis - was also assessed (Fig.2). The results obtained indicated that C14:0 showed no 
toxicity to HepG2 cells. Nevertheless, at 500 μM C14:0-BSA there was a slight (although 
statistically not significant) decrease of cell viability. For this reason, samples treated with 
C14:0 500 M were excluded from subsequent analyses. 
 
Fig.2 HepG2 cell viability, measured by using CASY technology, after 24h treatment with different 
concentration of C14:0 (0, 125, 250 M) dissolved in DMSO. All experiments were repeated in 
triplicate. 
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The evaluation of C14:0 effect on HepG2 cells was also performed by analyzing the lipid 
droplet (LD) accumulation. Cells were stained with Oil Red O solution (pink dye) for 
intracellular neutral lipid and hematoxylin (blue) for nuclei visualisation and were observed by 
microscopy at 100X magnification (Fig.3). While there were no visible lipid droplets in the 
untreated control cells, C14:0 treatment for 24 hours induced the accumulation of lipid droplets 
in HepG2 cells even at the lowest concentration (50 µM). Lipid droplets were particularly 
evident and distinct at 125 M. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 Intracellular lipid droplets in HepG2 cells stained with Oil Red O. No lipid droplets were 
observed in HepG2 cells in the control group (upper image), while they were present in HepG2 cells 
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after myristic acid treatments (50, 125, 250 and 500 μM). Cells were observed under 100X 
magnification. 
 
3.2 Quantitative analysis of proteins deregulated by myristic acid in HepG2 proteome and 
secretome. 
To elucidate the effects of C14:0 treatments (50, 125 and 250 μM for 24h) on HepG2 cells 
proteome and secretome, separated proteomics investigations were performed on cell lysates 
and secreted proteins in culture media respectively. Protein expression in biological triplicates 
from C14:0-treated and untreated cells was compared. For each sample equal amounts of 
digested protein were subjected to MS/MS analysis. Output data were analysed by MaxQuant 
software package employing label-free quantification (LFQ) of areas of extracted ion 
chromatograms of peptides from MS1 spectra to compare relative abundances of proteins 
between groups. Proteins with a minimum fold-change of 1.3 and an ANOVA p-value < 0.05 
in the post hoc test were considered deregulated.  
As concerns the proteome analysis, a total of 1,937 proteins with at least 99% confidence (FDR 
< 1%) were identified. After filtering for contaminants, for sequences read in the reverse 
direction and finally for proteins identified in all three biological replicates in at least one 
condition – C14:0 concentration -, a total of 1,362 proteins were found. Among these 47 
intracellular proteins showed fold change greater or equal of ± 1.3 when compared to controls 
and concurrent significantly altered levels of expression following ANOVA and Tukey’s 
comparison post hoc test (p < 0.05). Control versus 50 μM C14:0 analysis revealed 12 up and 
two down-regulated, control versus 125 μM C14:0 26 up and five down-regulated, and control 
versus 250 μM C14:0 30 up and eight down-regulated proteins (Tab. IIa and b). The most 
modulated intracellular protein (Eukaryotic peptide chain release factor GTP-binding subunit 
ERF3A) was five times induced in all C14:0 treated cells compared to the controls, as well as 
the most down-regulated intracellular protein (Protein-L-isoaspartate(D-aspartate) O-
methyltransferase).   
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Majority 
Protein 
ID 
Protein name 
Gene 
name 
ANOVA 
Fold 
change 
0-50 
p adj 
0-50 
Fold 
change 
0-125 
p adj 
0-125 
Fold 
change 
0-250 
p adj 
0-250 
P15170 
Eukaryotic peptide 
chain release factor 
GTP-binding subunit 
ERF3A 
GSPT1 0.0121 5.48 0.000 5.83 0.000 5.33 0.000 
Q9P035 
Very-long-chain (3R)-
3-hydroxyacyl-CoA 
dehydratase 3 
HACD3 0.029 3.04 0.025 5.08 0.003 4.95 0.003 
O95292 
Vesicle-associated 
membrane protein-
associated protein B/C 
VAPB 0.0005 3.58 0.000 4.03 0.000 4.07 0.000 
O75356 
Ectonucleoside 
triphosphate 
diphosphohydrolase 5 
ENTPD5 0.0171 2.71 0.002 3.30 0.000 3.04 0.001 
P0C0L5 Complement C4-B C4B 0.0171 2.61 0.001 2.97 0.001 2.97 0.001 
Q15424 
Scaffold attachment 
factor B1 
SAFB 0.0309 2.60 0.008 2.92 0.004 2.96 0.004 
Q96CN7 
Isochorismatase 
domain-containing 
protein 1 
ISOC1 0.0199 3.93 0.001 3.91 0.002 2.91 0.007 
O43765 
Small glutamine-rich 
tetratricopeptide 
repeat-containing 
protein alpha 
SGTA 0.0281 2.71 0.004 2.46 0.007 2.83 0.003 
Q9H444 
Charged 
multivesicular body 
protein 4b 
CHMP4B 0.0383 2.78 0.007 2.64 0.010 2.75 0.008 
Q99541 Perilipin-2 PLIN2 0.0001 1.28 0.000 
1.90 0.000 2.18 0.000 
P61011 
Signal recognition 
particle 54 kDa 
protein 
SRP54 0.0191 2.28 0.001 2.25 0.001 2.06 0.002 
Q9NX63 
MICOS complex 
subunit MIC19 
CHCHD3 0.0191 1.25 0.116 1.63 0.002 1.74 0.001 
P35580 Myosin-10 MYH10 0.0199 1.18 0.263 1.53 0.004 1.65 0.001 
Q16186 
Proteasomal ubiquitin 
receptor ADRM1 
ADRM1 0.0238 1.64 0.004 1.78 0.002 1.63 0.004 
P10606 
Cytochrome c oxidase 
subunit 5B. 
mitochondrial 
COX5B 0.015 1.19 0.038 1.37 0.001 1.56 0.000 
P02671 Fibrinogen  chain FGA 0.0245 1.04 0.951 1.33 0.024 1.53 0.002 
P10412 Histone H1.4 HIST1H1E 0.031 1.32 0.014 1.33 0.011 1.46 0.002 
Q9UJZ1 
Stomatin-like protein 
2. mitochondrial 
STOML2 0.0199 1.19 0.080 1.42 0.002 1.45 0.001 
P01023 
Alpha-2-
macroglobulin 
A2M 0.0272 1.29 0.023 1.47 0.002 1.43 0.003 
P02787 Serotransferrin TF 0.0171 1.12 0.096 1.20 0.007 1.39 0.000 
P29966 
Myristoylated alanine-
rich C-kinase substrate 
MARCKS 0.0353 1.01 0.998 1.10 0.523 1.39 0.004 
P04040 Catalase CAT 0.031 1.20 0.048 1.29 0.008 1.37 0.002 
P07305 Histone H1.0 H1F0 0.0245 1.07 0.584 1.10 0.280 1.36 0.001 
P08195 
4F2 cell-surface 
antigen heavy chain 
SLC3A2 0.0171 1.13 0.069 1.27 0.002 1.35 0.000 
P35613 Basigin BSG 0.015 1.11 0.076 1.28 0.001 1.35 0.000 
P07306 
Asialoglycoprotein 
receptor 1 
ASGR1 0.0171 1.12 0.079 1.27 0.001 1.35 0.000 
O60573 
Eukaryotic translation 
initiation factor 4E 
type 2 
EIF4E2 0.031 0.97 0.953 1.01 0.995 1.34 0.006 
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Tab. IIa Proteins significantly up-regulated by different concentrations of C14:0 in HepG2 cell 
proteome with relative fold change compared to controls (ANOVA p-value adjusted with Benjamini-
Hochberg method; Tukey’s HSD p-value adjusted for multiple comparisons (10 comparisons)). 
Significant p-values and fold change greater than 1.3 are highlighted in bold type. 
 
 
 
 
Tab. IIb Proteins significantly down-regulated by different concentrations of C14:0 in HepG2 cell 
proteome with corresponding fold change (ANOVA p-value adjusted with Benjamini-Hochberg method; 
Tukey’s HSD p-value adjusted for multiple comparisons (10 comparisons)). Significant p-values and 
fold change lower than -1.3 are highlighted in bold type. 
 
P05023 
Sodium/potassium-
transporting ATPase 
subunit alpha-1 
ATP1A1 0.0287 1.19 0.045 1.32 0.003 1.34 0.003 
Q8WWI1 
LIM domain only 
protein 7 
LMO7 0.039 1.16 0.142 1.33 0.006 1.31 0.007 
P02649 Apolipoprotein E APOE 0.015 1.09 0.063 1.21 0.001 1.30 0.000 
P05362 
Intercellular adhesion 
molecule 1 
ICAM1 0.023 1.11 0.251 1.36 0.001 1.29 0.005 
Q8IY81 
pre-rRNA processing 
protein FTSJ3 
FTSJ3 0.0226 1.20 0.022 1.36 0.001 1.29 0.003 
Q5JTV8 
Torsin-1A-interacting 
protein 1 
TOR1AIP1 0.039 1.15 0.133 1.34 0.003 1.23 0.021 
O43719 
HIV Tat-specific 
factor 1 
HTATSF1 0.0475 0.97 0.995 1.61 0.015 0.97 0.995 
Q7Z7A1 Centriolin CNTRL 0.0195 1.09 0.991 4.44 0.004 0.65 0.486 
Majority 
Protein 
ID 
Protein name 
Gene 
name 
ANOVA 
Fold 
change 
0-50 
p adj 
0-50 
Fold 
change 
0-125 
p adj 
0-125 
Fold 
change 
0-125 
p adj 
0-250 
P22061 
Protein-L-
isoaspartate(D-
aspartate) O-
methyltransferase 
PCMT1 0.0462 -1.02 1.000 -1.77 0.421 -5.02 0.008 
P50570 Dynamin-2 DNM2 0.0366 -1.01 1.000 -1.43 0.559 -3.67 0.005 
Q96FC7 
Phytanoyl-CoA 
hydroxylase-
interacting protein-like 
PHYHIPL 0.0464 -1.49 0.422 -2.93 0.010 -2.84 0.012 
P02753 
Retinol-binding 
protein 4 
RBP4 0.015 -1.40 0.024 -1.64 0.002 -2.31 0.000 
P48147 Prolyl endopeptidase PREP 0.0272 -1.21 0.412 -1.21 0.424 -2.04 0.001 
Q15003 
Condensin complex 
subunit 2 
NCAPH 0.014 -1.07 0.654 -1.12 0.236 -1.67 0.000 
Q8NEV1 
Casein kinase II 
subunit alpha 3 
CSNK2A3 0.0172 -1.21 0.013 -1.27 0.004 -1.44 0.000 
Q9BQE3 
Tubulin alpha-1C 
chain 
TUBA1C 0.0482 -1.24 0.062 -1.27 0.040 -1.43 0.005 
O43852 Calumenin CALU 0.0195 -1.27 0.002 -1.31 0.001 -1.22 0.005 
P60981 Destrin DSTN 0.0464 -1.94 0.469 -7.62 0.007 -1.17 0.983 
O94903 
Proline synthase co-
transcribed bacterial 
homolog protein 
PROSC 0.029 -2.27 0.014 -0.79 0.652 -0.79 0.657 
Q9BRA2 
Thioredoxin domain-
containing protein 17 
TXNDC17 0.0367 -3.88 0.068 -5.14 0.028 -0.59 0.661 
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Regarding the secretome analysis of HepG2 cells after C14:0 treatment, a total of 475 proteins 
were identified by MS/MS analysis. After applying the same filtering conditions also used for 
the proteome analysis, 282 proteins were detected as deregulated in their secretion in all three 
biological replicates of at least one condition with at least 99% confidence (FDR < 1%). 
Among these a total of 32 unique secreted proteins were found to be deregulated by C14:0 (p- 
value < 0.05 and 1.3 fold-change) as compared to controls. At 50 μM C14:0 four proteins had a 
reduced secretion, at 125 μM C14:0 eight proteins were over-secreted and three had lower 
secretion while at 250 μM C14:0 22 proteins were over-secreted and seven less secreted (Tab. 
IIIa and b). The most deregulated secreted protein (UDP-glucose 6-dehydrogenase) was two 
times more secreted in 250 M C14:0 treated cells as compared to controls, while the most 
down-regulated secreted proteins were 60S acidic ribosomal protein P0 at 50 M C14:0 with a 
fold change of six and  Phosphatidylcholine-sterol acyltransferase with a fold change of four at 
250 M C14:0.   
 
Majority 
Protein 
ID 
Protein name Gene name ANOVA 
Fold 
change 
0-50 
p adj 
0-50 
Fold 
change 
0-125 
p adj 
0-125 
Fold 
change 
0-250 
p adj 
0-250 
O60701 
UDP-glucose 6-
dehydrogenase 
UGDH 0.007 0.84 0.569 1.31 0.252 2.48 0.001 
O14745 
Na(+)/H(+) exchange 
regulatory cofactor 
NHE-RF1 
SLC9A3R1 0.006 1.02 0.998 1.61 0.012 2.41 0.000 
P22626 
Heterogeneous 
nuclear 
ribonucleoprotein 
A2/B1 
HNRNPA2B1 0.001 0.98 0.995 1.62 0.001 2.28 0.000 
P49327 Fatty acid synthase FASN 0.008 1.14 0.568 1.46 0.023 2.20 0.000 
O75874 
Isocitrate 
dehydrogenase 
[NADP] cytoplasmic 
IDH1 0.044 0.99 1.000 1.50 0.159 2.19 0.007 
P61981 14-3-3 protein  YWHAG 0.022 0.54 0.095 1.47 0.386 2.16 0.037 
Q16658 Fascin FSCN1 0.046 0.91 0.936 1.36 0.301 1.98 0.013 
P06733 Alpha-enolase ENO1 0.012 1.13 0.570 1.45 0.014 1.84 0.001 
P30086 
Phosphatidyl 
ethanolamine-binding 
protein 1 
PEBP1 0.046 1.02 0.999 1.44 0.101 1.84 0.008 
P11142 
Heat shock cognate 
71 kDa protein 
HSPA8 0.006 1.11 0.484 1.34 0.013 1.83 0.000 
P00338 
L-lactate 
dehydrogenase A 
LDHA 0.009 0.95 0.966 1.74 0.004 1.82 0.003 
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Tab. IIIa Proteins significantly modulated by different concentrations of C14:0 in HepG2 cell secretome 
with relative fold change (ANOVA p-value adjusted with Benjamini-Hochberg method; Tukey’s HSD p-
value adjusted for multiple comparisons (10 comparisons)). Significant p-values and fold change 
greater than 1.3 are highlighted in bold type. 
 
 
 
Tab. IIIb Proteins significantly modulated by different concentrations of C14:0 in HepG2 cell secretome 
with relative fold change (ANOVA p-value adjusted with Benjamini-Hochberg method; Tukey’s HSD p-
value adjusted for multiple comparisons (10 comparisons)). Significant p-values and fold change lower 
than -1.3 are highlighted in bold type. 
 
P02545 Prelamin-A/C LMNA 0.026 1.07 0.932 1.28 0.176 1.81 0.002 
P38646 
Stress-70 protein. 
mitochondrial 
HSPA9 0.004 1.26 0.012 1.36 0.002 1.78 0.000 
P08238 
Heat shock protein 
HSP 90-beta 
HSP90AB1 0.026 0.72 0.185 1.16 0.737 1.74 0.021 
P50395 
Rab GDP 
dissociation inhibitor 
beta 
GDI2 0.009 0.92 0.740 1.30 0.063 1.69 0.001 
P21333 Filamin-A FLNA 0.012 0.86 0.400 1.07 0.876 1.64 0.003 
P30101 
Protein disulfide-
isomerase A3 
PDIA3 0.048 0.87 0.691 1.12 0.809 1.63 0.020 
P68363 
Tubulin alpha-1B 
chain 
TUBA1B 0.044 0.91 0.842 1.12 0.748 1.62 0.012 
P0DMV8 
Heat shock 70 kDa 
protein 1A 
HSPA1A 0.026 0.81 0.316 1.15 0.651 1.60 0.015 
P15311 Ezrin EZR 0.013 0.99 1.000 1.26 0.063 1.59 0.001 
P00352 
Retinal 
dehydrogenase 1 
ALDH1A1 0.006 1.06 0.674 1.41 0.001 1.54 0.000 
P14618 Pyruvate kinase PKM PKM 0.035 0.97 0.988 1.16 0.395 1.54 0.006 
Majority 
Protein 
ID 
Protein name Gene name ANOVA 
Fold 
change 
0-50 
p adj 
0-50 
Fold 
change 
0-125 
p adj 
0-125 
Fold 
change 
0-250 
p adj 
0-250 
P04180 
Phosphatidylcholine-
sterol acyltransferase 
LCAT 0.007 -0.93 0.987 -1.11 0.962 -4.50 0.001 
Q9BRK5 
45 kDa calcium-
binding protein 
SDF4 0.044 -5.24 0.008 -0.96 1.000 -2.78 0.090 
P02750 
Leucine-rich alpha-2-
glycoprotein 
LRG1 0.014 -1.12 0.523 -1.37 0.016 -1.67 0.001 
P01033 
Metalloproteinase 
inhibitor 1 
TIMP1 0.008 -1.04 0.951 -1.46 0.003 -1.58 0.001 
Q6H9L7 Isthmin-2 ISM2 0.019 -1.13 0.284 -1.31 0.010 -1.48 0.001 
P02654 Apolipoprotein C-I APOC1 0.046 -1.57 0.004 -1.30 0.072 -1.42 0.017 
P07942 
Laminin subunit beta-
1 
LAMB1 0.008 -1.25 0.002 -1.25 0.002 -1.34 0.000 
P04004 Vitronectin VTN 0.019 -1.26 0.005 -1.21 0.013 -1.34 0.001 
Q92563 Testican-2 SPOCK2 0.046 -1.37 0.022 -0.94 0.903 -0.93 0.818 
P05388 
60S acidic ribosomal 
protein P0 
RPLP0 0.001 -6.34 0.000 -0.92 0.963 -0.80 0.593 
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Both in the proteome and in the secretome analysis the number of modulated proteins increased 
with the increasing concentration of C14:0 and many proteins were shared among the three 
different C14:0 treatments, as reported in Fig.4.  
 
 
 
Fig.4 Venn diagrams summarising the overlapping proteins among the three different C14:0 treatments, 
identified in proteome (A) and secretome (B) samples. Proteins were identified with a minimum of two 
unique peptides per protein. 
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Some of these identified proteins were further selected as representative for Western Blotting 
analysis. Different parameters were used for protein selection, such as the degree of the C14:0-
induced deregulation, over-secretion, novelty and biological relevance. The following 
intracellular deregulated proteins were selected: Eukaryotic peptide chain release factor GTP-
binding subunit ERF3A (eRF3a), Vesicle-associated membrane protein-associated protein B/C 
(VAP-B/C), Perilipin-2 (ADRP), Retinol-binding protein 4 (RBP4), Apolipoprotein E (APOE) 
and Complement C4 alpha (C4A) (Fig.5). 
 
 
 
Fig.5 Validation of some intracellular (A) and secreted (B) proteins modulated in HepG2 following 
myristic acid treatments (from 50 to 250 M) by means of Western Blot technique. 
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For the validation of the modulated proteins found in the HepG2 secretome Fatty acid 
Synthase, Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2/B1) and Heat shock 
cognate 71 kDa protein (HSC70) were selected. The levels of these proteins in two biological 
replicates of HepG2 control and C14:0 treated cells were compared. The level of expression of 
ADRP, ApoE, eRF3a and C4 (also of its isoforms alpha and beta) increased markedly as 
expected, while the level of VAP-B/C increased only slightly, and its detection was also 
difficult to obtain probably due to the lower abundance of the protein in HepG2 cell lysates. 
The Western Blotting analysis on the intracellular down-regulated protein RBP4 showed a 
marked signal coming from the protein and a significant decrease in its expression concurrent 
with the increase in C14:0 concentration in HepG2 culture media; instead, a marked increase in 
the secretion of all the three proteins analysed from secretome samples was observed. Overall 
these proteins investigated by Western Blotting technique confirmed the modulations observed 
in HepG2 cell proteome and secretome following C14:0 administration, corroborating in this 
manner the reliability of the MS/MS data. 
 
3.3 Prediction of secretion pathways  
To predict if the 35 proteins found to be modulated in the secretome of the C14:0 treated 
HepG2 cells are secreted through the classical (involving signal peptide) or non-classical 
pathway (not signal peptide) the on-line prediction server SecretomeP 2.0 was used. This tool 
relies on a large number of other feature prediction servers to obtain information on various 
post-translational and localisation aspects of the investigated protein, which are then integrated 
into the final prediction of secretion (Caccia et al., 2013). For those deregulated proteins 
predicted to be secreted by means of a non-classical pathway the Exocarta database was 
consulted. Exocarta is a manually curated exosomes database collecting proteins identified in 
exosome vesicles by different experiments on different cell types (Keerthikumar et al., 2016). 
According to Exocarta results, the majority of the deregulated secreted proteins identified ( 
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69%) were already found to be secreted through exosome release in other experiments.  22 
proteins out of the 32 modulated secreted proteins were found to be exosome released proteins. 
Only  31% proteins were predicted to be secreted by classical pathways with an N-terminal 
signal peptide by Secteome P 2.0 investigation (Tab. IV).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. IV Investigation of proteins secretion pathways by using SecretomeP server and Exocarta 
database (SP: Signal Peptide).   
Protein name 
Majority 
Protein IDs 
Gene names SecretomeP ExoCarta 
Retinal dehydrogenase 1 P00352 ALDH1A1 
 
Present 
Apolipoprotein C-I P02654 APOC1 SP 
 
Alpha-enolase P06733 ENO1 
 
Present 
Ezrin P15311 EZR 
 
Present 
Fatty acid synthase P49327 FASN 
 
Present 
Filamin-A P21333 FLNA 
 
Present 
Fascin Q16658 FSCN1 
 
Present 
Rab GDP dissociation inhibitor beta P50395 GDI2 
 
Present 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 
P22626 HNRNPA2B1 
 
Present 
Heat shock protein HSP 90-beta P08238 HSP90AB1 
 
Present 
Heat shock 70 kDa protein 1A P0DMV8 HSPA1A  
 
Present 
Heat shock cognate 71 kDa protein P11142 HSPA8 
 
Present 
Stress-70 protein, mitochondrial P38646 HSPA9 
 
Present 
Isocitrate dehydrogenase [NADP] 
cytoplasmic 
O75874 IDH1 
 
Present 
Isthmin-2 Q6H9L7 ISM2 SP 
 
Laminin subunit beta-1 P07942 LAMB1 SP 
 
Phosphatidylcholine-sterol acyltransferase P04180 LCAT SP 
 
L-lactate dehydrogenase A chain P00338 LDHA 
 
Present 
Prelamin-A/C P02545 LMNA 
 
Present 
Leucine-rich alpha-2-glycoprotein P02750 LRG1 SP 
 
Protein disulfide-isomerase A3 P30101 PDIA3 SP 
 
Phosphatidylethanolamine-binding protein 1  P30086 PEBP1 
 
Present 
Pyruvate kinase PKM P14618 PKM 
 
Present 
60S acidic ribosomal protein P0 P05388 RPLP0 
 
Present 
45 kDa calcium-binding protein Q9BRK5 SDF4 SP 
 
Na(+)/H(+) exchange regulatory cofactor 
NHE-RF1 
O14745 SLC9A3R1 
 
Present 
Testican-2 Q92563 SPOCK2 SP 
 
Metalloproteinase inhibitor 1 P01033 TIMP1 SP 
 
Tubulin alpha-1B chain P68363 TUBA1B 
 
Present 
UDP-glucose 6-dehydrogenase O60701 UGDH 
 
Present 
Vitronectin  P04004 VTN SP 
 
14-3-3 protein gamma P61981 YWHAG 
 
Present 
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3.4 Modulation of biological processes and pathways induced by myristic acid 
 
To disclose the interaction networks between the modulated proteins and to better elucidate 
biological process and molecular pathways involved in the response of HepG2 cells to C14:0 
treatments, specific bioinformatics analyses were performed. Different tools were used, 
including DAVID, STRING on-line database and Cytoscape software. This analysis promoted 
the illustration of biological context, association with diverse physiological pathways and 
network interactions of proteins whose expression was found to be influenced by C14:0. 
The GO analysis was performed by using DAVID on-line bioinformatics tool. As reported in 
Fig.6, Cellular Component analysis revealed that both in the proteome and in the secretome, 
most of the proteins are proteins commonly found in extracellular exosome. Many other 
proteins were reported to be present in the membrane fraction and cytosol in both types of 
samples and while in the proteome some proteins were typical of the endoplasmic reticulum 
and mitochondrion, in the secretome many proteins were typical of cellular junction, focal 
adhesion and extracellular space. The analysis of the Biological Process revealed that most 
deregulated intracellular and secreted proteins are involved in cell-cell adhesion. Moreover, 
deregulated intracellular proteins are also involved in the response to drug, while the secreted 
proteins in oxidation-reduction process, cell response to interleukin-4, as well as in protein 
folding. Finally, according to the Molecular Function analysis, most of the deregulated 
intracellular and secreted proteins exhibited “binding” activity, namely protein binding, 
poly(A) RNA binding, and cadherin binding involved in cell-cell adhesion. 
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Fig.6 Gene Ontology analysis of the HepG2 proteome (left) and secretome (right) deregulated after 
myristic acid treatment. Only overrepresented categories with p-value < 0.05 are shown. The area of 
each sector is proportional to the number of genes annotated to the corresponding GO category (i.e. 
cellular components, biological processes and molecular functions) which is also indicated. 
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STRING search tool was used to identify interaction networks of the proteins perturbed after 
C14:0 treatments. Two STRING criteria were selected: “database” based on the observation 
that functionally associated proteins have known interactions from curated databases and 
“experiments,” i.e. experimentally proven interactions from published studies. Among the 47 
proteins differentially expressed in the proteome, only 18 were connected in the String output 
and many interactions were highlighted mainly between pairs of proteins (for example between 
VAPB and COX5B, but also TF and DNM2, as well as between SLC3A2 and BSG) (Fig.7A). 
Two small clusters were identified that are related to cytoskeleton organisation and to proteins 
targeted to endoplasmic reticulum and/or proteasome (including for example TUBA1C, DSTN, 
and SGTA), as well as to complement and coagulation cascades (A2M, FGA, and ICAM1). In 
comparison with the proteome, the secretome showed the highest percentage of physically 
connected proteins; 15 out of 32 proteins found to be modulated by different concentrations of 
C14:0 were present in the String output (Fig.7B). HSPA8 (heat shock cognate 71 kDa protein, 
HSC70) was an important hub in this interaction network connecting a total of six proteins, 
suggesting that it may play an important role in mediating the effects of C14:0. Indeed, HSPA8 
resulted in a cluster involving proteins related to mRNA processing, translation, and protein 
folding (HNRNPA2B1, RPLP0, PDIA3), as well as including other heat shock proteins 
(HSP90AB1, HSPA1A, and HSPA9) which are key mediators of stress response, intracellular 
trafficking, cell proliferation. Moreover, the network produced by String contained a highly 
connected subnetwork of metabolism-associated enzymes (ALDH1A1, LDHA, PKM, ENO1) 
connected to scaffold proteins that regulate surface expression of plasma membrane proteins 
(EZR, SLC9A3R1, GDI2).  
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Fig.7 Analysis of interactions among the HepG2 intracellular (A) and secreted (B) proteins deregulated 
after myristic acid treatment. The predicted protein interactions that were found in the STRING 
interaction database were restricted to the categories “database” and “experiments”. Additional nodes 
are indicated as white nodes. 
 
In order to highlight the enriched biological processes and molecular pathways involving the 
proteins that exhibited a changed abundance in HepG2 cell proteome and secretome after 
C14:0 treatments, ClueGO plugin for Cytoscape was used with GO biological process and 
KEGG database selection. Only enriched pathways with p<0.05 and a Kappa score threshold of 
0.4 were considered. Different biological processes were found to be enriched when 
deregulated intracellular proteins were analysed, including positive regulation of ATPase 
activity and blood circulation, as well as regulation of protein activation cascade (Fig.8A). As 
concerns enriched KEGG pathways, positive regulation of complement activation was found to 
be involved in the response to C14:0 treatment.  
Cytoscape analysis of the deregulated secreted proteins influenced by C14:0 treatments 
revealed three main biological processes, namely response to interleukin-4, microvillus 
assembly and monosaccharide catabolic process, to be significantly enriched (Fig.8B). In the 
last biological process, glycolysis/gluconeogenesis and catabolism of hexose were the 
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dominant processes. Moreover, the main KEGG pathway related to secreted proteins 
modulated by C14:0 was antigen processing and presentation, grouping together many Heat 
Shock proteins.  
Fig.8 Results of ClueGo clustering analysis with Cytoscape for the visualisation of significantly 
enriched biological process (circles) and KEGG pathways (triangles) related to deregulated proteome 
Staphylococcus areus infection
Regulation of phagocytosis
Regulation of complement activation
Positive regulation of 
phagocytosisPositive regulation of 
endocytosis
Regulation of humoral immune 
response
Regulation of ATPase activity
Hexose catabolic process
Central carbon metabolism 
in cancer
Glycolysis/Gluconeogenesis
Response to interleukin-4
Microvillus organization
Establishment of 
mantenance of 
apical/basal cell polarity
Establishment of mantenance 
of bipolar cell polarity
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(A) and secretome (B) in HepG2 cells treated with myristic acid. Node size represents the enrichment of 
that specific process/pathway and the lines connecting different nodes indicate that these categories 
share gene(s). The group name is the leading group term based on highest significance (p -value 
corrected with Benjamini- Hochberg). 
 
 
3.5 Myristic acid influence on ER stress  
SFAs are known to cause ER stress in different cell types (Hetherington et al., 2016; Sramek et 
al., 2017). Accordingly, the proteome analysis revealed some proteins involved in protein 
homeostasis while in the secretome some stress signaling proteins – such as heat shock proteins 
- were found to be oversecreted. Therefore, the intracellular expression of some intracellular 
ER stress markers was investigated by means of Western Blot analysis. The expression of 
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF-6) was investigated. This 
protein is a membrane-bound transcription factor that upon ER stress conditions is cleaved by 
Site-1 protease (S1P) and Site-2 protease (S2P). Cleaved forms can enter the nucleus and 
activate Unfolding Protein Response (UPR) genes (Yoshida et al., 2000). Western blotting 
detection of the cleaved forms of this protein is used as a marker of ER stress (Oslowski et al., 
2011). As visible in Fig.9 two bands were detected when the expression of ATF6 was 
investigated in HepG2 cell lysates after C14:0 supplementations. Interestingly, the analysis 
revealed the presence of two bands. The molecular weights of these two bands correspond to 
the kDa of the two ATF6 cleaved subunits detected also by Mao et al. rather than the full 
form of the protein (Mao et al., 2007). The lower isoform showed an increase after C14:0 250 
M. The expression of two other ER stress markers was investigated. Both Serine/threonine-
protein kinase/endoribonuclease (IRE1) and Eukaryotic translation initiation factor 2-alpha 
kinase 3 (PERK), whose expression has already been used as ER stress markers (Hu et al., 
2015), showed an increase in their expression in HepG2 cells treated with C14:0. The Western 
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Blotting investigation of PERK showed the appearance of supplementary bands, which could 
be ascribed to the increase in PERK dimerisation in presence of ER stress (Liu et al., 2000). 
 
 
 
Fig.9 Investigation of the effects of different concentrations of C14:0 on ER stress markers in HepG2 
cells.  
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4. DISCUSSION 
 
4.1 Myristic acid induces lipid droplets formation, cytoskeleton reorganisation and ER 
stress 
To date only few studies have analysed the overall response of HepG2 cell to enhanced FA 
intake from a proteomic point of view (Vendel Nielsen et al., 2013; Krogager et al., 2015). 
Moreover, despite the fact that C14:0 is a minor plasma FA, it has attracted growing attention 
because of its ability to decrease HDL plasma levels and also as predictor of NASH, the most 
extreme form of NAFLD (Tomita et al., 2011; Noto et al., 2016). However, to date only few 
studies have investigated the biochemical effects of C14:0 when supplied in cell culture media. 
To date there have been no investigations of C14:0 effect from a proteomic point of view. 
Therefore, this is the first proteomic study describing and investigating both the proteomic 
(Fig.10) and secretomic effects of different concentrations of C14:0 on HepG2 cell model.  
 
 
 
 
 
 
 
 
 
 
Fig.10 Main effects of myristic acid on HepG2 cells proteome. 
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4.1.1 Lipid droplets 
Before performing the proteomic investigation, the dose-dependent absorption of C14:0 when 
dissolved in BSA was assessed. As can be observed in Fig.3 the treatment caused, in particular 
at concentration 125 M, the accumulation of LD, dynamic structures involved in lipid storage, 
metabolism as well as in many other cellular functions (Hashemi et al., 2015). These data are in 
agreement with the accumulation of LD observed in response to HepG2 supplementation with 
other FAs, in particular with C18:1 (Mei et al., 2011; Hetherington et al., 2016). These data are 
also in agreement with the C14:0-induced mild steatosis observed in primary mouse 
hepatocytes (Martinez et al., 2015). Nevertheless, this is the first time that LD formation has 
been reported after C14:0 treatment in a HepG2 cell model. 
Interestingly, among the deregulated intracellular proteins identified in this PhD research 
project, there was Perilipin2 (ADRP). ADRP is the most abundant protein on LD surface, 
(Sletten et al., 2014) and was found up-regulated with an increased fold change as a 
consequence of the increased C14:0 dosage used for cell treatment (Tab. IIa). While at 50 M 
C14:0 the increase was not statistically significant, at 125 and 250 M C14:0 ADRP was 
significantly increased as also confirmed also with Western Blotting analysis (Fig.5).  
As mentioned before, LD represent dynamic structures that, depending on nutrient availability, 
can undergo cycles of synthesis and catabolism through lipophagy. During this process LD are 
enclosed inside autophagosomes where lipids are depredated by hydrolases and later 
autolysosomal membranes are converted into a new lysosome for a new LD degradation cycle. 
An important role in this process is played by Dynamin-2 (DNM2), a regulator of vesicle 
trafficking that contributes to the generation of new protolysosomes; inhibition of its activity 
impairs generation of new protolysosomes and therefore LD catabolic process (Schulze et al., 
2014). Interestingly, DNM2 was found to be strongly down-regulated by 250 µM C14:0 
treatment in HepG2 cell lysate – nearly four times as much. These data could be indicative of a 
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probable decrease in LD catabolism because of the cellular need to enhance LD formation and 
TG storage. A physical interaction among this protein, DNM2, and transferrin (TF) was 
highlighted by the STRING analysis, because of the involvement of DNM2 in TF endocytosis 
(Cao et al., 2010). In contrast with DNM2 decrease, the expression of TF increased following 
C14:0 250 µM treatment. Accordingly, it has been demonstrated that iron-supplementation, as 
well as holotransferrin supplementation, can protect beta-cells from the lipotoxic effect of 
C16:0 (Jung et al., 2015). These findings suggest that the increased expression of this protein 
could represent a cell effort to overcome C14:0-induced stressful effect. 
4.1.2 Cytoskeleton remodelling 
In the proteome of HepG2 cell treated with C14:0 a decrease in the expression of some proteins 
involved in cytoskeleton remodeling, such as destrin (DSTN) and tubulin alpha-1C chain 
(TUBA1C) was observed (Tab. IIb). Interestingly, depletion of DSTN has been connected with 
the formation of contractile actin stress fibre associated with enlarged focal adhesion at the 
plasma membrane (Kanellos et al., 2015). Interestingly, these structures have already been 
identified in hepatic stellate cells treated with C16:0 (Hetherington et al., 2016). An increase in 
myosin-10 (MYH10) content in HepG2 cells treated with 125 and 250 µM C14:0 was also 
observed. As myosin is able to compete with DSTN for the binding to actin stress fibres, also 
causing nuclear deformation (Kanellos et al., 2015), this event could be connected with a 
possible increase in cell contractility.  
4.1.3 ER stress and protein homeostasis 
SFAs, in particular C16:0, were described as being involved in ER stress development and in 
the consequent UPR in many tissue and cell types, also including HepG2 (Cao et al., 2012; 
Hetherington et al., 2016; Liu et al., 2016). As far as we know, to date the probable effect of 
C14:0 on ER stress has never been investigated on HepG2 cell model. However, this effect 
could be considered as a plausible consequence, also in light of the fact that C14:0 was shown 
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to enhance C16:0-induced ER stress in primary mouse hepatocytes (Martìnez et al., 2015). 
When supplied alone in culture media, C14:0 caused a lower but significant increase in the 
expression of ER stress marker, as CCAAT/enhancer-binding protein homologous protein 
(CHOP) and X-box-binding protein 1 (XBP-1), common targets of canonical cell sensors of ER 
stress. Accordingly, in the present proteomic investigation an effect of C14:0 on intracellular 
proteins involved in protein folding homeostasis was observed. As reported in Tab. IIa all the 
different concentrations used of C14:0 induced an increase in the protein expression of the 
ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5), an ER protein which promotes 
protein N-glycosylation and folding in the ER. Literature data already connected perturbation 
in the expression of this protein with the ER stress; the knockdown of ENTPD5 in PTEN null 
cells caused ER stress while the increase of ENTPD5 was shown to prevent ER stress and 
consequent apoptosis in cancer cells (Fang et al., 2010; Shen et al., 2011). Small glutamine-rich 
tetratricopeptide repeat-containing protein alpha (SGTA) is another protein whose expression 
was found to be increased by C14:0 (50-250 M). This protein is involved in the regulation and 
maintenance of cellular proteostasis, as its main action is to act as a co-chaperone, binding 
mislocalised membrane proteins and maintaining them in a non-ubiquitylated state, so 
increasing their opportunity to be delivered to the ER (Wunderley et al., 2014; Roberts et al., 
2015). An increase in the expression of this protein already at low concentration of C14:0 (Tab. 
IIa) could be due to cells’ necessity to increase the possibilities of proteins to complete a proper 
folding, increasing their delivery to the ER. The STRING analysis does not highlight the 
important physical interaction of SGTA with the proteasomal ubiquitin receptor ADRM1 (also 
known as hRpn13) already known from literature data (Leznicki et al., 2015; Thapaliya et al., 
2016). It seems that SGTA can regulate the access of mislocalised membrane proteins to the 
proteasome, selectively modulating its substrate degradation. Interestingly, as SGTA, the 
expression of ADRM1 was also found to be stimulated by all C14:0 treatments in HepG2 cells. 
These findings give rise to the hypothesis that C14:0 may provoke ER stress due to an increase 
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in misfolded proteins that could enhance a more stringent control on cellular proteostasis 
through the increased expression of these key proteins. Proteasomal degradation by means of 
ERAD is a cellular response following ER stress caused by the accumulation of misfolded 
proteins (Vembar et al., 2008). As reported in Tab. IIa and from the weak but increasing signal 
detected in the Western Blot (Fig.5) Vesicle-associated membrane protein-associated protein 
B/C (VAPB) is another protein found to be modulated by C14:0 treatment. This protein is an 
ER protein involved in vesicle-trafficking, ER-mitochondrion connection, calcium 
homeostasis, autophagy and also in the UPR following ER stress as already observed in 
literature data (Kanekura et al., 2006; Kanekura et al., 2009; Gomez-Suaga et al., 2017). As one 
of the UPR adaptive response involves the upregulation of molecular chaperones and protein 
processing enzymes to increase protein folding and handling efficacy (Oslowski et al., 2011), 
the observation of a C14:0 influence on the expression of the mentioned proteins involved in 
the maintenance of cell proteostasis led to the hypothesis that C14:0 could stimulate ER stress 
in HepG2 cells, as already observed in primary mouse hepatocytes (Martìnez, 2015). Therefore, 
to detect the UPR possible activation level a Western Blotting investigation was conducted on 
the expression of the three main ER membrane stress sensors: ATF6, IRE1 and PERK. As 
can be inferred from Fig.9 this analysis confirmed the activation of the UPR due to the 
increased signal coming from these proteins in response to C14:0 treatments. When activated 
by the accumulation of unfolding proteins in the ER, ATF6 is transported to the Golgi where 
it is cleaved by site-1 protease (S1P) and site-2 protease (S2P) releasing a 50kDa fragment that 
migrates to the nucleus and activates a group of genes coding for chaperones and folding 
enzymes (Zhang et al., 2006). In the present investigation the 90 kDa form of ATF6 was not 
detected while two cleaved forms were present in all samples, also including the one present at 
36 kDa already reported also in a previous paper (Mao et al., 2007). The signal coming from 
this cleaved form seems to increase slightly at 250 M C14:0, as a possible sign of increased 
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ATF6 cleavage following ER stress. Moreover, when the expression of IRE1 was 
investigated an increase in its expression was detected compared to the control sample. 
Notably, IRE1 is a ER transmembrane protein that, when activated by the accumulation of 
unfolded proteins, dimerises and autophosphorylates to become active. Activated IRE1 
splices X-box binding protein 1 (XBP1) mRNA, that in turn encodes a transcription factor that 
activates UPR target genes; among them there are also genes involved in protein folding, such 
as Protein Disulfide Isomerase (PDI) (Lee et al., 2003), whose secretion was indeed found to be 
stimulated by C14:0 in the present investigation (Tab. IIIa). The main marker of UPR 
activation after C14:0 was the increase in the expression of PERK. This protein is an ER 
transmembrane protein and, when activated, it oligomerises and autophosphorylates. The 
present investigation demonstrated for the first time  the induction of PERK expression 
following increasing concentration of C14:0 supplementation and, as visible in Fig.9, an 
possible increase in the dimeric form was also observed, similar to the one previously observed 
in literature (Vatolin et al., 2016). Accordingly, previous investigations on the effects of 
palmitate on HepG2 cell model confirmed the activation of ER stress through the induction of 
PERK signaling pathway (Cao et al., 2012). Activated PERK inhibits protein biosynthesis 
through the phosphorylation of the eukaryotic translation initiator factor eiF2 and the 
inhibiting the formation of the ternary translation initiation complex eIF2/GTP/Met-tRNA. 
Interestingly, in the present proteome analysis the increased expression of eukaryotic peptide 
chain release factor GTP-binding subunit ERF3A (eRF3a) (Fig.5) was also reported; this 
protein has a role in the formation of a complex involved in the protein translation termination 
(Chauvin et al., 2005) and was the most induced intracellular protein following C14:0 
supplementation.  
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4.1.4 Other effects of myristic acid 
In addition, as also reported in the STRING analysis, the expression of Cytochrome c oxidase 
subunit 5B (COX5B), a component of the mitochondrial cytochrome c oxidase complex, was 
slightly and gradually increased following C14:0 treatment. Notably, SFAs have already been 
connected with mitochondrial dysfunction, cause of oxidative stress and mtDNA oxidative 
damage, and C16:0 was shown to impair the oxidative phosphorylation system (OXPHOS) 
activity, decreasing the expression of its subunits and accelerating the degradation of OXPHOS 
complex (Garcia-Ruiz et al., 2015). The slight and gradual increase in COX5B expression 
could therefore be ascribed to a mechanism activated by HepG2 cells in order to limit ROS 
generation following C14:0 supplementation (Campian et al., 2007). Interestingly, at 250 µM 
C14:0, and even more at 500 µM C14:0 (data not shown), there was a slight increase in the 
expression of Apolipoprotein E (ApoE). These data are not only in agreement with a previous 
proteomic analysis showing the increase in ApoE levels in the liver of mice fed with a high-fat 
diet (Kirpich et al., 2011), but also with the in vivo study reported in the first part of the present 
thesis, where C14:0 was shown to be the second predictor of ApoE in the plasma of analysed 
patients. This was therefore also a confirmation of the close connection existing between the in 
vivo and in vitro part of the study. As reported in the first chapter of the present thesis ApoE, a 
component of lipoproteins such as chylomicrons and VLDL, has an important role in lipid 
metabolism and its antioxidant activity has also been described in brain, plasma and adipose 
tissue (Miyata et al., 1996; Mabile et al., 2003; Davignon, 2005; Tarnus et al., 2009). The 
increase in ApoE expression can be interpreted both as a consequence of lipid metabolism 
alteration induced by C14:0 supplementation and also as an effort by cells to counteract the 
increasing oxidative stress.  
SFA have already been connected with the development of inflammation (Fritsche, 2015). In 
HepG2 cells treated with C14:0 a slight increase in protein connected with the inflammation 
pathway was observed. This may suggest that high concentrations of C14:0 are stressful for 
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HepG2 cells, as can be inferred from the slight reduction in cell viability and cell number 
following C14:0 incubation. In the present PhD thesis  a slight increase in proteins connected 
with the acute phase response has been observed, such as complement C4 (Fig.5), fibrinogen 
alpha chain (FGA) and the negative acute phase TF protein. Interestingly, these proteins were 
found to be modulated in the secretome of HepG2 cells when treated with TFA, suggesting that 
SFA as well as TFA, both known for their adverse effects on cardiovascular health, have an 
influence on inflammation pathways (Krogager et al., 2015). Another protein involved in acute 
phase response and modulated by C14:0 treatment was alpha 2- macroglobulin (A2M), whose 
expression has already been described in HuH7 hepatocarcinoma cells treated cells following 
FA treatment (Chavez-Tapia et al., 2012).   
Finally, the proteomic investigation highlighted an important decrease in Retinol Binding 
Protein (RBP) in HepG2 cell proteome (Fig.5). RBP4 has been correlated during previous years 
with enhanced metabolic risk and atherogenesis (Dessein et al., 2014) as well as with hepatic 
steatosis and also mitochondrial dysfunction (Liu et al., 2016; Meex et al., 2017). Interestingly, 
as opposed to the expectations, this investigation revealed a decreasing trend of this protein, 
suggesting a positive influence of C14:0 on mitochondrial dysfunction and fatty liver, that 
could differentiate it from C16:0 lipotoxic action. 
4.2 Myristic acid causes deregulation of secreted proteins involved in exosome and 
extracellular miRNA sorting 
In the present project the analysis of the differently secreted proteins following C14:0 
supplementation was also reported for the first time (Tab. IIIa and IIIb). As highlighted by the 
DAVID GO analysis (Fig.6) of cellular components, both intracellular proteins and secreted 
deregulated proteins were described to be exosomes component. Accordingly, the analysis of 
secretion pathways using both SecretomeP tool and Exocarta database (Tab. IV) confirmed that 
most of the secreted proteins were proteins already found by literature papers to be secreted by 
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means of exosome release (Fig.11). Moreover, many of these proteins have already been 
identified specifically in hepatocytes exosomes (Conde-Vancells et al., 2008). 
 
Fig.11 Myristic acid effects on the secretion of exosome proteins and miRNA sorting in HepG2 cells. 
4.2.1 Proteins related to exosomes   
Fatty acid synthase (FASN) was one of the proteins whose secretion was significantly 
increased following C14:0 treatment, particularly at 125 and 250M, as also confirmed by 
Western Blot investigation (Fig.5). This enzyme has a well-known intracellular role, being 
involved in the formation of long-chain fatty acids. However, its secretion by means of 
exosomes has already been demonstrated in cancer cell line, suggesting an extracellular role for 
this protein (Duijvesz et al., 2013). Interestingly circulating FASN has also been detected in 
serum of patients and its levels have been described as a possible marker of insulin resistance 
(Fernandez-Real et al., 2010). Moreover, FASN serum levels were found to be elevated in 
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patients with liver injury, mainly steatohepatitis (Marsillach et al., 2009); this observation led 
therefore to the hypothesis that C14:0 could be connected with the development of liver injury.  
4.2.2 miRNA sorting 
As confirmed by Western Blot analysis (Fig.5) an increase in the secretion of Heterogeneous 
nuclear ribonucleoproteins A2/B1 (hnRNPA2/B1) was observed. The hnRNP family is 
comprised of >20 proteins that contribute to the complex around nascent pre-mRNA and are 
thus able to modulate RNA processing. It has been described that secreted hnRNPA2B1 is a 
key player in miRNA sorting into exosomes and is released by cells during this process 
(Villarroya-Beltri et al., 2013). hnRNPA1, another protein of the same family similar in its 
structure to hnRNPA2B1, showed increased translocation from the nucleus to the cytosol 
following ER stress and in particular following FAs supplementation in HepG2 cells (Damiano 
et al., 2013; Siculella et al., 2016). It is therefore possible to hypothesise that C14:0 also has an 
influence on the increased cell localisation of hnRNPA2B1 that can cause an increase in its 
exosomal loading. The presence of hnRNP A2/B1 in the secretome of HepG2 treated cells 
supported the evidence of increased protein secretion through exosomes following C14:0 
supplementation. Interestingly, in the last few years microRNA and exosomes have emerged as 
important players in the atherosclerotic process (Huber et al., 2015; Loyer et al., 2015) and the 
involvement of C14:0 in their liver release would be an important aspect for further research..   
4.2.3 Other effects of myristic acid 
Interestingly, the secretion of many interacting Heat Shock Proteins (HSPs) was induced by 
C14:0, including Heat Shock protein 70 (HSPA1), Heat shock cognate protein 71 (HSPA8), 
Heat Shock Protein Family A Member 9 (HSPA9) and Heat Shock protein HSP 90-beta 
(HSP90AB1) (Fig.8B). HSPs are molecular chaperones and their intracellular role is connected 
with the response to various stress stimuli. Recent investigations however have highlighted the 
extracellular role of these proteins: they have described HSPs as “alert stress signals” secreted 
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by non-conventional pathways, that can inform other cells - in particular immune system cells - 
about the stressor presence, avoiding the propagation of the stress insult and increasing stress 
resistance (De Maio et al., 2013; Santos et al., 2017). Although the role of HSPs in 
atherosclerosis remains controversial, HSPs were thought to act as autoantigens, and trigger 
both cell- and antibody-mediated immune responses (Lu et al., 2010). In particular, Hsp70 
represented an important node in this hub, as it has been proposed as a predictor of acute 
coronary syndrome risk and was found to be elevated in patients with chronic heart failure 
(Genth-Zotz et al., 2004; Zhang et al., 2010). Taken together these observations on the 
increased secretion of HSPs confirmed the conclusion of a stressful influence of C14:0 on 
HepG2 cells, that could eventually enhance the atherosclerotic process.  
The over-secretion of Protein Disulfide-Isomerase A3 (PDIA3) was also observed at 250 µM 
C14:0. Interestingly, previous studies demonstrated that treatment of liver cells with saturated 
fatty acids cause ER stress, UPR and apoptosis together with an increase in the expression of 
PDIA3, a protein involved in protein folding; moreover this protein was found to be induced in 
liver samples of patients affected by NAFLD (Wang et al., 2010; Zhang et al., 2015). These 
studies highlight an important role of PDIA3 in the development of steatosis. In addition, 
according to the present obtained data, this protein could play an important part in the 
extracellular environment, as it has already been demonstrated  that the ER stress attenuates the 
secretion of misfolded proteins and prevent their extracellular aggregation through the secretion 
of molecular chaperones (Genereux et al., 2015). The presence of this protein among the over-
secreted following C14:0 treatment strengthens the demonstration of ER stress induction and 
the evidence supporting the influence on UPR on the regulation of extracellular protein 
homeostasis.   
As reported in the Cytoscape analysis in Fig.8B, another cluster of over-secreted proteins 
following C14:0 supplementations included enzymes involved in carbohydrate metabolism, 
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such as Enolase-1 (ENO1), Lactate dehydrogenase (LDHA) and Pyruvate kinase (PKM). The 
presence of these proteins in the secretome of HepG2 should not come as a surprise as they 
have been previously identified in the exosomes derived from hepatocytes (Conde-Vancells et 
al., 2008).  Glycolytic enzymes can have important extracellular roles such as cell-cell 
communication and infections (Gomez-Arreaza et al., 2014). ENO-1 in particular has been 
described as a multifunctional protein, with an important role in pathophysiological situations 
(Diaz-Ramos et al., 2012). It is also expressed on the surface of many cell types and has been 
defined as a marker of pathological stress. Moreover, the secretion by HepG2 cells of ENO1 
has already been described following viral cell infection (Higa et al., 2014). Taking together 
these observations led to the assumption that the secretion of glycolytic enzymes can also 
represent a cell stress signal following increasing concentration of C14:0 in cell culture media.   
In summary, this proteomic research permitted for the first time the detection of both 
intracellular and secreted proteins deregulated by C14:0 in HepG2 cells. These findings 
certainly contribute to the disclosure of the biological effects induced by C14:0 at a molecular 
level, involved in its adverse health effects on the atherosclerotic process, in the development 
of NAFLD, and consequently in the onset of CAD. While in the proteome of HepG2 cells some 
proteins involved in cytoskeleton reorganisation and ER stress response were found to be 
modulated indicating their possible involvement in the development of NAFLD, in the 
secretome of HepG2 cells many proteins involved in cellular stress have been reported that 
could in the future be evaluated as a possible marker of liver stress and steatosis.  
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CHAPTER 3 
COMPARATIVE PROTEOMIC STUDY OF THE BIOCHEMICAL 
EFFECTS INDUCED BY MYRISTIC, OLEIC AND PALMITIC ACIDS  
 
1. INTRODUCTION 
While the molecular effects induced by C14:0 treatment of HepG2 cells are still poorly known, 
the effects of C16:0 and C18:1 have been analysed in depth during the last few years. The 
investigations relating to the effects of these two FAs mainly aimed at elucidating cellular 
mechanisms involved in FA-related hepatic lipotoxicity and in the consequent development of 
NAFLD. The earliest studies investigated the effects induced by the combination of these two 
FAs on hepatic lipotoxicity. In particular, Feldstein et al. used a combination of C18:1 and 
C16:0 (2:1 ratio) on the HepG2 cell model and reported an increase in lysosomal 
permeabilisation and an NF-B-dependent stimulation of TNF- expression, an important 
mediator of insulin resistance, TG accumulation and hepatic steatosis (Feldstein et al., 2004). 
Further studies reported that the same combination of FAs induces LD accumulation in HepG2 
cells in a concentration-dependent manner (Yao et al., 2011). The authors also reported 
induction of nuclear condensation and fragmentation typical of late apoptosis and necrosis 
confirming the lipotoxic effect triggered by FAs.  
However, C16:0 and C18:1 behave extremely different as they belong to two different FA 
classes. C18:1, an important component of many vegetable oils, such as olive oil, represents the 
MUFA, with C18:1 being the most abundant MUFA in human plasma. Accordingly, (as 
reported in Tab. III Chapter 2 Section1 of the present thesis) C18:1 was the most abundant 
unsaturated FA in the studied population, representing 24.5% of total detected FAs.  
On the other hand, C16:0, present in cheese, meat, butter and in some oils, is the most abundant 
SFA (24% of total FA plasma content) and is a representative of the SFAs class. When the 
cellular effects of FAs were compared in the HepG2 cell model, by means of DAPI staining of 
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apoptotic nuclei and measuring caspase activation, all the individual FAs induced cellular 
steatosis but saturated FAs, including C16:0 and stearic acid (C18:0), caused increased toxicity 
and apoptosis (Malhi et al., 2006). Cell death was caspase-dependent and associated with 
mitochondrial membrane depolarisation and cytochrome c release. Further comparative studies 
demonstrated that steatosis extent was greater in presence of C18:1 in cell culture media, but 
cell apoptosis was inversely proportional to LD accumulation (Ricchi et al., 2009). Therefore, 
while C16:0 increased the rate of apoptosis and impaired insulin signaling, C18:1 showed a 
more steatogenic but less apoptotic behaviour. A subsequent study confirmed the higher ability 
of C18:1 to induce TG-enriched LD formation when compared to C16:0 treatment (Mei et al., 
2011). Moreover, together with LD accumulation the appearance of autophagosomes was 
observed in C18:1-treated HepG2 cells. On the other hand, C16:1 was found to be poorly 
converted into TG-enriched LD, to suppress autophagy and induce a caspase-dependent 
cleavage of Beclin-1, suggesting a connection between the apoptotic and autophagic processes. 
This study highlighted the fact that C18:1 LD formation and autophagy induction could 
represent an important protective mechanism against FAs-induced lipotoxicity. A more recent 
comparative study confirmed the cytotoxicity induced only by C16:0 supplementation in cell 
culture media and showed that this FA induced ER stress in both HepG2 and primary human 
activated hepatic stellate cells (Hetherington et al., 2016). The influence of C16:0 on ER stress 
markers had been already demonstrated by previous studies that reported the concurrent 
decrease of Hypoxia-inducible factor-1 (HIF-1), a transcription factor that acts as regulator of 
oxygen homeostasis (Yoo et al., 2014). Mitochondrial dysfunction, oxidative stress, decreased 
mitochondrial DNA damage and a decrease in OXPHOS activity were also described as key 
features of HepG2 cell supplemented with SFAs (Garcia-Ruiz et al., 2015). Taken together, 
C16:0 and C18:1 have been found to have divergent cellular effects, with C16:0 inducing ER 
stress, ROS and apoptosis and C18:1 enhancing TG formation, lipoproteins assembly and LD 
accumulation as well as autophagy (Fig.1).  
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Fig.1 Main known effects induced by palmitic and oleic acid on HepG2 cell model. Adapted from 
Hetherington, 2016. CLD: cytosolic lipid droplets, ER: endoplasmic reticulum; Lp: lipoproteins; ROS: 
Reactive Oxygen Species.   
 
However, a comprehensive investigation and comparison of the overall effects of these FAs on 
the HepG2 cellular proteome is still missing. Therefore, the aim of the following investigation 
was to assess the effects of C14:0, C16:0, or C18:1 on protein expression of HepG2 cells as 
determined by shotgun LC-MS/MS analysis. In the present chapter the proteomic effects of 
C14:0 were compared with those of these two well-known FAs, in order to highlight proteomic 
modulations and molecular mechanisms shared among all the three FAs, SFAs and to identify 
in particular proteome changes specifically induced by C14:0. This additional comparison 
could therefore be essential in order to better describe the specific and unique effects of C14:0 
at cellular levels, facilitating elucidation of C14:0-related biological process and pathological 
consequences.    
↑ROS  
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2. EXPERIMENTAL DESIGN AND PROCEDURES 
This experimental part, and in particular the MS analysis, was performed thanks to the kind 
collaboration of Prof. Ruth Birner-Gruenberger laboratory (Laboratory of “Functional Proteomics and 
Metabolic Pathways” at the Medical University of Graz, Austria).  
 
2.1 Cell culture and fatty acid conditioning 
 
HepG2 cells were grown in the same conditions mentioned in the previous chapter (Chapter 2 
Section 2). Briefly, they were cultured in RPMI 1640 media (Sigma-Aldrich), supplemented 
with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin, 4mM L-glutamine and were 
maintained in a humidified incubator at 37°C in an atmosphere of 5% CO2. The FBS was 
removed from the HepG2 culture media six hours before FA conditioning. C16:0 and C18:1 
were complexed to Bovine Serum Albumin (Fatty Acid Free BSA, Sigma-Aldrich) in a 6:1 
molar ratio, similarly to the C14:0 solution and as previously described (Pike et al., 2011). 
Sodium palmitate and oleate (Sigma-Aldrich) were dissolved in 150 mM sodium chloride 
stirring at 70°C in water bath. FAs solutions were then added dropwise to a previously prepared 
BSA solution dissolved in 150mM NaCl, and stirred one hour at 37°C. The obtained C16:0-
BSA and C18:1-BSA stock solutions 1mM were filtered and stored at -20°C until further use. 
At the time of the experiments the solutions of FAs conjugated with BSA were added to cell 
culture FBS-free media at the following concentrations: 50, 125, 250 μM and 500 μM, while 
only the BSA was added to controls. Again, incubations were carried out for 24 hours and three 
biological replicates were used for each FAs concentration. As performed for C14:0 samples, 
after the incubation cells were washed with PBS solution and harvested using trypsin. Cell 
viability and number were evaluated by means of CASY technology and then samples were 
subjected to the following experimental workflow (Fig.2): 
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Fig.2 Experimental workflow 
 
 
2.2 Oil Red O staining 
To assess C16:0 and C18:1 incorporation the LD formation was investigated by means of Oil 
Red O solution, as performed for C14:0-treated HepG2 and described in Chapter 2 Section 2. 
Briefly, HepG2 cells were grown on a cover slip inside a 6-well plate and incubated with 
C16:0-BSA and C18:1-BSA at the highest concentration used for the analysis for 24 hours. 
After fixation, cells were stained with a solution of 0.6 % Oil Red O in 60% isopropanol for 15 
minutes, for LD visualisation and with hematoxylin for 4 minutes highlight cell nuclei. Slide 
were removed from the well and examined using 100X magnification under light microscope.  
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2.3 Sample preparation and mass spectrometry analysis 
Due to the negative effect of high concentrations of FAs on cell viability and to maintain the 
same concentrations of FAs used in the C14:0 investigation, only treatments with 50, 125 and 
250 M FAs were selected for the proteomic analysis. The procedure used for sample 
preparation and analysis by means of mass spectrometry was the same as used for C14:0-
treated HepG2 cells sample preparation, described in Chapter 2 of the present section. Cells 
were lysed in PBS by sonication and cell debris was removed with centrifugation at 3000g for 
ten minutes at 4°C. Protein concentrations were determined using Bradford Protein assay (Bio-
Rad). 10 g of protein was taken from each sample for protein digestion. Tris-HCl-TFE buffer 
pH 8.5 (25% trifluoroethanol, 25% H2O, 50% Tris-HCl 100 mM) was added to each sample. 
Reduction step was performed using TCEP, (tris(2-carboxyethyl)phosphine),  pH 8.5 10mM 
final concentration. CAA (chloroacetamide) 40 mM  dissolved in Tris-HCl pH 8.5 was used for 
alkylation. Samples were shaken for ten minutes at 95°C and diluted to have 10% TFE with 
50mM ammonium bicarbonate. Protein digestion was performed by adding 1g/L of trypsin 
to every 50 g of proteins and an overnight incubation at 37 °C was performed. Obtained 
peptides were then diluted in solvent A (0.3% FA, 5% ACN) and stored at -20 °C until further 
LC-MS/MS analysis. For each sample an aliquot of 500 ng of each sample was injected in a 
nano-HPLC (Dionex Ultimate 3000) equipped with a C18, 5 µm, 100 Å, 5 x 0.3 mm, 
enrichment column and an Acclaim PepMap RSLC nanocolumn (C18, 2 µm, 100 Å, 500 x 
0.075 mm) (Thermo Fisher Scientific). Each sample was then analysed by means of an II
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ETD high-resolution LC-QTOF mass spectrometer (Bruker Daltonics). Details on the 
enrichment and settings of the mass spectrometry instrument are reported in Chapter 2 of the 
present section. The MS/MS data were analysed for protein identification and quantification 
using Data analysis software (Bruker), Sum Peak algorithm, and by MaxQuant 1.5.3.30 against 
the human public database SwissProt database with taxonomy homo sapiens (downloaded on 
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11.06.2015, 42150 sequences) and common contaminants. Modification settings and search 
criteria were maintained equal to the C14:0 samples analysis described above. Importantly, two 
identified peptides were used as minimum requirement for protein identification. Data 
processing was performed with Perseus software version 1.5.0.31. Known contaminants were 
removed from the result list. LFQ intensities were log2 transformed to lower the effect of the 
outlier values. 
The protein lists were filtered to keep only protein groups with at least three valid values in at 
least one FA concentration, meaning that in at least one FA treatment the protein had to be 
identified in all three biological replicates. For protein groups missing LFQ values, this value 
was obtained by means of an imputation step with Perseus software in which the values were 
replaced with random values taken from the Gaussian distribution of values, to simulate an 
LFQ value for those low abundant protein groups. Perseus default parameters -width of 0.3 and 
downshift of 1.8 separately for each column - were used for imputation. For each protein group 
log2 differences were calculated as the difference between the averages of log2 LFQ intensities 
of the treated samples and controls. For statistical analysis R software (RCoreTeam, 2015) was 
employed. ANOVA with subsequent multiple testing correction with Benjamini-Hochberg 
(Benjamini et al., 1995) method was used to identify altered protein groups. Tukey's Honest 
Significant Differences test on protein groups significant after the ANOVA was used for the 
comparison of protein groups among different samples. Only proteins with p-value < 0.05 and 
fold change greater than ± 1.3 were considered significantly modulated both in C16:0 and 
C18:1 treated samples.  
 
2.4 Comparative proteomic analysis to assess the effects of myristic, oleic and palmitic 
acid 
The analysis of deregulated proteins shared among different FA treatments was performed by 
means of Functional Enrichment Analysis Tool (FunRich) (http://www.funrich.org/) which was 
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used for the generation of Venn diagrams (Pathan et al., 2015). The Gene Ontology (Finegold 
et al.) analyses were performed on proteins specifically regulated by single FAs by means of 
the DAVID v6.8 Functional Annotation Bioinformatics Tools (https://david.ncifcrf.gov/) 
(Huang da et al., 2009) as previously described (Chapter 2, Section 2).   
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3. RESULTS 
 
3.1 Effects of palmitic and oleic acid on HepG2 cell viability and lipid droplets  
The effects of C16:0 and C18:1 (50-125-250-500 M) on HepG2 cell viability after 24 hours of 
incubations were investigated by means of CASY technology.  Graphical representation of the 
results of viability measurements following C16:0 and C18:1 supplementations are reported in 
Fig.3 and Fig.4 respectively.  
 
Fig.3 HepG2 cell viability, measured by using CASY technology, after 24h treatment with different 
concentrations of C16:0 (0, 50, 125, 250 and 500 M) conjugated with BSA. All experiments were 
performed at least in triplicate. 
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Fig.4 HepG2 cell viability, measured by using CASY technology, after 24h treatment with different 
concentrations of C18:1 (0, 50, 125, 250 and 500 M) conjugated with BSA. All experiments were 
repeated at least in triplicate. 
 
HepG2 cell viability decreased with both FAs treatments and this was particularly true in a 
concentration dependent manner for C18:1. However, while a slight decrease in cell viability 
was observed with the highest concentration of C18:1, the viability decreased significantly with 
the highest concentration of C16:0 treatment to 76%.  
To be able to confirm the cellular uptake of FAs dissolved in BSA from the culture media and 
their incorporation into TG and LD, HepG2 treated with both FAs were stained with the lipid-
soluble Oil Red O, as previously performed on C14:0-treated cells. C16:0 induced a significant 
accumulation of LD inside cell cytoplasm (Fig.5B) and condensed hematoxylin-stained nuclei 
when compared to control cells (Fig.5A). C18:1 induced an even more pronounced increase in 
LD content, and LD reached greater dimensions and highest number per single cell (Fig.5C) 
when compared to C16:0.  
 
150 
 
 
 
Fig.5 Effects of C16:0 and C18:1 loading on lipids and LD accumulation. A) control HepG2 cells, B) 
C16:0-treated HepG2 cells and C) C18:1-treated HepG2 cells.   
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3.2 Quantitative analysis of proteins deregulated by palmitic and oleic acid in HepG2 cell 
proteome  
MS analyses were performed on HepG2 cells treated with C16:0 and C18:1 (0-50-125-250 
M).  Only protein groups identified with at least three valid values in one condition –at least 
one concentration in which the identification succeeded in all three biological replicates- were 
considered for further analyses.  The abundance of proteins was determined by label free MS1-
based quantitation and subjected to statistical analysis, namely ANOVA test followed by 
Tukey's Honest Significant Differences test, to disclose proteins differently modulated in 
HepG2 cells by C16:0 and C18:1. The 37 proteins whose expression was found to be increased 
by C16:0 in culture media are reported in Tab. I, while the 34 down-regulated proteins are 
reported in Tab. II. The expressions of 80 proteins were found to be modulated by C18:1 
treatments in HepG2 cells. Details on the 40 up-regulated proteins are reported in Tab. III while 
the 40 down-regulated proteins are listed in Tab. IV.  
Major 
Protein 
ID 
Protein name 
Gene 
name 
ANOVA 
50-0 
p adj 
Fold 
change  
0-50 
125-0 
 p adj 
Fold 
change  
0-125 
250-0 
 p adj 
Fold 
change  
0-250 
Q99541 Perilipin-2 PLIN2 0.0003 0.433 0.60 0.139 2.11 0.001 5.76 
Q15043 Zinc transporter ZIP14 SLC39A14 0.0007 0.498 1.43 0.024 2.27 0.000 5.08 
P07305 Histone H1.0 H1F0 0.0031 0.003 3.05 0.008 2.65 0.000 4.41 
P13995 
Bifunctional 
methylenetetrahydrofol
ate 
dehydrogenase/cyclohy
drolase. mitochondrial 
MTHFD2 0.0000 0.000 2.74 0.000 2.83 0.000 3.60 
P09874 
Poly [ADP-ribose] 
polymerase 1 
PARP1 0.0076 0.178 1.59 0.132 1.66 0.001 3.22 
Q9HCU5 
Prolactin regulatory 
element-binding 
protein 
PREB 0.0048 0.767 1.37 0.301 1.75 0.035 2.59 
P43307 
Translocon-associated 
protein subunit alpha 
SSR1 0.0000 0.010 1.52 0.033 1.41 0.000 2.57 
P61803 
Dolichyl-
diphosphooligosacchari
de--protein 
glycosyltransferase 
subunit DAD1 
DAD1 0.0397 1.000 1.00 1.000 1.01 0.034 2.29 
Q9Y2V2 
Calcium-regulated heat 
stable protein 1 
CARHSP1 0.0204 0.246 1.76 0.017 2.77 0.087 2.11 
O95573 
Long-chain-fatty-acid--
CoA ligase 3 
ACSL3 0.0042 0.840 1.20 0.028 1.90 0.014 2.06 
P08195 4F2 cell-surface SLC3A2 0.0000 0.003 1.43 0.005 1.40 0.000 2.01 
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antigen heavy chain 
Q7L0Y3 
Mitochondrial 
ribonuclease P protein 
1 
TRMT10C 0.0037 0.139 1.72 0.044 2.01 0.056 1.95 
Q9NVI7 
ATPase family AAA 
domain-containing 
protein 3A 
ATAD3A 0.0152 0.462 1.41 0.312 1.51 0.049 1.94 
P05141 ADP/ATP translocase 2 SLC25A5 0.0000 0.201 1.26 0.376 1.20 0.001 1.83 
P22695 
Cytochrome b-c1 
complex subunit 2. 
mitochondrial 
UQCRC2 0.0002 0.683 1.24 0.565 1.28 0.032 1.78 
P52292 
Importin subunit alpha-
1 
KPNA2 0.0001 0.002 2.19 0.024 1.69 0.019 1.73 
P06576 
ATP synthase subunit 
beta. mitochondrial 
ATP5B 0.0000 0.354 1.12 0.078 1.20 0.000 1.71 
P21796 
Voltage-dependent 
anion-selective channel 
protein 1 
VDAC1 0.0009 1.000 0.98 0.993 1.06 0.026 1.67 
Q9HDC9 
Adipocyte plasma 
membrane-associated 
protein 
APMAP 0.0000 0.800 1.07 0.430 1.12 0.000 1.66 
P84098 
60S ribosomal protein 
L19 
RPL19 0.0012 0.185 1.26 0.028 1.42 0.003 1.63 
P28331 
NADH-ubiquinone 
oxidoreductase 75 kDa 
subunit. mitochondrial 
NDUFS1 0.0000 0.119 1.23 0.049 1.29 0.001 1.62 
Q9UHG3 
Prenylcysteine oxidase 
1 
PCYOX1 0.0052 1.000 1.01 0.912 1.12 0.039 1.57 
P00387 
NADH-cytochrome b5 
reductase 3 
CYB5R3 0.0033 0.960 1.06 0.621 1.14 0.010 1.48 
P25705 
ATP synthase subunit 
alpha. mitochondrial 
ATP5A1 0.0000 1.000 1.00 1.000 1.00 0.002 1.48 
P10606 
Cytochrome c oxidase 
subunit 5B. 
mitochondrial 
COX5B 0.0000 1.000 1.01 0.983 0.95 0.038 1.44 
P04843 
Dolichyl-
diphosphooligosacchari
de--protein 
glycosyltransferase 
subunit 1 
RPN1 0.0008 0.986 1.05 0.729 1.14 0.046 1.44 
Q9UJS0 
Calcium-binding 
mitochondrial carrier 
protein Aralar2 
SLC25A13 0.0005 0.976 0.95 1.000 1.01 0.035 1.38 
P40939 
Trifunctional enzyme 
subunit alpha. 
mitochondrial 
HADHA 0.0000 0.819 1.04 0.913 1.03 0.000 1.37 
P55084 
Trifunctional enzyme 
subunit beta. 
mitochondrial 
HADHB 0.0004 0.969 0.95 0.991 1.03 0.016 1.37 
P10809 
60 kDa heat shock 
protein. mitochondrial 
HSPD1 0.0001 0.682 1.13 0.737 1.12 0.045 1.36 
Q16822 
Phosphoenolpyruvate 
carboxykinase [GTP]. 
mitochondrial 
PCK2 0.0000 0.890 0.94 0.309 1.14 0.005 1.35 
Q6UB35 
Monofunctional C1-
tetrahydrofolate 
synthase. mitochondrial 
MTHFD1L 0.0003 0.888 1.07 0.045 1.29 0.019 1.34 
O75390 
Citrate synthase. 
mitochondrial 
CS 0.0000 0.974 1.04 0.998 0.98 0.006 1.33 
P24752 
Acetyl-CoA 
acetyltransferase. 
mitochondrial 
ACAT1 0.0000 0.999 0.98 0.999 0.98 0.044 1.33 
P49748 
Very long-chain 
specific acyl-CoA 
dehydrogenase. 
mitochondrial 
ACADVL 0.0000 0.999 0.99 0.087 1.18 0.004 1.32 
153 
 
 
Tab. I Proteins significantly up-regulated by different concentrations of C16:0 treatment in HepG2 cell 
proteome with relative fold change compared to controls (ANOVA p-value adjusted with Benjamini-
Hochberg method; Tukey’s HSD p-value adjusted for multiple comparisons). Significant p-values and 
fold changes higher than 1.3 are highlighted in bold type. 
 
 
Q9NX58 
Cell growth-regulating 
nucleolar protein 
LYAR 0.0006 0.001 2.36 0.002 2.17 0.828 1.16 
P53396 ATP-citrate synthase ACLY 0.0104 0.031 1.40 0.387 1.19 0.737 1.12 
Major 
Protein 
ID 
Protein name 
Gene 
name 
ANOVA 
50-0 p 
adj 
fold 
change 
0-50 
125-0 
p adj 
fold 
change 
0-125 
250-0 
p adj 
fold 
change 
0-250 
P62854 
40S ribosomal protein 
S26 
RPS26 0.0221 0.028 -9.36 0.694 -2.22 0.018 -11.18 
P62318 
Small nuclear 
ribonucleoprotein Sm 
D3 
SNRPD3 0.0340 0.583 -2.49 0.021 -10.31 0.021 -10.30 
O43852 Calumenin CALU 0.0091 1.000 -1.07 0.588 -1.90 0.013 -5.99 
P62266 
40S ribosomal protein 
S23 
RPS23 0.0254 0.714 -1.76 0.956 -1.35 0.019 -5.63 
O14980 Exportin-1 XPO1 0.0008 0.994 1.10 1.000 -1.00 0.001 -4.13 
O43493 
Trans-Golgi network 
integral membrane 
protein 2 
TGOLN2 0.0080 0.786 -1.34 0.149 -1.96 0.003 -3.75 
Q9NVS9 
Pyridoxine-5-phosphate 
oxidase 
PNPO 0.0088 0.945 -1.27 0.980 -1.19 0.022 -3.45 
Q9UHB9 
Signal recognition 
particle subunit SRP68 
SRP68 0.0000 1.000 1.01 1.000 -1.00 0.000 -3.16 
P50552 
Vasodilator-stimulated 
phosphoprotein 
VASP 0.0168 0.028 -2.58 0.076 -2.18 0.012 -3.00 
Q9H773 
dCTP pyrophosphatase 
1 
DCTPP1 0.0104 0.987 1.14 0.922 -1.24 0.042 -2.47 
P02751 Fibronectin FN1 0.0288 0.042 -3.27 0.291 -2.08 0.240 -2.18 
Q9BY77 
Polymerase delta-
interacting protein 3 
POLDIP3 0.0006 0.643 -1.18 0.774 -1.15 0.001 -2.13 
Q86TG7 
Retrotransposon-
derived protein PEG10 
PEG10 0.0060 0.035 -1.88 0.014 -2.10 0.039 -1.85 
Q00839 
Heterogeneous nuclear 
ribonucleoprotein U 
HNRNPU 0.0007 0.997 -1.05 0.899 -1.12 0.007 -1.83 
P63261 Actin. cytoplasmic 2 ACTG1 0.0168 0.219 -1.31 0.263 -1.29 0.016 -1.61 
P63162 
Small nuclear 
ribonucleoprotein-
associated protein N 
SNRPN 0.0267 0.447 -1.80 0.022 -3.61 0.640 -1.60 
Q16181 Septin-7 SEPT7 0.0398 0.045 -1.73 0.996 -1.06 0.148 -1.52 
Q7L5N1 
COP9 signalosome 
complex subunit 6 
COPS6 0.0062 0.925 -1.08 0.976 1.05 0.008 -1.51 
Q9BQP7 
Mitochondrial genome 
maintenance 
exonuclease 1 
MGME1 0.0029 0.022 -2.20 0.372 -1.48 0.340 -1.51 
P22626 
Heterogeneous nuclear 
ribonucleoproteins 
A2/B1 
HNRNPA2
B1 
0.0000 0.908 -1.08 0.253 -1.22 0.014 -1.45 
Q13428 Treacle protein TCOF1 0.0000 0.572 -1.14 0.620 -1.13 0.017 -1.40 
Q16698 
2.4-dienoyl-CoA 
reductase. 
mitochondrial 
DECR1 0.0033 0.034 -1.70 0.575 -1.26 0.273 -1.38 
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Tab. II Proteins significantly down-regulated by different concentrations of C16:0 treatment in HepG2 
cell proteome with relative fold change compared to controls (ANOVA p-value adjusted with Benjamini-
Hochberg method; Tukey’s HSD p-value adjusted for multiple comparisons). Significant p-values and 
fold changes lower than -1.3 are highlighted in bold type. 
 
 
 
P11717 
Cation-independent 
mannose-6-phosphate 
receptor 
IGF2R 0.0182 0.129 -1.22 0.006 -1.42 0.015 -1.35 
Q04828 
Aldo-keto reductase 
family 1 member C1 
AKR1C1 0.0246 0.019 -1.48 0.449 -1.19 0.081 -1.35 
P27797 Calreticulin CALR 0.0161 0.995 -1.03 0.022 -1.31 0.013 -1.35 
P14174 
Macrophage migration 
inhibitory factor 
MIF 0.0367 0.788 -1.12 0.020 -1.49 0.162 -1.29 
P22307 
Non-specific lipid-
transfer protein 
SCP2 0.0122 0.111 -1.25 0.007 -1.44 0.121 -1.24 
Q9H8Y8 
Golgi reassembly-
stacking protein 2 
GORASP2 0.0011 0.402 -1.20 0.036 -1.42 0.282 -1.24 
Q06830 Peroxiredoxin-1 PRDX1 0.0017 0.006 -1.31 0.125 -1.17 0.030 -1.23 
Q16555 
Dihydropyrimidinase-
related protein 2 
DPYSL2 0.0335 0.009 -1.40 0.053 -1.28 0.221 -1.19 
Q09666 
Neuroblast 
differentiation-
associated protein 
AHNAK 
AHNAK 0.0377 0.012 -1.41 0.092 -1.26 0.698 -1.11 
P07339 Cathepsin D CTSD 0.0002 0.022 -1.44 0.629 -1.15 0.825 -1.11 
O75521 
Enoyl-CoA delta 
isomerase 2. 
mitochondrial 
ECI2 0.0076 1.000 -1.00 0.024 -3.46 1.000 -1.01 
O14949 
Cytochrome b-c1 
complex subunit 8 
UQCRQ 0.0000 0.648 1.22 0.023 -1.72 1.000 1.02 
Majority 
Protein 
ID 
Protein name 
Gene 
name 
ANOVA 
50-0 p 
adj 
fold 
change 
0-50 
125-0 
p adj 
fold 
change 
0-125 
250-0 
p adj 
fold 
change 
0-250 
Q99541 Perilipin-2 PLIN2 0.0000 0.006 3.06 0.000 7.45 0.000 18.94 
P60228 
Eukaryotic translation 
initiation factor 3 
subunit E 
EIF3E 0.0247 0.004 4.20 0.010 3.47 0.002 4.90 
P30046 
D-dopachrome 
decarboxylase 
DDT 0.0371 0.404 1.77 0.942 0.80 0.020 3.33 
P09874 
Poly [ADP-ribose] 
polymerase 1 
PARP1 0.0056 0.012 1.83 0.003 2.13 0.000 3.27 
O14929 
Histone 
acetyltransferase type B 
catalytic subunit 
HAT1 0.0140 0.002 2.41 0.001 2.85 0.001 2.62 
P11388 
DNA topoisomerase 2-
alpha 
TOP2A 0.0275 0.011 2.47 0.004 2.90 0.010 2.51 
P28288 
ATP-binding cassette 
sub-family D member 3 
ABCD3 0.0323 0.137 1.48 0.083 1.56 0.001 2.42 
P62805 Histone H4 HIST1H4A 0.0140 0.757 1.17 0.003 1.98 0.001 2.26 
P16401 Histone H1.5 HIST1H1B 0.0130 0.005 2.03 0.000 2.74 0.003 2.16 
Q9Y5B9 
FACT complex subunit 
SPT16 
SUPT16H 0.0024 0.002 1.65 0.000 2.36 0.000 2.11 
O75367 
Core histone macro-
H2A.1 
H2AFY 0.0247 0.028 1.58 0.005 1.82 0.001 2.11 
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Q15785 
Mitochondrial import 
receptor subunit 
TOM34 
TOMM34 0.0495 0.010 2.02 0.012 2.00 0.008 2.08 
P52292 
Importin subunit alpha-
1 
KPNA2 0.0004 0.000 2.46 0.000 2.58 0.005 1.75 
Q99879 Histone H2B type 1-M 
HIST1H2B
M 
0.0140 0.789 0.90 0.038 1.40 0.003 1.65 
P02679 
Fibrinogen gamma 
chain 
FGG 0.0034 0.997 1.03 0.807 1.10 0.002 1.62 
P02647 Apolipoprotein A-I APOA1 0.0006 0.970 0.94 0.814 1.12 0.014 1.55 
P04844 
Dolichyl-
diphosphooligosacchari
de--protein 
glycosyltransferase 
subunit 2 
RPN2 0.0250 0.186 1.19 0.057 1.25 0.002 1.46 
P26196 
Probable ATP-
dependent RNA 
helicase DDX6 
DDX6 0.0063 0.002 1.29 0.002 1.30 0.000 1.46 
Q01581 
Hydroxymethylglutaryl
-CoA synthase. 
cytoplasmic 
HMGCS1 0.0065 0.010 2.14 0.025 1.92 0.340 1.41 
P09525 Annexin A4 ANXA4 0.0476 0.997 0.97 0.078 1.27 0.012 1.39 
Q14152 
Eukaryotic translation 
initiation factor 3 
subunit A 
EIF3A 0.0324 0.452 1.10 0.012 1.27 0.002 1.36 
P05141 ADP/ATP translocase 2 SLC25A5 0.0052 0.001 1.26 0.000 1.34 0.000 1.35 
Q15392 
Delta(24)-sterol 
reductase 
DHCR24 0.0360 0.939 1.05 0.050 1.25 0.008 1.35 
P32754 
4-
hydroxyphenylpyruvate 
dioxygenase 
HPD 0.0243 0.005 1.35 0.003 1.38 0.005 1.34 
P78527 
DNA-dependent 
protein kinase catalytic 
subunit 
PRKDC 0.0147 0.004 1.29 0.001 1.37 0.001 1.34 
P49748 
Very long-chain 
specific acyl-CoA 
dehydrogenase. 
mitochondrial 
ACADVL 0.0360 0.485 1.15 0.865 1.08 0.038 1.33 
P51149 
Ras-related protein 
Rab-7a 
RAB7A 0.0147 0.020 1.20 0.181 1.12 0.002 1.30 
Q13765 
Nascent polypeptide-
associated complex 
subunit alpha 
NACA 0.0493 0.005 1.38 0.008 1.35 0.024 1.29 
Q02809 
Procollagen-lysine.2-
oxoglutarate 5-
dioxygenase 1 
PLOD1 0.0250 0.002 1.31 0.006 1.25 0.007 1.25 
P25205 
DNA replication 
licensing factor MCM3 
MCM3 0.0275 0.007 1.39 0.005 1.42 0.068 1.25 
Q6UB35 
Monofunctional C1-
tetrahydrofolate 
synthase. mitochondrial 
MTHFD1L 0.0370 0.004 1.29 0.003 1.30 0.024 1.22 
Q9Y2X3 Nucleolar protein 58 NOP58 0.0175 0.001 1.35 0.005 1.26 0.035 1.18 
O60841 
Eukaryotic translation 
initiation factor 5B 
EIF5B 0.0235 0.002 1.32 0.004 1.30 0.062 1.18 
P02786 
Transferrin receptor 
protein 1 
TFRC 0.0010 0.000 1.65 0.387 1.12 0.148 1.17 
P49327 Fatty acid synthase FASN 0.0061 0.001 1.32 0.007 1.23 0.154 1.12 
Q03252 Lamin-B2 LMNB2 0.0332 0.002 1.35 0.049 1.20 0.328 1.11 
P31930 
Cytochrome b-c1 
complex subunit 1. 
mitochondrial 
UQCRC1 0.0140 0.000 1.34 0.006 1.22 0.173 1.11 
P17844 
Probable ATP-
dependent RNA 
helicase DDX5 
DDX5 0.0065 0.000 1.38 0.014 1.22 0.434 1.09 
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Tab. III Proteins significantly up-regulated by different concentrations of C18:1 treatment in HepG2 
cell proteome with relative fold change compared to controls (ANOVA p-value adjusted with Benjamini-
Hochberg method; Tukey’s HSD p-value adjusted for multiple comparisons). Significant p-values and 
fold changes higher than 1.3 are highlighted in bold type. 
 
 
O94906 
Pre-mRNA-processing 
factor 6 
PRPF6 0.0147 0.005 1.31 0.843 1.06 0.387 0.90 
P78330 
Phosphoserine 
phosphatase 
PSPH 0.0056 0.004 2.70 1.000 1.01 0.188 0.62 
Majority 
Protein 
ID 
Protein name 
Gene 
name 
ANOVA 
50-0 p 
adj 
fold 
change 
0-50 
125-0 
p adj 
fold 
change 
0-125 
250-0 
p adj 
fold 
change 
0-250 
Q13148 
TAR DNA-binding 
protein 43 
TARDBP 0.0052 0.317 -1.36 0.437 -1.30 0.000 -2.91 
Q15020 
Squamous cell 
carcinoma antigen 
recognized by T-cells 3 
SART3 0.0493 0.012 -2.85 0.031 -2.46 0.075 -2.13 
Q00839 
Heterogeneous nuclear 
ribonucleoprotein U 
HNRNPU 0.0422 0.757 -1.18 0.176 -1.40 0.005 -1.95 
Q86TG7 
Retrotransposon-
derived protein PEG10 
PEG10 0.0006 0.000 -1.78 0.000 -1.96 0.000 -1.85 
Q8NC51 
Plasminogen activator 
inhibitor 1 RNA-
binding protein 
SERBP1 0.0161 0.306 -1.24 0.452 -1.20 0.001 -1.83 
P22307 
Non-specific lipid-
transfer protein 
SCP2 0.0275 0.709 -1.15 0.018 -1.52 0.002 -1.80 
P84090 
Enhancer of 
rudimentary homolog 
ERH 0.0161 0.004 -1.69 0.001 -1.97 0.003 -1.74 
Q9Y2W1 
Thyroid hormone 
receptor-associated 
protein 3 
THRAP3 0.0403 1.000 -1.01 0.136 -1.28 0.005 -1.57 
Q15942 Zyxin ZYX 0.0056 1.000 1.00 0.020 -1.26 0.000 -1.56 
Q9BXP5 
Serrate RNA effector 
molecule homolog 
SRRT 0.0422 0.732 -1.13 0.036 -1.40 0.008 -1.54 
Q32MZ4 
Leucine-rich repeat 
flightless-interacting 
protein 1 
LRRFIP1 0.0447 0.385 -1.20 1.000 1.01 0.015 -1.50 
P23588 
Eukaryotic translation 
initiation factor 4B 
EIF4B 0.0070 0.606 -1.09 0.007 -1.30 0.000 -1.49 
P50552 
Vasodilator-stimulated 
phosphoprotein 
VASP 0.0363 0.022 -3.69 0.003 -5.88 0.776 -1.48 
P06730 
Eukaryotic translation 
initiation factor 4E 
EIF4E 0.0100 0.777 -1.09 0.469 -1.13 0.002 -1.48 
P27797 Calreticulin CALR 0.0275 0.009 -1.35 0.005 -1.38 0.002 -1.45 
Q13428 Treacle protein TCOF1 0.0006 0.173 -1.09 0.000 -1.40 0.000 -1.44 
Q15370 
Transcription 
elongation factor B 
polypeptide 2 
TCEB2 0.0195 0.003 -3.44 0.995 1.10 0.647 -1.40 
Q9P2E9 
Ribosome-binding 
protein 1 
RRBP1 0.0002 0.070 -1.09 0.000 -1.22 0.000 -1.38 
P14314 
Glucosidase 2 subunit 
beta 
PRKCSH 0.0403 1.000 1.00 0.616 -1.10 0.006 -1.36 
P14174 
Macrophage migration 
inhibitory factor 
MIF 0.0000 0.001 -1.92 0.031 -1.49 0.104 -1.36 
P08621 
U1 small nuclear 
ribonucleoprotein 70 
kDa 
SNRNP70 0.0059 1.000 1.01 0.004 -1.26 0.001 -1.36 
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Tab. IV Proteins significantly down-regulated by different concentrations of C18:1 treatment in HepG2 
cell proteome with relative fold change compared to controls (ANOVA p-value adjusted with Benjamini-
Hochberg method; Tukey’s HSD p-value adjusted for multiple comparisons). Significant p-values and 
fold changes lower than -1.3 are highlighted in bold type. 
 
3.3 Comparison between proteins modulated by myristic, palmitic and oleic acids  
To detect which C14:0 modulated proteins were unique for this FA or shared with other FAs, a 
comparative analysis was performed between proteins deregulated by C14:0, C16:0 and C18:1. 
By means of FunRich bioinformatics tool a Venn diagram (Fig.6) was generated in order to 
graphically illustrate common and unique proteins whose expression was significantly altered 
in HepG2 cells after FAs treatments. Interestingly, the analysis revealed that only the 
expression of one single protein, Perilipin2, was modulated by all three FAs and the shared 
P04040 Catalase CAT 0.0052 0.003 -1.24 0.000 -1.37 0.000 -1.36 
Q9NZT2 
Opioid growth factor 
receptor 
OGFR 0.0403 0.457 1.16 0.904 -1.07 0.030 -1.35 
P38919 
Eukaryotic initiation 
factor 4A-III 
EIF4A3 0.0097 0.945 1.04 0.124 -1.15 0.002 -1.35 
Q9Y4L1 
Hypoxia up-regulated 
protein 1 
HYOU1 0.0059 0.050 1.22 0.999 1.01 0.006 -1.33 
P61916 
Epididymal secretory 
protein E1 
NPC2 0.0296 0.031 -1.26 0.002 -1.44 0.022 -1.28 
P51665 
26S proteasome non-
ATPase regulatory 
subunit 7 
PSMD7 0.0052 0.637 -1.18 0.012 -1.64 0.599 -1.19 
Q04828 
Aldo-keto reductase 
family 1 member C1 
AKR1C1 0.0052 0.002 -1.47 0.001 -1.48 0.236 -1.17 
O96008 
Mitochondrial import 
receptor subunit 
TOM40 homolog 
TOMM40 0.0173 0.030 -2.20 0.001 -3.62 0.953 -1.16 
P07910 
Heterogeneous nuclear 
ribonucleoproteins 
C1/C2 
HNRNPC 0.0422 0.015 -1.31 0.016 -1.31 0.248 -1.16 
P01023 Alpha-2-macroglobulin A2M 0.0021 0.028 -1.45 0.003 -1.68 0.741 -1.13 
P63220 
40S ribosomal protein 
S21 
RPS21 0.0000 0.839 1.13 0.000 -11.01 0.932 -1.10 
O75477 Erlin-1 ERLIN1 0.0250 0.931 1.17 0.005 -2.70 1.000 -1.02 
P62333 
26S protease regulatory 
subunit 10B 
PSMC6 0.0498 0.006 -1.58 0.882 -1.10 1.000 -1.01 
P08758 Annexin A5 ANXA5 0.0323 0.121 -1.16 0.004 -1.31 1.000 1.01 
Q14137 
Ribosome biogenesis 
protein BOP1 
BOP1 0.0328 0.187 -1.28 0.004 -1.65 0.999 1.03 
P02751 Fibronectin FN1 0.0147 0.036 -7.71 0.127 -4.77 1.000 1.03 
Q96IX5 
Up-regulated during 
skeletal muscle growth 
protein 5 
USMG5 0.0494 0.013 -5.62 0.469 -2.02 1.000 1.04 
P11766 
Alcohol dehydrogenase 
class-3 
ADH5 0.0422 0.014 -1.33 0.806 -1.08 0.745 1.09 
Q13724 
Mannosyl-
oligosaccharide 
glucosidase 
MOGS 0.0360 0.010 -2.76 0.928 -1.20 0.950 1.18 
158 
 
proteins were only few with respect to the number of total of proteins modulated by each FA. 
While 14 proteins were shared between C16:0 and C18:1, C14:0 shared only four proteins 
exclusively with C16:0 and two proteins exclusively with C18:1. Therefore 40 out of 47 
proteins whose expression were found to be altered by C14:0 treatment were exclusively 
modulated by this saturated FA. 
 
Fig.6 Graphical representation of unique and overlapping proteins whose expression was found to be 
modulated by myristic (C14:0), palmitic (C16:0) and oleic acid (C18:1).  
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3.4 Biological processes exclusively modulated by myristic, palmitic or oleic acid 
The results obtained showed a high number of “specifically altered” proteins, for each FA 
treatment, suggesting specific actions of the individual FAs analysed. To disclose the specific 
effects of each of these FAs, and in particular the biological processes involved in the specific 
response to C14:0 treatment, GO analyses were performed of up- and down-regulated proteins 
specifically modulated by the individual FAs analysed. Results of DAVID GO analysis on 
proteins specifically modulated by C14:0 are reported in Fig.7. Regulation of calcium ion 
homeostasis, cellular matrix organisation and negative regulation of the apoptotic process were 
among the biological processes mainly up-regulated by C14:0. 
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Fig.7 Gene Ontology analysis of HepG2 proteins modulated exclusively by C14:0. In blue down-
regulated and in red up-regulated protein biological processes (A), cellular components (B) and 
molecular functions (C) are reported. Horizontal axis represents the number of proteins involved and 
enrichment p-value is reported at the end of each bar.  
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Fig.8 Gene Ontology analysis of HepG2 proteins modulated exclusively by C16:0. In blue down-regulated and in 
red up-regulated protein biological processes (A), cellular components (B) and molecular functions (C) are 
reported. Horizontal axis represents the number of proteins involved and enrichment p-value is reported at the 
end of each bar.  
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Fig.9 Gene Ontology analysis of HepG2 proteins modulated exclusively by C18:1. In blue down-regulated and in 
red up-regulated protein biological processes (A), cellular components (B) and molecular functions (C) are 
reported. Horizontal axis represents the number of proteins involved and enrichment p-value is reported at the 
end of each bar.  
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Proteins specifically up-regulated by C14:0 were mainly present in exosome compartment as 
described in the cellular component GO analysis (Fig.7B). Many other cellular compartment 
proteins were also found to be significantly up-regulated by C14:0 treatments such as focal 
adhesion proteins, endoplasmic reticulum proteins and actin cytoskeleton proteins. Concerning 
proteins specifically up-regulated by C16:0, the GO analysis revealed that the pool of proteins 
was particularly enriched in proteins involved in ATP biosynthetic process, fatty acid beta-
oxidation - more in general lipid metabolic processes - apoptotic mitochondrial changes and 
cellular respiration (Fig.8A). Down-regulated proteins were instead involved in mRNA 
splicing, protein targeting to membrane and cell-cell adhesion. In line with the GO biological 
process analysis, the cellular component analysis demonstrated that the majority of the up-
regulated proteins were mitochondrial proteins and they were mitochondrial membrane, 
membrane and nucleoid proteins (Fig.8B). Moreover, extracellular exosome, membrane and 
endoplasmic reticulum proteins were also significantly up-regulated. Some proteins of the 
mitochondrion were also found to be significantly present in C16:0 down-regulated proteins, 
together with nuclear proteins, focal adhesion proteins, membrane proteins and cytoplasm 
protein. Molecular functions of up-regulated proteins involved many specific function, such as 
poly(A)RNA binding, long-chain 3 hydroxyacyl-CoA dehydrogenase activity and protein 
transporting ATPsynthase activity (Fig.8C). Poly(A) RNA binding, nucleotide binding and 
mRNA 3’ –UTR binding were some of the molecular functions involving proteins 
downregulated by C16:0. Regarding proteins involved in C18:1 response, the GO analysis 
revealed that main up-regulated biological processes involved nucleosome assembly, regulation 
of translational initiation, cholesterol biosynthetic process, protein localisation to chromatin, 
response to drug and oxidation-reduction process (Fig.9A). On the other hand, down-regulated 
proteins involved mRNA processing and stability, translational initiation and mRNA splicing. 
The proteins up-regulated by C18:1 mainly belonged to membranes, extracellular exosomes, 
nucleus, cytosol and autophagosome membranes while down regulated proteins were 
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principally extracellular exosome, nucleoplasm and membrane proteins (Fig.9B). Molecular 
functions of significantly C18:1 up-regulated proteins were poly(A) RNA binding, enzyme 
binding and protein homodimerization activity (Fig.9C).  
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4. DISCUSSION 
A correlation of C14:0 to NASH and lipid metabolism - strictly connected with the onset of 
cardiovascular diseases – has recently been recently highlighted (Tomita et al., 2011; Noto et 
al., 2016). C14:0-induced proteomic modulations on HepG2 cells intracellular proteins were 
investigated in depth for the first time in this PhD research project. In the present chapter, the 
HepG2 proteome changes following C16:0 and C18:1 supplementation were also analysed. 
Even though the mechanisms underlying their effects on liver metabolism have been studied in 
depth during recent years (Hetherington et al., 2016) a complete investigation on their 
proteomic effects still lacked. The comparison of proteome modulations induced in HepG2 
after C14:0, or after C16:0, C18:1 treatments, shown for the first time in the present part of the 
thesis, helped the identification of proteins that are exclusively modulated by C14:0, as well as 
proteins that are deregulated not only by C14:0 but also by C16:0 and/or C18:1.  
The present investigation revealed a surprisingly scarce overlap between proteins modulated by 
all three FAs, which was limited to just one protein (Fig.6). This important result underlines 
that these molecules, all belonging to the family of FAs, behave very differently and have 
distinct effects on liver metabolism. Interestingly, the protein whose expression was up-
regulated by all three FAs treatment was the Perilipin 2 (ADRP) (in Fig.6 illustrated with its 
corresponding gene name PLIN2), the main structural protein of LD. This data is therefore in 
line with the dose-dependent appearance of cytosolic LD following C14:0 (Fig.3 Chapter 2), 
C16:0 and C18:1 treatments (Fig.5) and represents a confirmation of the reliability of the 
obtained MS/MS proteomic data. The increase in the protein expression levels of ADRP was 
especially elevated in presence of C18:1 at 250 M in HepG2 culture media, with its fold 
change increasing nearly 19-fold by the treatment (Tab. III). As can also be seen from the Oil 
Red O staining (Fig.5), C18:1 was the most steatogenic FA and has the highest propensity for 
LD formation compared to C14:0 and C16:0. This data is in agreement with the Ricchi et al. 
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investigation, reporting a greater accumulation of LD in C18:1-treated HepG2 cells, together 
with an increase in TG accumulation, when compared to C16:0 treated HepG2 cells (Ricchi et 
al., 2009). They finally speculated that this property protects C18:1-treated cell against FA’s 
pro-apoptotic effects.  
 
4.1 Proteins modulated exclusively by myristic acid 
The present investigation was aimed at disclosing proteins specifically modulated by C14:0. 
The proteomic comparison performed revealed a total of 40 proteins whose expression is 
regulated in HepG2 cells specifically by the C14:0. The GO analysis indicated the up-
regulation of protein involved in calcium homeostasis. The Vesicle-associated membrane 
protein-associated protein B/C (VAPB), already mentioned in the previous chapter as involved 
in calcium homeostasis regulation, was found to be modulated exclusively by C14:0. 
Interestingly, this protein is involved in the protection of ER-stress and has been reported to be 
activated by the UPR (Kanekura et al., 2009). Loss of function of this protein has been 
connected to ER-stress related death (Suzuki et al., 2009). This may suggest that the increase in 
this protein may be a mechanism specific to C14:0-treated HepG2 cells, to counteract ER stress 
and survive general stress conditions, that is not activated in presence of C16:0, which also 
induces ER stress (as showed in Fig.1 of Introduction, Chapter 3, Section 2). Moreover, another 
protein involved in cell calcium homeostasis is Stomatin-like protein 2 (STOML2), up-
regulated only in presence of C14:0. Interestingly, this protein has been found to be important 
for the mitochondrial respiratory chain (Mitsopoulos et al., 2015). This may therefore have an 
essential role in contrasting the mitochondrial stress and ROS generation induced by SFA (as 
showed in Fig.1 of Introduction, Chapter 3, Section 2), possibly distinguishing C14:0 to C16:0 
mechanisms. The previously described Small glutamine-rich tetratricopeptide repeat-containing 
protein alpha (SGTA) and proteasomal ubiquitin receptor ADRM1 are proteins also found to be 
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regulated exclusively by C14:0. As described in the previous chapter, SGTA is involved in the 
regulation of the ubiquitination state of the proteins and in the maintenance of the cellular 
proteostasis by selectively modulating proteasomal substrate degradation (Wunderley et al., 
2014; Roberts et al., 2015). Proteasomal degradation by means of ERAD is a cellular response 
following ER stress conditions. The presence of these proteins among the proteins up-regulated 
exclusively by C14:0 led to the hypothesis that this process could help HepG2 cells to maintain 
cellular proteostasis, decreasing the cytotoxicity that is induced by SFA. Moreover, 
Ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) was another protein found to be 
specifically modulated by C14:0 in HepG2 cells. This protein, also described in the previous 
chapter, is important for a proper protein N-glycosylation and folding in the ER compartment 
and its increase has been reported to counteract ER stress in cancer cells (Fang et al., 2010; 
Shen et al., 2011). The concurrent up-regulation of all these proteins, involved in the 
maintenance of a proper cell protein homeostasis, could therefore suggest the activation of a 
peculiar mechanism aimed at opposing C14:0-induced ER stress in HepG2 cells.  
Furthermore, the GO analysis on proteins modulated specifically by C14:0 revealed that many 
proteins up-regulated by this FA are present in extracellular exosomes, confirming the data 
observed in the previous chapter regarding the exosomal origin of many C14:0-deregulated 
secreted proteins detected by the MS/MS analysis.  
Finally, another protein specifically induced by C14:0 is Apolipoprotein E (ApoE). As 
described in detail in Chapter 1 Section 1 of the present thesis, this protein is present on many 
lipoprotein types and has many important physiological roles. Interestingly, the analysis 
performed in Chapter 2 Section 1 of the present thesis showed that – besides its important role 
on ApoC-III plasma levels - C14:0 was the second FA predictor of ApoE plasma levels. The 
present data, showing the exclusive influence of C14:0 on HepG2 cellular levels, suggest a 
positive influence of C14:0 on ApoE levels. Plasma levels of ApoE have been described as 
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regulators of TRLs metabolism, explaining 20-40% of plasma TG variability in humans 
(Mahley et al., 2009). In vivo studies on animal models also demonstrated that ApoE plasma 
levels are strictly connected with the development of hypertriglyceridemia. In particular, the 
overexpression of ApoE3 in transgenic rabbits caused hypertriglyceridemia through the 
increase in VLDL production (Huang et al., 1999). On the contrary, the effects of the ApoE 
deficiency on the secretion of VLDL-associated TG was investigated in mice and a 46% 
reduction in VLDL-TG was observed compared to controls (Kuipers et al., 1997). The same 
study reported a 23% reduction in VLDL-TG in cultured ApoE-deficient mouse hepatocytes. 
An important effect of ApoE on VLDL assembly and secretion has therefore been established. 
Moreover, the influence of this apolipoprotein on TG levels is also due to its ability to impair 
VLDL lipolysis (Huang et al., 1998). As reported by Jong et al., the increased amount of ApoE 
particles on nascent VLDL significantly decreased TG lipolysis when compared to ApoE-
deficient VLDL (Jong et al., 1997). The presence of ApoE on lipoproteins can therefore 
decrease their suitability for lipolysis in a dose-dependent manner. Taken together, these 
studies confirm an important influence of ApoE on cholesterol and TG plasma levels. 
Interestingly, in Chapter 2 Section 1 of the present thesis the most important statistical 
relationship observed in vivo was between C14:0 and plasma TG levels. The present in vitro 
proteomics research highlighted that, beyond the positive influence demonstrated on ApoC-III 
plasma levels, C14:0 may be connected to TG metabolism through the regulation of ApoE 
levels. The positive influence of C14:0 on both ApoC-III and ApoE levels could therefore 
represent a partial explanation of the statistical correlation observed between C14:0 and TG 
levels in the plasma of studied subjects.  
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4.2 Proteins modulated by both myristic and palmitic acid 
C14:0-treated HepG2 cells shared more modulated proteins with the saturated FA C16:0 than 
with C18:0, providing proteomic evidences of common mechanisms induced by the two 
saturated FAs. In the present investigation four proteins were found to be modulated by both 
C14:0 and by C16:0 with the same trend. Among these, the Cytochrome c oxidase subunit 5B, 
mitochondrial (COX5B), the component of the terminal oxidase in the mitochondrial electron 
transport was found to be down-regulated. The presence of this protein suggests a common 
propensity for the production of ROS by both FAs. This process has also been reported in 
C14:0 treated primary mouse hepatocytes (Martìnez, 2015). Another protein found to be down-
regulated by both C14:0 and C16:0 was Calumenin (CALU), a calcium-binding protein located 
in the ER membrane. This protein is involved in the alleviation of ER-stress in rat 
cardiomyocytes and exerts chaperone-like properties (Lee et al., 2013; Tripathi et al., 2014). 
The slight decrease in Calumenin induced by C14:0 (1.3 fold lower in 125 M C14:0 HepG2 
cell proteome) as compared to the strong decrease observed with C16:0 (almost six times lower 
in the 250 M) could suggest an important difference between the effects of these two FAs, on 
ER-stress and cytotoxicity. The 4F2 cell-surface antigen heavy chain (SLC3A2) is another 
protein up-regulated by both C14:0 and C16:0 treatments. This protein is involved in amino 
acids transport but a recent investigation based on RNA-sequencing revealed the presence of 
SLC3A2 among the new genes involved in the ER-stress response of rat cardiomyocytes. 
Taken together these proteins found to be modulated by both C14:0 and C16:0 treatments 
suggest a common involvement on ROS production and in ER-stress. 
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4.3 Proteins modulated by both myristic and oleic acid 
Only two of the C18:1 modulated proteins were also found to be deregulated by C14:0 
treatment: Alpha-2-macroglobulin (A2M) and Catalase (Santos-Gallego et al.) (Fig.6).  
Catalase is important for its role in protecting cells from the toxic effects of ROS generation, 
particularly from hydrogen peroxide. Interestingly, the treatment with C18:1 decreased the 
expression of this protein while C14:0 slightly and gradually increased it (even more at 500 
M, data not shown). The decrease in antioxidant molecules following HepG2 treatment with 
C18:1 has already been reported, together with the increase in LD and TG accumulation 
(Vidyashankar et al., 2013). The increase in the expression of Catalase, after C14:0 treatment, 
could instead represent the activation of a cell mechanism to counteract the oxidative stress 
induced by the treatment with this FA and could help explain the limited degree of cytotoxicity 
induced by C14:0 in HepG2 when compared with other saturated FAs.  
 
4.4 Proteins modulated exclusively by palmitic and oleic acid 
The comparison performed has also permitted the identification of proteins which are 
specifically modulated by C16:0 and C18:1. C16:0 is the major saturated FA in human plasma 
and previous investigations reported its poor ability to increase LD and TG accumulation in 
favour of more pro-apoptotic and cytotoxic behavior (Ricchi et al., 2009; Mei et al., 2011). Its 
positive influence on PPAR and therefore on -oxidation has been reported (Ricchi et al., 
2009) and is in line with the result obtained in the present investigation, where -oxidation was 
among the first biological processes up-regulated in presence of C16:0 in HepG2 cell culture 
(Fig.8A). It has been demonstrated that increased -oxidation by C16:0 causes excess electron 
flux in the mitochondrial respiratory chain yielding an increase in ROS generation (Nakamura 
et al., 2009). In agreement with this data, the present GO analysis reported an increase in the 
ATP biosynthetic process and in the respiratory chain proteins. Furthermore, the cellular 
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component analysis revealed that the most up-regulated proteins following C16:0 treatment in 
HepG2 cells were mitochondrial proteins, confirming the important effect of this FA on 
mitochondrial processes. The GO analysis reported the enrichment in proteins involved in 
apoptotic mitochondrial changes that were up-regulated following C16:0 supplementation. One 
of these proteins is the Voltage-dependent anion-selective channel protein 1 (VDAC1) that is 
involved in the regulation of mitochondrion pore formation during the apoptotic process and in 
the release of pro-apoptotic proteins (Ben-Hail et al., 2016). The slight dose-dependent increase 
in the expression of this protein confirmed the cytotoxic effects of this FA (shown in Fig.3). 
The most down-regulated proteins by C16:0 treatment were found to be two subunits of the 
40S ribosomal protein S26 (RPS26 and RPS23), with a negative fold change of -11 in the 
treatment with 250 M C16:0. The ubiquitination of these proteins has been reported during 
UPR, which triggers elevated protein folding capacity and attenuated protein synthesis (Higgins 
et al., 2015). The reduction in 40S ribosomal proteins could therefore be due to ER-stress 
induced by C16:0, which activates the UPR. Another protein whose expression was found to be 
decreased up to ten times in C16:0 treated HepG2 cell was the Small Nuclear 
Ribonucleoprotein SmD3 (SNRPD3). This protein is a component of the spliceosome 
machinery and has been described as a mediator of the metabolic stress response (Scruggs et 
al., 2012). Interestingly, it has been shown that cells with SmD3 haploinsufficiency acquire 
resistance to palmitate-induced cell death as SmD3 disruption protects cells from generalised 
oxidative stress and its strong decrease in the present proteomic investigation may represent a 
cellular effort to counteract C16:0-induced oxidative stress. 
On the other hand, C18:1, representing the category of MUFA, showed to regulate the highest 
number of proteins in HepG2 cells when compared with the other two fatty acids.  After ADRP 
the second most up-regulated protein in C18:1 treated HepG2 cells was the eukaryotic 
translation initiation factor 3 subunit E (EIF3E), implicated in the organisation of initiation 
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factor and ribosome required for protein translation and in the control of specific mRNA 
involved in growth control processes (Lee et al., 2015). Together with the GO analysis, 
showing the regulation of translational initiation among first biological processes up regulated 
by C18:1, this evidence suggests an involvement of this unsaturated FA in the protein 
translation process.  Moreover, another protein up-regulated by C18:1 was ApoA-I. This data 
was consistent with both the in vivo results obtained from regression analysis between FAs and 
lipid plasma levels in Chapter 2 Section 1 of the present PhD thesis - where C18:1 resulted as 
the first FA predictor of ApoA-I plasma levels - and also with the reported influence of MUFA 
on HDL levels (Michas et al., 2014).  In addition, some lipogenic proteins were found to be up-
regulated by the treatment with C18:1, such as FASN involved in fatty acids synthesis and 
Hydroxymethylglutaryl-CoA synthase (HMGCS1) involved in cholesterol biosynthesis. 
Accordingly, the GO analysis highlighted the regulation of cholesterol biosynthetic process 
among the most significantly up-regulated biological process following C18:1 supplementation. 
These data are in agreement with previously reported investigations on HepG2 cells, where 
FASN protein and gene expression were found to be up-regulated by the presence of C18:1 
(Kang et al., 2013; Hwang et al., 2014) and also with previous observations on its positive 
influence on the expression of lipogenic genes (e.g. SREBP-1) rather than -oxidation 
stimulating genes (Ricchi et al., 2009).  
 
In conclusion, this investigation provided evidence for the first time elucidating the specific 
proteomics effects induced by C14:0, as well as the non-specific proteomics modulation 
induced by C14:0 but also by C16:0 and/or by C18:1.  
The results obtained revealed that C14:0 shared a higher number of proteins with the saturated 
C16:0 compared to the unsaturated C18:1, mainly involved in ER-stress and ROS production. 
However, this research also highlighted the unique influence of C14:0 on different stress-
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mitigating proteins that could make this FA less cytotoxic in comparison to C16:0. Finally, the 
specific C14:0 influence on ApoE, strictly connected with TG plasma levels, has also been 
revealed, shedding light on the possible mechanism showing the significant association 
observed in the first section of the present thesis between C14:0 and TG plasma levels, and 
possibly CAD.     
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5. Concluding remarks 
For the first time the overall effects of different concentration C14:0 on HepG2 cell proteome 
and secretome have been evidenced in the present PhD thesis. Furthermore, the specific 
proteomic modulation induced by this FA on HepG2 cell proteome, when compared to the 
effects induced by the better studied C16:0 and C18:1, have been shown for the first time. 
Results highlighted a limited overlapping of proteins modulated by the three different FAs, 
demonstrating the unique influence of C14:0 on the expression of 40 proteins. This 
investigation contributes to elucidating the overall proteomic modulation induced by this less 
studied FA, providing important clues for a deeper comprehension of the possible mechanisms 
connecting C14:0 with steatohepatitis and CAD.  
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